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Abstract 
This thesis considers two aspects of the value of clinical information: the value of 
information provided by diagnostic technology; and the value of information 
generated by clinical research. It is motivated by the methodological problems 
which are encountered when faced with the economic evaluation of sequential 
clinical decision problems. A strategy for the evaluation of diagnostic information 
which could avoid the need for randomised clinical trials is examined. This is 
generalised to more complex clinical decision problems. It is shown that this 
strategy will fail in most clinical settings and prospective research will be required. 
However it is argued that the traditional approach to the design of clincial 
research is inconsistent with concepts of efficiency even when an economic 
evaluation is conducted alongside a clinical trial. This poses the problem of how 
to establish allocative and technical efficiency in clinical research. These issues are 
addressed by developing decision-analytic and dynamic programming approaches 
to clinical trial design and research priority- setting. T~o hurdles are proposed for 
clinical research. The first ensures that only potentially cost-effective research is 
considered. The second ensures that this research will be cost-effective ~hen 
conducted at the technically efficient scale. The dynamic programming approach 
enables relevant alternatives which should be compared in a clinical trial to be 
identified consistently and explicitly. The approach provides a measure of the net 
benefit of proposed research which can be used to establish allocative efficiency in 
research and development across clinical decision problems or broader areas of 
clinical research. Perhaps most importantly, it can be used to establish the optimal 
allocation of resources between research and development and service provision. 
Indeed what is clear from this approach is that the value of information and 
research priorities cannot be separated from the budgetary constraints on service 
provision. 
List of Contents 
Chapter 1 Introduction 
Page 
1 
1-1 Introduction 2 
1.2 The Value of Diagnostic Information 4 
1.2.1 Clinical Measures of the Value of Diagnostic Information 4 
1.2.2 A Strategy for the Economic Evaluation of Diagnostic 
Information 6 
1.2.3 Consistency in the Economic Evaluation of Diagnostic 
Information 7 
1.3 Allocative and Technical Efficiency in Clinical Research 9 
1.3.1 A Decision-analytic Approach to Clinical Trial Design 9 
1.3.2 A Dynamic Programming Approach to Optimal Patient 
Allocation 10 
1.3.4 Setting Priorities is Clinical Research 10 
Chapter 2 The Value of Diagnostic Information 12 -
2.1 Introduction 13 
2.2 A Strategy for the Evaluation of Diagnostic Information 18 
2.2.1 A Numerical Example of the Phelps Mushlin Strategy 18 
2.2.2 Selecting the Fallback Strategy 21 
2.2.3 The TestlTreatment Decision 26 
2.2.4 The Expected Value of (Imperfect) Clinical Information 27 
2.3 -A Strategy for Focusing Clinical Research 31 
2.3.1 Hurdle I: The Expected Value of Perfect Information. 31 
2.3.2 Hurdle II: The Expected Value of (Imperfect) Clinical 
Information. 34 
2.3.3 The Optimal Test Operation 36 
2.3.4 Focusing Clinical Research 
Appendix A Tables and Figures for Chapter 2 
Chapter 3 Consistency in the Evaluation of Diagnostic 
Information 
3.1 Introduction 
3.2 Generalising the Phelps Mushlin Strategy 
3.2.1 Selecting the Fallback Strategy 
3.2.2 The Expected Value of Clinical Information 
3.2.3 Hurdle I: The Expected Value of Perfect Information. 
3.2.4 Hurdle II: The Expected Value of (Imperfect) Clinical 
Information. 
3.3 Consistency in the Evaluation of Diagnostic Wormation 
3.3.1 Errors at the First Hurdle 
3.3.2 ErrorS at the Second Hurdle 
3.4 Implications for Focusing Clinical Research 
Appendix B Tables and Figures for Chapter 3 
Chapter 4 An Economic Approach to Clinical Trial Design 
38 
40 
41 
42 
42 
43 
45 
47 
50 
54 
55 
58 
60 
64 
and Research- Priority-Setting 65 
4.1 Introduction 66 
4.1.1 The Traditional Approach to Trial Design 66 
4.1.2 A Decision-Analytic Approach to the Value of Sample 
Information 69 
4.2 A Single-Stage Clinical Decision Problem 70 
4.2.1 Hurdle I: The Expected Value of Perfect Information 72 
4.3 
4.2.2 Hurdle II: The Expected Net Benefit of Sample 
Information 
Conclusions 
Appendix C Tables and Figures for Chapter 4 
77 
85 
87 
- Chapter 5 The Value of Information for Sequential Clinical Decision 
Problems 
5.1 Introduction 
5.2 A Two Stage Sequential Clinical Decision Problem 
5.2.1 Hurdle I: The Expected Value of Perfect Information 
5.2.2 Hurdle II: The Expected Net Benefits of Sample 
Information 
5.2.3 Implications for Research Design 
5.3 A Four-Stage Sequential Clinical Decision Problem 
5.3.1 Hurdle I: The Expected Value of Perfect Information 
5.3.2 Hurdle II: The Expected Net Benefit of Sample 
Information 
5.3.3 Implications for Research Design 
5.4 Conclusions 
Appendix D Tables and Figures for Chapter 5 
Chapter 6 The Value of Sample Information with Optimal Patient 
Allocation 
6.1 Introduction 
6.2 A Single-Stage Clinical Decision Problem 
6.2.1 Optimal Allocation at Stage 2 
6.2.2 Optimal Sample Size at Stage 1 
88 
89 
91 
92 
97 
108 
110 
111 
114 
123 
124 
129 
131 
132 
135 
137 
141 
6.2.3 Expected Net Benefits of Sample Information 143 
6.3 A Two-Stage Clinical Decision Problem 148 
6.3.1 Optimal Allocation at Stage 3 149 
6.3.2 Optimal Allocation at Stage 2 151 
6.3.3 Optimal Sample Size at Stage 1 156 
6.3.4 Expected Net Benefit of Sample Information 157 
6.4 A Four-Stage Sequential Clinical Decision Problem 163 
6.4.1 Optimal Allocation at Stage 5 164 
6.4.2 Optimal Allocation at Stage 4 166 
6.4.3 Optimal Allocation at Stage 3 168 
6.4.4 Optimal Allocation at Stage 2 172 
6.4.5 Optimal Sample Size at Stage 1 176 
6.4.6 Expected Net Benefits of Sample Information 178 
6.5 Conclusions 182 
Appendix E Tables and Figures for Chapter 6 185 
Chapter 7 Conclusions 187 
7.1 Introduction 188 
7.2 Consistency in the Evaluation of Diagnostic Information 192 
7.3 A Decision-analytic Approach to Trial Design and Research Priority 
Setting 198 
7.3.1 Hurdle I: The Expected Value of Perfect Information 200 
7.3.2 Hurdle II: The Expected Net Benefit of Research 203 
7.3.3 Setting priorities in Research and Development 205 
7.4 A Dynamic Programming Approach 208 
7.5 Further Developments 212 
List of References 215 
List of Tables and Figures 
Appendix A Tables and Figures for Chapter 2 
Page 
40 
Table 2.2 A Numerical Example 
Figure 2.2.1 Decision Tree for the Fallback Decision 
Figure 2.2.2 Treatment Threshold (flO) 
Figure 2.2.3 Decision Tree for the Test/Treatment Decision 
Figure 2.3.1a Expected Value of Perfect Information (EVPI) (lIg=£4,OOO) 
Figure 2.3.1b Expected Value of Perfect Information (EVPI) 
Figure 2.3.1c Expected Value of Perfect Information (EVPI) 
Figure 2.3.2a Expected Value of Clinical Information (EVCI) (1Ig=£4,OOO) 
Figure 2.3.2b Expected Value of Clinical Information (EVCI) 
Figure 2.3.2c Expected Value of Clinical Information (EVCI) 
Figure 2.3.3 Receiver Operating Characteristic (ROC) Curve 
Appendix B Tables and Figures for Chapter 3 
Table 3.2.1 A Numerical Example 
Figure 3.2.1 Decision Tree for the Test Treatment Decision 
Figure 3.2.2 Treatment Thresholds (~J _ 
Figure 3.2.3a Expected Value of Perfect Information (EVPI) (lIg=£4,OOO) 
Figure 3.2.3b Expected Value of Perfect Information (EVPIIU) 
Figure 3.2.3c Expected Value of Perfect Information (EVPIh) 
Table 3.2.2 Optimal Strategies with Perfect Information 
64 
Figure 3.2.4a Expected Value of Clinical Information (EVCIh) (lIg=£4,OOO) 
Figure 3.2.4b Expected Value of Clinical Information (EVCIIU) 
Figure 3.2.4c Expected Value of Clinical Information (EVCIh) 
Table 3.2.3 Optimal Strategies with Clinical Information 
Figure 3.3.la Errors at the First Hurdle (when CCER=£4,000) 
Figure 3.3.1b Errors at the First Hurdle (when 1/g>CCER=£4,000) 
Figure 3.3.2a Errors at the First Hurdle (when CCER=£4,000) 
Figure 3.3.2b Errors at the First Hurdle (when 1/g>CCER) 
Figure 3.3.3 Errors at the Second Hurdle (when CCER=£4,000) 
Figure 3.3.4a Errors at the second Hurdle (when CCER=£4,000) 
Figure 3.3.4b Errors at the Second Hurdle (when 1/g>CCER=£4,000) 
Appendix C Tables and Figures for Chapter 4 
Figure 4.2.1 Decision Tree for the Single -Stage Decision Problem 
Table 4.2 Numerical Example for the Single-Stage Decision Problem 
Figure 4.2.2 Opportunity Loss Function for t1 and to 
Figure 4.2.3 EVPI for the Single-Stage Decision Problem 
85 
Figure 4.2.4a Standardised Distance (Do) for the Single -Stage DeCision Problem 
Figure 4.2.4b Loss Integral (L(Do) for the Single-Stage Decision Problem 
Figure 4.2.5 EVPI and the Strength of Prior Information. 
Figure 4.2.6a ENBS, EVSI, and Cm.n (when 1/g=£4,000) 
Figure 4.2.6b ENBS, EVSI, and Cm.n (when 1/g=£10,000) 
Figure 4.2.6c ENBS, EVSI, and Cm.n (when 1/g=£20,000) 
Figure 4.2.7 Optimal Sample Size (n*) and the Strength of Prior Information 
Figure 4.2.8 ENBSln* and the Strength of Prior Information 
Appendix D Tables and Figures for Chapter 5 
Figure 5.2.1 
Table 5.2 
Figure 5.2.2 
Decision Tree for the Two-Stage Decision Problem 
Numerical Example for the Two-Stage Decision Problem 
EVPI for the Two-Stage Decision Problem 
Figure 5.2.3a Standardised Distance (DO(s» at Stage 1 and Stage 2 
Figure 5.2.3b Loss Integral (L(Do» at Stage 1 and Stage 2 
Figure 5.2.4 EVPI and the Strength of Prior Information 
129 
Figure 5.2.5a ENBS for the Two-Stage Decision Problem (1/g=£4,000) 
Figure 5.2.5b ENBS for the Two-Stage Decision Problem (1/g=£10,000) 
Figure 5.2.5c ENBS for the Two-Stage Decision Problem (1/g=£20,000) 
Figure 5.2.6 Optimal Sample Size for the Two-Stage Decision Problem 
Figure 5.2.7a ENBS at Optimal Sample Size for the Two-Stage Decision 
Problem 
Figure 5.2.7b ENBS and the Strength of Prior Information 
Figure 5.2.8a ENBS for the Two and Single-Stage Decision problem 
Figure 5.2.8b Optimal Sample Size for the Two and Single-Stage Decision 
Figure 5.3.1 
Table 5.3 
Problem 
Decision Tree for the Four-Stage Decision Problem 
Numerical Example for the Four-Stage decision Problem 
Figure 5.3.2a EVPI for the Four-Stage Decision Problem 
Figure 5.3.2b EVPI at Each Stage 
Figure 5.3.3a Standardised Distance at Stage s (DO(S») 
Figure 5.3.4 
Figure 5.3.5 
Figure 5.3.6a 
Figure 5.3.6b 
Figure 5.3. 6c 
Figure 5.3.7 
EVPI and the Strength of Prior Information 
EVPI for the Four and Two-Stage Decision Problems 
ENBS for the Four-Stage Decision Problem (1/g=£4,000) 
ENBS for the Four-Stage Decision Problem (1Ig=£10,000) 
ENBS for the Four Stage Decision Problem (1Ig=£20,000) 
Optimal Sample Size for the Four-Stage Decision Problem 
Figure 5.3.8a ENBS at Optimal Sample Size of the Four-Stage Decision Problem 
Figure 5.3.8b ENBS and the Strength of Prior Information 
Figure 5.3.9a ENBS for Two and Four Stage Decision Problems 
Figure 5.3.9b Optimal Sample Size for the Two and Four-Stage Decision 
Problem 
Appendix E Tables and Figures for Chapter 6 185 
Figure 6.2.1 Decision Tree for the Single-Stage Decision Problem 
Table 6.2.1a Optimal Allocation of the Sample Entering Stage 2 (l/g=£4,OOO) 
Figure 6.2.2 Optimal Allocation at Stage 2 
Table 6.2.1b Optimal Sample Size at Stage 1 (l/g=£4,OOO) 
Figure 6.2.3a Optimal Allocation: ENBS, EVSI and Cs (l/g=£4,OOO) 
Figure 6.2.3b Fixed Allocation: ENBS, EVSI, and Cs (l/g=£4,OOO) 
Figure 6.2.4a Optimal Allocation: ENBS, EVSI, and Cs (l/g=£lO,OOO) 
Figure 6.2.4b Fixed Allocation: ENBS, EVSI, and Cs (lIg=£10,OOO) 
Figure 6.2.5a Optimal Allocation: ENBS, EVSI, Cs (l/g=£20,OOO) 
Figure 6.2.5b Fixed Allocation: ENBS, EVSI, and Cs (lIg=£20,OOO) 
Figure 6.2.6 Optimal Sample Size with Fixed and Optimal Allocation 
Figure 6.2.7 Difference between Optimal and Fixed Allocation 
Figure 6.3.1 Decision Tree for the Two Stage Decision Problem 
Table 6.3.1a Optimal Allocation of the Sample Entering Stage 3 (lIg£4,OOO) 
Figure 6.3.2a Optimal Allocation at Stage 3 
Table 6.3.lb Optimal Allocation of the Sample Entering Stage 2 (lIg=£4,OOO) 
Figure 6.3.2b Optimal Allocation of Sample at Stage 2 
Table 6.3.1c Optimal Sample Size at Stage 1 (l/g=£4,OOO) 
Figure 6.3.3a ENBS with Optimal Allocation (1/g=£4,OOO) 
Figure 6.3.3b ENBS with Fixed A:llocation (1Ig=£4,OOO) 
Figure 6.3.4a ENBS with Optimal Allocation (l/g=10,OOO) 
Figure 6.3.4b ENBS with Fixed Allocation (lIg=£lO,OOO) 
Figure 6.3.5a ENBS with Optimal Allocation (1Ig=£20,OOO) 
Figure 6.3.5b ENBS with Fixed Allocation (l/g=£20,OOO) 
Figure 6.3.6 Optimal Sample Size with Fixed and Optimal Allocation 
Figure 6.3.7 Difference between Optimal and Fixed Allocation 
Figure 6.3.8a ENBS for the Single and Two-Stage Decision Problems 
Figure 6.3.8b Optimal Sample Size for the Single and Two stage Decision 
Problems 
Figure 6.4.1 Decision Tree for the Four-Stage Decision Problem 
Table 6.4.1a Optimal Allocation of the Sample Entering Stage 5 (1/g=£4,000) 
Figure 6.4.2a Optimal Allocation at Stage 5 
Table 6.4.1b Optimal Allocation of the Sample Entering Stage 4 (1/g=£4,000) 
Figure 6.4.2b Optimal Allocation at Stage 4 
Table 6.4.1 c Optimal Allocation of the Sample Entering Stage 3 (1/g=£4,000) 
Figure 6.3.2c Optimal Allocation at Stage 3 
Table 6.4.1d Optimal Allocation of the Sample Entering Stage 2 (1/g=£4,000) 
Figure 6.4.2d Optimal Allocation at Stage 3 
Table 6.4.1e Optimal Sample Size at Stage 1 (1/g=£4,000) 
Figure 6.4.3a ENBS with Optimal Allocation (1/g=£4,000) 
Figure 6.4.3b ENBS with Fixed Allocation (1/g=£4,000) 
Figure 6.4.4a ENBS with Optimal Allocation (1/g=£10,000) 
Figure 6.4.4b ENBS with Fixed Allocation (1/g=£10,000) 
Figure 6.4.5a ENBS with Optimal Allocation (1/g=£20,OOO) 
Figure 6.4.5b ENBS with Fixed Allocation (1/g=£20,000) 
Figure 6.4.6 Optimal Sample Size with Fixed and Optimal Allocation 
Figure 6.4.7 Difference between Optimal and Fixed Allocation 
Figure 6.48a ENBS for the Four and Two-Stage Decision Problem 
Figure 6.4.8b Optimal Sample Size for the Four and Two-Stage Decision 
Problems 
Acknowledgement 
I would like to acknowledge the support and guidance of my supervisor Dr John 
Posnett and the members of my thesis advisory group: Professor Peter Smith; and 
Professor Alan Williams. 
Chapter 1 Introduction 
Contents: Page 
1-1 Introduction 2 
1.2 The Value of Diagnostic Information 4 
1.2.1 Clinical Measures of the Value of Diagnostic Information 4 
l.2.2 A Strategy for the Economic Evaluation of Diagnostic 
Information 6 
1.2.3 Consistency in the Economic Evaluation of Diagnostic 
Information 7 
1.3 Allocative and Technical Efficiency in Clinical Research 9 
1.3.1 A Decision-analytic Approach to Clinical Trial Design 9 
1.3.2 A Dynamic Programming Approach to Optimal Patient 
Allocation 10 
l.3.4 Setting Priorities is Clinical Research 10 
1 
1-1 Introduction 
This thesis considers two aspects of the value of clinical information: the value of 
information provided by diagnostic technology; and the value of information 
generated by clinical research. It is motivated by the methodological problems 
which are encountered when faced with the economic evaluation of sequential 
clinical decisions which include one or more diagnostic processes and a number of 
treatment strategies. The issues posed by this type of decision problem are: (a) 
can diagnostic information be valued without the prospective evaluation of all 
feasible strategies of patient management; (b) if not, is it worth collecting 
additional information about this decision problem through prospective research; 
(c) ifit is, what is the optimal scale of this research; and (d) which of the many 
competing strategies of patient management should be included (regarded as 
relevant alternatives) in the evaluation? The thesis is an attempt to address these 
practical problems which are the issues of allocative and technical efficiency in 
research and development. 
The thesis presents an approach which can address each of these problems. The 
methods developed are illustrated in each chapter using simple numerical examples 
which are introduced in chapters two and three. In chapter two a strategy for the 
evaluation of diagnostic information which could in principle avoid prospective 
clinical research with randomised patient selection is examined. In chapter three 
this approa.ch is generalised to a more complex decision problem. It is shown that 
this strategy will only provide consistent valuations if critical assumptions, which 
are unlikely to be met in most ciinical settings, hold. This poses a number of 
problems which include the issues of allocative and technical efficiency in clinical 
research. These issues are addressed in chapters four, five and six by developing 
decision-analytic and dynamic programming approaches to clinical trial design and 
research priority-setting. 
2 
Methodological and Policy Issues 
In the process of addressing these problems some interesting methodological 
issues are highlighted. One of the implications from chapter three is that there may 
be problems when using league tables of cost-effectiveness ratios to set priorities 
in service provision. Chapter four demonstrates that the traditional approach to 
clinical trial design is inconsistent with concepts of efficiency even when an 
economic evaluation is conducted alongside a clinical trial. The decision-analytic 
approach to the value of information shows that there are circumstances when it 
will not be efficient to conduct a clinical trial and clinical practice should be based 
only on prior information. Establishing the expected net benefit of research also 
means that ethical judgements about proposed research can be based on consistent 
estimates of the opportunity cost of particular ethical concerns. 
The thesis also provides tools which can address some interesting policy 
questions, in particular methods for research priority-setting. In chapters four, 
five and six two hurdles are proposed for clinical research. The first ensures that 
only potentially cost-effective research is considered. The second ensures that this 
research will be cost-effective when conducted at the technically efficient scale. 
The expected net benefits of research can be used to establish allocative efficiency 
in research and development across clinical decision problems or broader areas of 
clinical research. Perhaps most importantly, it can be used to establish the optimal 
allocation of resources between research and development and service provision. 
Indeed what is clear from the analysis is that the value of information and research 
priorities cannot be separated from the budgetary constraints on service provision. 
3 
1.2 The Value of Diagnostic Information 
The clinical approach to the evaluation of diagnostic information using measures 
of accuracy is inadequate because it is not founded on the proposition that 
information is only valuable insofar as it changes subsequent decision-making. 
The use of performance measures for diagnostic technology which are 
independent of the consequences of subsequent treatment decisions will not reflect 
the most important impact of diagnostic information: the consequences of 
subsequent changes in patient management. 
1.2.1 Clinical Measures of the Value of Diagnostic Information 
The simple measures of accuracy of a diagnostic device suffer from a number of 
problems. Measures of the sensitivity and specificity of a test do not directly 
address the issue of concern for the clinician; namely the probability of disease for 
a given test result. Predictive values, although more intuitively appealing, depend 
on the prior probability of disease (via Bayes) and are context and population 
specific. Both these types of measures of accuracy are not independent of the 
positivity criterion (the cut-off used to operate the diagnostic test) and are to 
some extent arbitrary. The optimal positivity criterion can only be established by 
considering the net consequences of classifying a test result as positive and the net 
consequence of classifying a result as negative 137. This requires information not 
only on the accuracy of the test but also on the expected costs and health 
outcomes of subsequent treatment strategies. 
More sophisticated measures of accuracy which take account of the possible 
trade-off between sensitivity and specificity claim to overcome this problem and 
provide measures of accuracy which are independent of the positivity criterion. 
The area under the Receiver Operating Characteristic (ROC) curve 2, 24, 67, 97, 130 is a 
measure of accuracy which is independent of the positivity criterion, because it is a 
4 
measure of accuracy across all possible combinations of sensitivity and specificity 
that the test can provide 92. The area criterion is really an average of true positive 
rates over the full range of possible false positive rates 107. The use of the whole 
area under the ROC curve implies that the false positive and false negative results 
are equally valued. However only a small range of false positive rates will be 
clinically relevant and there will be a large range of false positive rates which will 
never be considered. The relevant range of false positive rates depends on the 
patient population with a particular prior probability of disease and also depends 
on the subsequent treatment strategies which are available. This is a particular 
problem if the ROC curves of alternative diagnostic test cross 72, 106. In these 
. circumstances the analyst needs to know where on the ROC curve each test 
should be operated. But to establish this requires information about the expected 
costs and health outcomes of the subsequent treatment decisions. Finally it has 
been argued that the interpretation of the area under the ROC curve is not directly 
relevant to the decision problem the clinician faces and the energy expended on 
estimation techniques 68 for ROC curves suggests the imprudent use of a 
potentially misleading and inconsistent performance measure which lacks 
relevance to clinical practice 72. 
The conclusion that unambiguous and reliable measures require an assessment of 
the impact of information on the outcome of subsequent treatment choices and not 
simply diagnostic accuracy seems unavoidable. The economic evaluation of 
diagnostic information requires information about the accuracy of the test but also 
the expected costs and health outcomes of the subsequent treatment alternatives 46, 
. 66,150. A number of measures have been proposed based on treatment thresholds 
103,104, lOS. In the absence of a diagnostic test a treatment threshold can be 
estimated based on knowledge of the prior probability of disease and the health 
outcomes with and without treatment. This threshold indicates the prior 
probability of disease where the clinician should be indifferent between treatment 
and no treatment. Thresholds for a new diagnostic test can be established based 
on an assessment of the accuracy and the existing information about current 
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practice embodied in the treatment threshold. The testing threshold, the point at 
which the clinician switches from no treatment to testing, and the test/treatment 
threshold, the point at which the clinician switches form testing to treatment, 
defines the range of prior probability of disease where the diagnostic test should 
be used. Clearly a more accurate diagnostic test will generate a greater range 
where the test should be used. 
There have been a number of approaches to the use of thresholds. Patient 
orientated performance measures for a diagnostic test have been proposed based 
on treatment thresholds 64. These attempt to measure the impact of diagnostic 
information on patient management: assignment potential 63 is the probability that 
the diagnostic test result will change clinical practice by moving the post test 
probability of disease across the treatment threshold; assignment strength 23 
measures the distance from the threshold following the results of the test. Other 
developments have generated stochastic thresholds 69,70,98. However all these 
approaches share the assumption that current practice is the appropriate baseline 
against which to compare a new diagnostic technology. It implies that a new 
diagnostic technology can simply be added to the existing strategies of patient 
management. These approaches assume that new information has an impact only 
on whether the patient is assigned to the treatment which was used before the new 
test was available. This seems an appropriate assumption when considering 
examples where only one treatment option is available for a given diagnosis, but 
may not be appropriate when considering more complex sequential clinical 
decision problems. 
1.2.2 A Strategy for the Economic Evaluation of Diagnostic Information 
A strategy for the economic evaluation of diagnostic information has been 
proposed by Phelps and Mushlin 107. In chapter two this strategy is applied to a 
simple numerical example. By using information on the costs and outcomes of 
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current practice prior to the introduction of a new diagnostic technology 
(assuming it is available) the value of perfect information can be established based 
only on this prior information. This is the maximum value that any diagnostic 
technology can provide. By comparing this to an estimate of the cost of the new 
technology it can be used as a first hurdle that must be overcome. If a proposed 
diagnostic technology passes the first hurdle then it is potentially cost-effective 
and prospective research is needed to establish the accuracy of the test. If the new 
diagnostic technology is non-invasive then random patient selection is unnecessary 
and a clinical trial of the full diagnostic and treatment process can be avoided 
Once the accuracy of the test is established the prior information about current 
practice is used to estimate the expected value of clinical information. If this 
exceeds the estimated cost of the test then the new technology is cost-effective 
and passes the second hurdle. The value of diagnostic information can be 
established without recourse to a randomised clinical trial of the diagnostic and 
treatment process, and clinical research can be focused on those diagnostic 
technologies which are potentially cost-effective. 
1.2.3 Consistency in the Economic Evaluation of Diagnostic Information 
This strategy assumes that current practice is the appropriate baseline to evaluate 
a new diagnostic technology. This requires current practice to be cost-effective at 
the critical cost-effectiveness ratio which will be used to set priorities in service 
provision when the new technology has been evaluated. In 'chapter three the 
Phelps Mushlin strategy is generalised to the more realistic situation where there is 
m<:>re than one treatment option available following diagnosis. Consistency 
requires that the value of health outcome which is implicit in current practice is the 
same as the critical ratio which will be used to decide if the new technology will be 
cost-effective. The analysis in chapter three shows that if this assumption does 
not hold (because clinicians have a higher implicit value of health outcome or do 
7 
not perceive all the costs of the alternative patient management strategies) then 
current practice may not be the appropriate baseline. The analysis can be subject 
to two types of error at each of the two hurdles: the value of clinical information 
may be overestimated and a diagnostic technology which is not cost-effective is 
evaluated and may be implemented; or the value of clinical information is 
underestimated and a potentially cost-effective diagnostic technology may be 
rejected. 
The analysis in chapter three shows that the Phelps Mushlin strategy like the 
threshold approach, assumes that a new diagnostic technology can simply be 
added to the existing strategies of patient management. However when there is 
more than one possible treatment for a given diagnosis it is possible that the 
optimal treatment following diagnosis is not part of existing strategies of patient 
management. In these circumstances information about current practice will be 
inadequate to establish the value of diagnostic information. Evaluation will 
require random patient selection in a trial which includes the diagnostic and 
treatment processes even when the new test is non-invasive. This poses a number 
of problems which are addressed in the following chapters of the thesis. 
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1.3 Allocative and Technical Efficiency in Clinical Research 
The analysis of the Phelps Mushlin strategy in chapter three suggests that it is 
likely to fail when applied to more complex decision problems because: the key 
assumption of consistency between the value of health outcome implicit in current 
practice and the critical cost-effectiveness ratio used by an analyst is unlikely to 
hold; when this assumption is violated the values of both the first and second 
hurdles will be biased; and it is not necessarily the case that information available 
about current practice before the test is introduced will be sufficient to establish 
the value of diagnostic information. The Phelps Mushlin strategy may fail, but if 
the prospective evaluation of all possible alternatives in a sequential clinical 
decision problem is not possible then this poses a number of questions: (a) how 
should information of different quality from different sources be combined 
consistently and explicitly; (b) which clinical decision problems will be worth 
evaluating in a clinical trial; (c) if a clinical decision problem is worth evaluating 
which of the competing alternatives should be compared in a clinical trial; and (d) 
what is the optimal scale of this prospective research? These are the questions of 
how to establish both technical efficiency in research design, and how to achieve 
allocative efficiency in research and development across clinical decision 
problems and between research and service provision. It is these questions which 
are addressed in chapters four, five and six. 
1.3.1 A Decision Analytic Approach to Clinical Trial Design 
The analysis in chapter four uses a decision-analytic approach to the value of 
information which combines a Bayesian view of probability with a framework for 
decision making. This approach is used to establish the cost of uncertainty 
surrounding the clinical decision problem (the expected value of perfect 
information). The marginal benefit and the marginal cost of acquiring sample 
information is then explicitly considered. This enables the technically efficient 
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scale of the research to be identified and the expected net benefit of proposed 
research to be established. These methods are generalised from the single-stage 
decision problem considered in chapter four to the two- and four-stage sequential 
clinical decisions in chapter five. However, although the decision-analytic 
approach taken in these chapters addresses the issues of which clinical decision 
problems are worth evaluating and what the technically efficient scale of the 
research should be, it does not allow the relevant alternatives to be identified. 
1.3.2 A Dynamic Programming Approach to Optimal Patient Allocation 
In chapter six the fixed and equal allocations rule used in chapters four and five, 
which assigns equal numbers of trial entrants to each of the alternative arms of the 
trial, is relaxed. A dynamic programming approach is used to identify the optimal 
allocation of trial entrants at each stage of the decision problem. By explicitly 
considering the marginal benefit and marginal cost of assigning trial entrants to the 
alternative arms of the trial the expected net benefit of the proposed research is 
higher than with fixed allocation rules. The optimal allocation of trial entrants 
enables relevant alternatives to be identified because it is possible to assign no 
sample to an arm of the trial and in this case it can be ruled out as an irrelevant 
alternative. By the end of chapter six each of the methodological problems which 
motivate this thesis are addressed and methods are proposed which can provide a 
practical solution. 
1.3.4 Setting Priorities in Clinical Research 
The decision-analytic approach which is developed in chapters four, five and six 
can provide practical policy tools for research priority-setting. The information 
generated by clinical research is valued in a way which is consistent with concepts 
of efficiency, and with the methods used to set priorities in service provision. The 
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simple numerical examples show that these techniques can be used to identify 
areas of clinical practice where the cost of uncertainty is high, and where the 
potential benefits of clinical research will also be high. 
Two hurdles are constructed which proposed research must overcome before it 
can be considered cost-effective. The first hurdle can eliminate proposed research 
which will not be cost-effective before issues of research design must be 
addressed. Those proposals which pass the first hurdle can be regarded as 
potentially cost-effective and can be considered at the second hurdle. The second 
hurdle ensures that the design of potentially cost-effective research is technically 
efficient, and that it will be cost-effective when conducted at the optimal scale. 
The value of proposed research to the providers and consumers of health services 
can be established. This approach provides a means to decide which clinical 
decision problems are worth evaluating in a clinical trial and what is the technically 
efficient scale of this research. 
These methods can be used to rank competing research proposals so that the 
maximum health benefits can be gained for limited research and development 
resources. These tools can be used to establish the optimal level of research and 
development; the optimal allocation of resources between research and 
development and service provision; and the optimal allocation between different 
areas of clinical research. There are also further methodological developments 
which could be pursed and the application of these methods to research priority-
setting suggests a programme of empirical work. It also poses the issue of how to 
implement this type of approach to research priority-setting. These issues are 
discussed in chapter seven. 
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2.1 Introduction 
Approaches to the evaluation of diagnostic information which are based on 
treatment thresholds combine measures of accuracy and the consequences of 
subsequent treatment decisions 23, 63, 64, but they are essentially qualitative: 
measuring whether information changes patient management by assigning those 
with positive test results to treatment and those with negative test results to no 
treatment. They do not attempt to measure the value to patients of the changes in 
clinical practice brought about by the diagnostic information. However these 
measures do require information on the consequences of the treatment options 
which are assumed to be used following diagnosis. This prior information can be 
used and combined with information on the costs of treatment and testing to 
provide estimates of the expected value of diagnostic information. 
This is the strategy for the economic evaluation of diagnostic information 
proposed by Phelps and Mushlin 107. By using information on the costs and 
outcomes of current practice prior to the introduction of a new diagnostic 
technology, the value of diagnostic information can be estimated based only on 
this prior information and on estimates of the accuracy of new diagnostic 
technology. The prospective evaluation of subsequent treatment following 
diagnosis in a full clinical trial is then unnecessary. This strategy is an attempt to 
combine information from a number of sources and to focus clinical research more 
sharply by (a) eliminating new technologies which will not be cost-effective, (b) by 
avoiding randomised experimental design where possible, and ( c) by focusing on a 
clinically relevant range of test and patient characteristics. 
This is achieved by constructing two hurdles that a new diagnostic technology 
must overcome before it can be considered cost-effective. The first hurdle 
compares the expected value of the test assuming that it provides perfect 
information (the maximum value that any diagnostic technology can provide) with 
an estimate of the cost of the new technology. If the Expected Value of Perfect 
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Information (EVPI) is greater than the estimated cost of the test then it is 
potentially cost-effective and passes the first hurdle. This first hurdle does not 
require prospective research and is constructed using only information about 
current practice which is available before the new technology is introduced. 
If a proposed diagnostic technology passes the first hurdle then prospective 
clinical research is required to establish the accuracy of the test. Once the 
accuracy of the test is established existing information about current patient 
management is used to estimate the expected value of this imperfect clinical 
information. If the Expected Value of Clinical Information (EVCI) is greater than 
the cost of implementing the new diagnostic technology, the test passes the 
second hurdle and will be cost-effective over some range of prior probability of 
disease. 
This strategy means that an economic evaluation of a new diagnostic technology 
can be based on measures of accuracy and information which is available prior to 
the introduction of the test, combining information which is available from a 
variety of sources. If the new diagnostic technology is non-invasive then 
randomised patient selection to establish the accuracy of the test is unnecessary, 
because double-blind diagnosis with the new test and with a "gold standard" test 
can be performed on the same patient. A controlled clinical trial of the full 
diagnostic and treatment process can be avoided: saving research and 
development resources; avoiding delay in adopting cost-effective technology, and 
avoiding potential health costs to patients who would otherwise have been 
enrolled in a clinical trial. 
In this chapter I apply the Phelps Mushlin strategy to a ~imple numerical example 
of the test/treatment decision and explore the relationship between the value of 
diagnostic information and the critical cost-effectiveness ratio (the shadow price 
of the budget constraint on service provision) 108, 140, 141. This demonstrates that 
both hurdles are dependent on this decision rule and that the explicit monetary 
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valuation of health outcome is unavoidable in the valuation of clinical information. 
The Phelps Mushlin strategy, in common with test/treatment thresholds, assumes 
that current practice is the appropriate baseline to evaluate a new diagnostic 
technology. In the context of economic evaluation this requires current practice to 
be optimal or the most cost-effective strategy at the critical cost-effectiveness 
ratio which will be used to set priorities in service provision when the new 
technology has been evaluated. In the next chapter I generalise the Phelps 
Mushlin strategy to the more realistic situation where there is more than one 
treatment option available for a particular diagnosis. This requires consistency 
between the value of health outcome which is implicit in current practice and the 
critical cost-effectiveness ratio which will be used to decide if the new technology 
will be cost-effective. If this assumption is violated (because clinicians have a 
higher implicit value of health outcome or do not perceive all the costs of 
alternative patient management strategies) then current practice may not be the 
appropriate baseline (or the relevant alternative), and the analysis can be subject to 
two types of errors at each of the two hurdles. Type I errors occur when the 
value of clinical information is overestimated and a diagnostic technology which is 
not cost-effective is evaluated and implemented. Type II errors will be made when 
the value of clinical information is underestimated and a potentially cost-effective 
diagnostic technology is rejected. 
This strategy, like the threshold approach, assumes that a new diagnostic 
technology can simply be added to the existing strategies of patient management 
and that diagnostic information changes clinical practice by assigning those with a 
positive test result to treatment and negative test result to no treatment. This 
assumption will be appropriate when there is only one possible treatment for a 
particular diagnosis. However, when there is more than one possible treatment for 
a given diagnosis, the optimal treatment following the test result may not be the 
same as the optimal treatment choice without the test. In these circumstances 
diagnostic information may change patient management in two ways: by changing 
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the optimal treatment choice for a particular diagnosis; and by changing the 
probability of assigning a patient to a particular diagnosis. 
If the diagnostic information changes the optimal treatment for a given diagnosis it 
is possible that this treatment may not be part of current practice. This is more 
likely to be the case if the value of health outcome implicit in existing strategies of 
patient management is not consistent with the critical cost-effectiveness ratio used 
by the analyst. It may be reasonable to assume that information on the costs and 
health outcomes of current practice will be available. However it is very unlikely 
that information about treatment options which are not part of current practice 
will be available. In these circumstances existing information will be inadequate 
to estimate the value of new diagnostic information and the investigator may be 
forced to consider an experimental design which includes these alternative 
treatments. 
The implications are that when approaches to economic evaluation which are 
based on existing clinical practice are generalised to more complex sequential 
decision problems they can only provide reliable information in a limited set of 
circumstances which impose restrictive assumptions that are unlikely to hold in 
many clinical settings. However, if it is not possible to draw reliable inferences 
from existing strategies of patient management then prospective clinical research 
using randomised controlled clinical trials which consider all feasible strategies of 
patient management may be required. This poses a number of methodological and 
practical questions. First is the practical question that it will not be feasible, in 
terms of resource cost, time, and ethical implications to evaluate every possible 
alternative strategy in this way. If the prospective evaluation of all possible 
alternatives is not possible or efficient, but simply relying on existing clinical 
practice is unreliable, this posses a number of methodological questions including: 
(a) which clinical decision problems should be subject to prospective clinical 
research; (b) if a clinical decision problem is worth evaluating in a clinical trial 
which alternatives should be regarded as relevant and should be compared in the 
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trial; and (c) what is the optimal or technically efficient scale of this research? 
These are the methodological issues of allocative and technical efficiency in 
clinical research which are dealt with in chapters 4, 5 and 6. The purpose of this 
chapter and the next is to show that approaches to the economic evaluation of 
diagnostic information which rely on existing strategies of patient management 
may be inadequate and to pose the problems which are taken up in subsequent 
chapters of the thesis. 
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2.2 A Strategy for the Evaluation of Diagnostic Information 
The strategy for the economic evaluation of a new diagnostic technology 
proposed by Phelps and Mushlin 107 will now be presented and applied to a simple 
numerical example, and the relationship between the value of information and the 
value placed on health outcome will be explored. This example uses their 
approach and notation before it is generalised in chapter 3 to the situation where 
there is more than one treatment option for a particular diagnosis. 
2.2.1 A Numerical Example of the Phelps Mushlin Strategy 
Phelps and Mushlin take a simple decision problem to illustrate their approach, 
and consider a single disease with only two possible health states (i=O, 1): disease 
(i=l); and no disease (i=O). It is assumed that clinicians hold prior beliefs about 
the likelihood of disease in a particular patient or group of identical patients. 
f = prior probability of disease 
(l-f) = prior probability of no disease 
A simple binary diagnostic test is considered, and following Phelps and Mushlin 
the standard approach to characterising the performance of the test in terms of 
sensitivity and specificity is used: 
p = probability of a true positive test result (sensitivity) 
(l-p) = probability of a false negative test result 
q = probability of a false positive test result 
(l-q) = probability of a true negative test result ( specificity) 
The clinician is faced with a simple decision problem with only two possible 
treatment options (tj; j=O, 1): treatment (t1); and no treatment (to), where tl follows 
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a positive test result and to follows a negative result. The decision problem facing 
the clinician is whether to (a) test and treat according to the test results, or (b) not 
to test and either treat or not treat. In this simple decision problem there is only 
one possible treatment for a given diagnosis and it is this restriction which will be 
relaxed in the next chapter. 
The health outcomes of patients depend on health state and the treatment option 
chosen, and are described as health state utilities, Vij were i indicates health state 
and j indicates the treatment selected. 
V ll = utility ofa diseased patient treated (t l ) 
V 10 = utility of a diseased patient not treated (to) 
VOl = utility of a healthy patient treated (t l ) 
Voo = utility of a healthy patient not treated (to) 
The costs of treatment Cij also depend on health state i and treatment j: 
Cll = cost of a diseased patient treated (tl ) 
CIO = cost of a diseased patient not treated (to) 
COl = cost of a healthy patient treated (t l ) 
Coo = cost of a healthy patient not treated (to) 
It is assumed that all patients are identical with the same characteristics and 
preferences towards health states and costs. It is also assumed that the costs and 
utilities of the treatment options for a given health state are the same before and 
after the introduction of the test. This excludes the possibility that: (a) the test 
itself has any therapeutic value; (b) it is an essential prerequisite to certain 
treatment; or (c) involves any notion of "process utility" where some value is 
gained by the patient from the process of testing over and above the increased 
probability of being treated appropriately following the test. This also excludes the 
possibility of the test providing prognostic as well as diagnostic information and it 
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ensures that knowledge of the costs and utilities of current practice before the test 
is introduced will be sufficient to evaluate the new diagnostic device. In this 
simple example it is assumed that the test is non-invasive and poses no risks to the 
patient. 
Following the notation of Phelps and Mushlin incremental utilities (IlUjjJ can also 
be defined as the utility gained from treating a patient correctly according to their 
health state, so that !lUijk is the utility gained by treating a patient in health state i 
with treatment j rather than treatment k. 
!lUllO = (Ull-UIO) 
!lUOOI = (UOO-UOI) 
= incremental utility of treating a diseased patient with tl 
= incremental utility of not treating a healthy patient 
Similarly incremental costs (!lCjjk) can also be defined as the cost of treating a 
patient in state i with treatment j rather than treatment k. 
!lClIO = (Cll-C IO) 
!lCOOI = (COO-COl) 
= incremental cost of treating a diseased patient with tl 
= incremental cost of not treating a healthy patient 
The decision problem facing the clinician for an individual patient before the 
diagnostic device is available is a simple choice between treatment with tl and no 
treatment. When the diagnostic test is available the clinician can also decide to 
test and treat according to the test results, where tl will follow a positive result 
and to will follow a negative test result. 
Using the notation for this simple problem the question of whether the clinician 
should choose treatment or no treatment without the diagnostic test and whether 
the clinician should use the diagnostic test when it becomes available can be 
addressed. The impact on the expected health outcomes and expected costs of 
implementing this diagnostic technology can also be established. Indeed with this 
limited information it is possible to estimate how much the clinician should be 
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willing to pay for perfect information, and also for the imperfect clinical 
information generated by the new test. These two values of information are the 
essential elements in the first and second hurdles respectively, and can be 
compared to an estimate of the cost of the new diagnostic technology to establish 
whether it will be cost-effective. 
Table 2.2 
It is assumed that information on the U ij and Cij (which are part of current practice 
before the new test is introduced) is available. The values of all the variables used 
in this simple numerical example are reported in table 2.2. The approach 
proposed by Phelps and Mushlin combines information from a variety of sources 
including observations of current practice and makes inferences about a new 
diagnostic technology based solely on information which should be available 
before the new test is introduced. However the Phelps Mushlin strategy does not 
provide any explicit method to take into account the variable quality of 
information from different sources. This issue is addressed in chapters 4, 5 and 6 
by using a Bayesian approach where prior distributions are assigned to the key 
variables. 
2.2.2 Selecting the Fallback Strategy 
The first step in the evaluation of a new diagnostic device is to establish the 
appropriate baseline against which it should be compared. The appropriate 
baseline or the relevant alternative is what the clinician should do in the absence of 
further ~iagnostic information. This is called the fallback strategy by Phelps and 
MushIin. The value of information is the additional value that it provides and this 
depends crucially on what the clinician would do if the information was not 
available. In this simple example before the introduction of the test the decision 
problem facing the clinician is to treat with t, or not to treat (to). With no other 
21 
diagnostic information this decision must be based on the clinician's prior belief 
about the likelihood of disease (f). This single-stage decision problem is 
illustrated in figure 2.2.1 and it represents current practice before the new test is 
available. The problem is to select the optimal fallback strategy in the absence of 
diagnostic information. This optimal fallback strategy will be the appropriate 
baseline (relevant alternative) with which to compare a new diagnostic device. 
Figure 2.2.1 
Following the decision rules used in the traditional cost-effectiveness approach to 
the choice between two mutually exclusive alternatives 78, 136, 139, 141, the first step is 
to establish the expected utility oftj (E(U) = f.U1j + (l-f).UOj)' The incremental 
expected utility of choosing tl rather than to is the difference between E(U1) and 
E(Uo): 
E(U1) - E(Uo) = f(Ull-UIO)-(l-f),(Uoo-Uol) 
= fL\Ullo-(I-f).L\Uool 2.2.1a 
The expected cost oftj (E(C) = fC1j+(1-f).Coj) must also be established and the 
incremental cost of choosing tl rather than to is the difference between E(C1) and 
E(Co): 
E(C1) - E(Co) = f(CU-CIO)-(I-f).(COO-C01 ) 
= fL\C llO-(I-f).L\COOl 2.2.1b 
The traditional cost-effectiveness approach is to establish the incremental cost-
effectiveness ratio of choosing tl rather than to. This represents the cost per unit 
of health utility gained by moving from to to t1. To choose between these two 
options (in the absence of dominance) this ratio must be compared to the critical 
cost-effectiveness ratio (1/g) which, with a fixed budget or capital constraints, is 
the cost-effectiveness ratio of the marginal project which will be displaced iftl is 
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implemented and the positive incremental costs of tl are incurred 78, 108, 141. The 
critical cost-effectiveness ratio is the cost per unit of health utility gained which 
should be worth paying given the budgetary restrictions on service provision. It 
is the implicit monetary value placed on health outcome by the existing budget 
constraint. The decision rule is to choose tl if: 
2.2.2a 
An equivalent decision rule would be to choose tl if the effectiveness-cost ratio is 
greater than the critical effectiveness-cost ratio (g): 
2.2.2b 
The critical effectiveness-cost ratio (g) is the shadow price of the budget 
constraint on service provision and is the minimum improvement in health 
outcome per additional unit of cost the clinician should accept. When one 
alternative does not dominate the other it is not possible to make consistent 
decisions without reference to a critical ratio or a value of health outcome. 
However once the a critical ratio has been established 16, 57, 71, 77, 86, 141 then health 
utilities can be rescaled into monetary terms using 1/g, or equivalently monetary 
values can be rescaled into health utilities using g. Equation (2.2.2a) can be 
rearranged and the same decision rule can now be expressed in terms of net 
benefit measured in health utility. The clinician should choose tl if the net benefit 
of tl is greater than the net benefit of to, and the incremental net benefit of tl is 
positive: 
2.2.2c 
Or alternatively choose tl if the net benefit of treating those with disease is greater 
than the net benefit of not treating those without the disease: 
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2.2.2d 
Iftl is chosen then the gains from treating those with disease (LlUllO-g.LlCllO) with 
a probability of f should exceed the benefits forgone (opportunity costs) from 
being unable to not treat those with no disease (LlUoo.-g.LlCOO1 ) with probability 
(I-f). 
An entirely equivalent decision rule would be to rescale health outcome into 
monetary terms by multiplying (2.2.2c) or (2.2.2d) through by Ilg, and then the 
net benefits would be measured on a monetary rather than a health utility scale. 
These decision rules will be equivalent to the net present value decision rule used 
in a Paretian cost-benefit analysis in the special case where all individuals have 
identical preferences and their marginal willingness to pay for additional health 
utility is the same and is equal to Ilg 108. 
What is clear from this discussion of decision rules is that when dominance does 
not exist placing a monetary value on health outcome is absolutely unavoidable if 
decisions based on cost-effectiveness (or "cost-utility") analysis are to be made. 
The only issue is whether this decision rule is made explicit by the analyst or 
whether it is abdicated to social decision-makers, where it may remain implicit and 
not open to criticism or alternative formulation. In this example, where the 
fallback strategy must be selected before the value of information can be 
established, the decision rule must be explicit and the explicit monetary valuation 
of health outcome by the analyst is unavoidable. This is a general characteristic of 
all sequential clinical decision problems (which involve contingent decisions and 
the comparison of a number of mutually exclusive alternative strategies) which 
poses some in~eresting methodological issues which are discussed in chapter 3. 
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Treatment Thresholds 
The selection of the fallback strategy can also be expressed in terms of a treatment 
threshold for f. The information in 2.2.2d can be rearranged to solve for the prior 
probability of disease where the clinician should be indifferent between tl and to. 
The point of indifference can be found by simply setting both sides of2.2.2d 
equal to each other and solving for fto give the treatment threshold flO: 
The clinician should select tl if the prior probability (f) is greater than flO but select 
to if f is less than flO' When f is equal to flO the clinician is indifferent between tl 
and to. At this point the clinician is most uncertain about which fallback treatment 
to select, and one would expect the value placed on information to reach a 
maximum at this point of uncertainty. The following parts of this chapter 
-demonstrate that the value of diagnostic information does indeed reach a 
maximum at these treatment thresholds. 
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The relationship between flO and the value of health outcome in this numerical 
example is illustrated in figure 2.2.2 and this demonstrates that the treatment 
threshold falls as the value placed on health outcome increases. 
Figure 2.2.2 
Figure 2.2.2 summarises efficient clinical practice for a range of possible values of 
health outcome. When the value placed on health outcome is low (less than 
£3,500) flO=1, and tl is never selected because the additional health benefits oftl 
are not worth the additional costs. Indeed at extreme values when 1/g=O no value 
is placed on health benefits and this "accountancy decision rule" is simple cost-
minimisation irrespective of health benefits. The least cost option (to) will be 
selected in all circumstances. At the other extreme when g is equal to zero 2.2.3 
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collapses to the clinical treatment threshold. No value is placed on resource costs 
and this purely clinical decision rule selects the most effective treatment. An 
infinite value is placed on health outcome. As l/g approaches infinity flO tends to 
its limit (lim(ftO)) which in this numerical example is at a prior probability of 
disease of 1/3. 
2.2.3 The TestITreatment Decision 
Selecting the efficient fallback strategy is essential because it provides the 
appropriate baseline or relevant alternative against which the information provided 
by a diagnostic device can be valued. When the new diagnostic device is available 
the clinician faces the choice of whether to use the test and treat according to the 
test results, where t1 follows a positive test result and to follows and negative 
result, or to choose not to test and use the efficient fallback strategy. The value of 
information is the difference between the net benefit when the test is used and the 
net benefit of the fallback strategy. The clinician should choose to test if the value 
of information is greater than the costs of the test. This decision problem is 
illustrated in figure 2.2.3. 
Figure 2.2.3 
Almost all diagnostic devices are imperfect and the accuracy of this proposed new 
test is expressed in terms of sensitivity (p) and specificity (I-q). The test is 
imperfect and it produces false positive results (q), and false negative results (l-p). 
Initially it is assumed that there is only one way to operate the test and there is no 
possible trade-off between sensitivity and specificity. However this will be relaxed 
when optimal test operation and ROC challenge regions are discussed. 
The decision problem illustrated in figure 2.2.3 follows the presentation adopted 
by Phelps and Mushlin 107. The "no test" arm of the decision tree represents the 
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fallback strategies which were illustrated in figure 2.2.1. However, the "test" arm 
of the decision tree does not follow the actual chronology of events because the 
first event should be the result of the diagnostic test rather than the disease state 
and the second event should be the predictive values rather than sensitivity and 
specificity. These should occur after the treatment choice has been made. This 
presentation was adopted by Phelps and Mushlin (and has been used by others) 
because sensitivity and specificity enter directly into the tree and this avoids 
Bayesian probability revision. Although it is not intuitively appealing, in this case 
it is equivalent to a structure which follows the correct chronology using Bayes. 
The presentation in this chapter and the next follows Phelps and Mushlin for 
consistency with their approach, but in later chapters of the thesis decision 
problems will be structured in the correct chronology 39, 56, 59, 115, 132, 137. 
2.2.4 The Expected Value of (Imperfect) Clinical Information 
The Expected Value of Clinical Information (EVCI) is the difference between the 
expected net benefit of using the test and using the fallback strategy, so there is an 
expression (EVClj ) for each of the possible fallback strategies (j). 
The expected net benefit of testing is the difference between the expected utility of 
testing and the expected cost of testing (which is rescaled to utility values using 
g). For the diagnostic test in figure 2.2.3 the expected utility of testing is: 
f(p,UIl +( I-p ).UlO)+( I-f).« I-q). Uoo+q· VOl) 2.2.4a 
and the expected cost of testing is: 
f (p. CIl +( I-p). ClO)+( I-f). « I-q). Coo +q. COl) 2.2.4b 
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The EVeI when treatment is the fallback 
The incremental utility of testing when treatment tl is the fallback strategy is 
simply the difference between the expected utility of testing (2.2.4a) and the 
expected utility of the fallback tl (fUll+(1-f).U01): 
-f( I-p ).~ UllO+( I-t).(l-q).~ UOOl 2.2.Sa 
Similarly the incremental cost of testing (rescaled to utility using g) when tl is the 
fallback strategy is the difference between 2.2.4b and the expected cost of 
treatment (fC11+(I-t).Co1): 
2.2.Sb 
The Expected Value of Clinical Information when tl is the fallback strategy 
(EVCI1) is the incremental net benefit of testing, or the difference between the 
incremental utility (2.2.Sa) and the rescaled incremental cost of testing (2.2.Sb). 
The clinician should use the diagnostic test if the EVCI1 is greater than the 
average variable cost of the test (C'te) rescaled to health utility: 
EVCI1 = -f(l-p).(aUuo-g·aCllo) 
+(I-t).(I-q).(au()(ll-g·aCool) > g.C /te 
2EVCI/c3f = -(I-p).(aUllo-g.aClJo) 
-(I-q).(aUoo1-g.aCOO1 ) < 0 
2.2.Sc 
. 2.2.5d 
This derivation shows that when the fallback is to treat then the key issue in 
deciding whether to use the test is the net losses arising from testing and not 
treating false negatives (~Ullo-g.~CllO) compared with the gains from testing and 
not treating true negatives (aUoocg·aCOOl). The value of information will fall as f 
increases (2.2.Sd) because when f=1 the test will generate some negative results 
28 
all of which will be false and some patients with the disease will not be treated, but 
treatment without testing will not incur any costs of unnecessarily treating healthy 
patients. So at this extreme the value of imperfect information will be negative 
(with a fixed combination ofp, and q). 
The EVeI when no treatment is the fallback 
The incremental utility of testing when no treatment (to) is the fallback strategy is 
simply the difference between the expected utility of testing (2.2.4a) and the 
expected utility of no treatment (fUlO+(l-f).Uoo): 
fp.~UllO+(l-f).q.~UOOl 2.2.6a 
Similarly the rescaled incremental cost of testing when to is the fallback strategy is 
the difference between 2.2.4b and the expected cost of no treatment (fClO+(l-
f).Coo):-
2.2.6b 
The Expected Value of Clinical Information when to is the fallback strategy 
(EVCIo) is the difference between the incremental utility (2.2.6a) and the rescaled 
incremental cost of testing (2.2.6b). The clinician should use the diagnostic test if 
EVCIo> g.C'lc 
EVCIo = fp.(~UI10-g·~CllO) 
-(1-f).q.(~UOO1-g·~COO1) > g.c1c 
2EVCIJaf= P.(~UllO-g.~CllO) 
+q.(~Uool-g.~COO1) > 0 
2.2.6c 
2.2.6d 
When the fallback is not to treat then the decision can be based on the loss from 
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testing and treating false positives (~UOOl-g.~COOl) compared with the gains from 
testing and treating true positives (~Ullo-g.LlCllO). The EVClo will fall as fis 
reduced (2.2.6d) because when f=0 the test will generate some positive results all 
of which will be false and some healthy patients will be treated, but no treatment 
without testing will not incur any costs of not treating patients with the disease. 
At this extreme the value of imperfect information will also be negative because of 
false positive results. 
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2.3 A Strategy for Focusing Clinical Research 
2.3.1 Hurdle I: The Expected Value of Perfect Information 
The Expected Value of Perfect Information (EVPI) is the maximum value that any 
proposed diagnostic test could provide. It is an upper bound on the value of 
information and is used to create the first hurdle in the strategy proposed by 
Phelps and Mushlin. If the costs of the diagnostic test exceed the maximum EVPI 
then the test can never be cost-effective and further evaluation is unnecessary. 
However ifEVPI>g.C'te then the diagnostic device is potentially cost-effective 
over some range of prior -probability of disease and the test passes the first hurdle. 
The EVPI can be derived from the expressions for EVCIj by simply setting the 
sensitivity (p) and specificity (l-q) of the test equal to one in (2.2.Sc) and (2.2.6c). 
The expected value of perfect information when tl is the fallback strategy (EVPI1) 
is as follows: 
EVPII = (l-f),(~Uool-g·~C()()J) 
aEVPI1/af= -(Uoo1-g.Coo1) < 0 
2.3.1a 
2.3.1b 
The EVPII falls with f, but now when f=1 the value of information will be zero 
because a perfect test does not incur the cost of not treating patients with false 
negative results. 
The EVP10 (when to is the fallback) is as follows: 
EVPIo = f(~Ullo-g,~CllO) 
aEVPIoIaf= (UllO-g.CllO) > 0 
2.3.1c 
2.3.1d 
The EVPIo increases with f but now when f=0 the value of information is zero 
because there are no costs of treating false positive results. 
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The EVPlj can be calculated based solely on the utilities and costs oftl and to and 
the prior probability of disease. Since tl and to are part of current practice and the 
utilities, costs, and probabilities required are implicit in current clinical decision-
making, it may be reasonable to assume that this information is available prior to 
the introduction of the test. Indeed this first hurdle can be constructed without any 
knowledge of the characteristics of a proposed diagnostic device and it relies only 
on the decision-problem currently facing clinicians. 
This first hurdle is constructed for the numerical example by calculating the EVPI 
for the full range of the prior probability of disease. The EVPI for this numerical 
example is illustrated in figure 2.3.1a and is rescaled to monetary values using a 
value of health outcome of £4,000 per unit of health utility gained. 
Figure 2.3.la 
From equation (2.2.3) and figure 2.2.2 when lIg=£4,000 the treatment threshold 
flo is equal to 0.8. When f<flO no treatment is the fallback strategy and the EVPIo 
rises with f, but when t>flO treatment is the fallback and the EVPII falls with f, and 
when f=flO the clinician is indifferent between tl and to. At this point the EVPI 
reaches a maximum of £3,200 in figure 2.3.1 a where the clinician is most 
uncertain about which fallback strategy to adopt. 
The first hurdle compares the EVPI to an estimate of the variable cost of the new 
diagnostic device. Figure 2.3.1a illustrates two proposed diagnostic technologies. 
The first has an estimated variable cost ofC'lcl=£3,500, which is greater than the 
maximum EVPI. It will never be cost-effective and should be rejected at this first 
hurdle. The second test has a cost of C 'lc2=£2, 500 and it is potentially cost-
effective for patients with a prior probability of disease between fo and fl. This 
diagnostic test passes the first hurdle and is potentially cost-effective, but clinical 
research to establish the characteristics of the test is required before the cost-
effectiveness of this test can be established and the new technology implemented. 
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The EVPI in figure 2.3.1a represents the value of perfect information for an 
individual patient with a particular prior probability of disease. However a new 
diagnostic technology may have large fixed costs (c ) associated with its te 
implementation, and the prevalence of disease in patient population which enters 
the decision problem in figure 2.2.3 may have a continuous distribution of <j>(f). 
The first hurdle can be amended so that the population EVPI is compared to the 
total cost of implementing the proposed technology. The proposed test will pass 
the first hurdle if: 
flo f\ f\ f EVPIoCf)cpCf)df + f EVPI[Cf)<j>Cf)df > g.C'te J <j>(f)df + g,C te 2.3.1e 
~ ~o ~ 
The relationship between the expected value of perfect information and the value 
placed on health outcome is illustrated in figure 2.3.1b and 2.3.1c. As the value of 
health outcome increases the value of information also increases and the first 
hurdle is dependent on the selec~ion of l/g. 
The value of health outcome determines two aspects of the EVPI: the point at 
which information is most valuable; and the value placed on that information. In 
figure 2.3.1b the treatment threshold flO where the EVPI reaches a maximum falls 
with 1/g from 0.8 when 1/g=£4,000, to 0.414 when l/g =£20,000. This 
relationship between l/g and fLO was illustrated in figure 2.2.2 and indicates that as 
the value placed on health outcome increases the more effective but more costly 
alternative becomes optimal at lower prior probabilities. The value of information 
also increases and wh~n 1/g=£4,000 the maximum EVPI is £3,200, but when 11g 
is increased to £20,000 the maximum EVPI rises to £28,128. 
Figure2.3.1b 
Figure 2.3.1c 
These two aspects of the relationship between the EVPI and l/g are illustrated in 
figure 2.3.1c, but this also illustrates that when l/g is low (less than £3,100) the 
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EVPI is negative. This is because treatment following a true positive test result is 
not worth the additional costs, and this is also demonstrated in figure 2.2.2 where 
flO=1 when IIg<£3,100, and it is never efficient to choose tl even when the 
probability of disease is very high. 
2.3.2 Hurdle n: The Expected Value of (Imperfect) Clinical Information 
If a proposed diagnostic technology passes the first hurdle it is potentially cost-
effective and the next step is to establish the characteristics of the test through 
prospective clinical research. Once the sensitivity (p) and specificity (l-q) of the 
test are established the EVCI can be estimated and compared the cost of the test. 
If the new test is non-invasive then randornised patient selection will be 
unnecessary because diagnosis with the new test and with a "gold standard test" 
can be conducted on the same patients. 
The EVCI is calculated for this numerical example and is illustrated in figure 
2.3.2a. The EVCI reaches a maximum at flO=0.8, but the maximum EVCI is 
lower than the maximum EVPI due to false positive and false negative results. 
The EVCI1 falls with fwhen t>flO and the EVCIo rises with fwhen f<flO, 
illustrating equations (2.2.Sd), and (2.2.6d) above. 
Figure 2.3 .2a 
The EVCI becomes negative at extreme values of f: when f= 1 the imperfect test 
will produce some negative results all of which will be false and some patients 
with the disease will not be treated, in this case it is better to use the fallback 
strategy of treating everybody; when f=0 the test will produce some positive 
results all of which will be false and some patients will receive unnecessary 
treatment, in this case it will be better not to treat without testing. 
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At the second hurdle the EVCI of a potentially cost-effective test is compared to 
an estimate of the variable cost of the new test. Three estimates of the cost of the 
new device are illustrated in figure 2.3.2a. If the estimated cost of the new test is 
high (C"cl=£3,500) the test fails at the first hurdle: it is not potentially cost-
effective and no further research is required. When the estimated costs are lower 
(C,c2=£2,500) the test passes the first hurdle and is potentially cost-effective, but 
when the accuracy of the test is established it fails at the second hurdle. However 
if the estimated cost was lower still (C"c3=£1,500) the test will pass both the first 
and second hurdles and will be cost-effective for patients with a prior probability 
of disease between fo and fl' 
The second hurdle can be amended in the same way as the first so that the 
population EVCI can be compared to the total cost of implementing the proposed 
technology including any fixed element. The proposed test will pass the second 
hurdle and should be implemented if: 
flo fl fl f EVCIo(t)<t>(t)df + f EVCI1Cf)<t>Ct)df > g,Cte f <t>(f)df + g,C te 2.3.2 
fo flo fo 
The relationship between the EVCI and lIg is illustrated in figure 2.3 .2b and 
2.3.2c, and the value of imperfect clinical information also increases with the value 
placed on health outcome. Both the first and second hurdles are dependent on the 
value selected for 1/g. 
Figure 2.3.2b 
Figure 2.3 .2c 
The value of health outcome determines the point at which information is most 
valuable, as well as the value placed on clinical information. Just as in figure 
2.3.2b the treatment threshold (fiO) where the EVCI reaches a maximum falls with 
I/g. The maximum EVCI also increases with I/g: from £2,240 when lIg=£4,OOO 
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to £19,416 when lIg = £20,000. However figure 2.3.2b and 2.3.2c also illustrate 
that the value placed on false negative and false positive results also increases with 
lIg and the EVCI at extreme values of f where EVCI<O falls as lIg increases. 
2.3.3 The Optimal Test Operation 
The construction of the second hurdle requires information on the accuracy of the 
test. So far it has been assumed the test is binary and there is only one 
combination of p and q which is available. However most diagnostic tests allow a 
trade-off between the sensitivity of the test and the specificity. The possible 
combinations of p and q, and the trade-off available can be described by an ROC 
curve. The information used to construct the first hurdle can also be used to 
identify the optimal combinations of p and q where the test should be operated. 
The approach taken by Phelps and Mushlin takes the full differential with respect 
to p and q of an expression for the net benefit of testing (NBtc)' The optimal 
trade-off between p and q (dp/dq) or slope of the ROC curve can then be found. 
The net benefit of testing is given by: 
NBte = f (p. Ull +(l-p). U 1O)+(l-f)· ((I-q). V 10 +q. VOl) 
-g.(f(p. Cll+(l-p ).ClO)+( I--f).((I-q). ClO+q· COl» 
The full differential of the net benefit of testing: 
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2.3.3a 
2.3.3b 
by setting dNB tc =0 and solving for dp/dq: 
dp/dq = (l-f).(DoUool-g.DoCool) /f.( DoUllo-g.DoCllo) 
= EVPI/EVPIo 2.3.3c 
The optimal dp/dq or slope of the ROC curve is the ratio of the expected value of 
perfect information when t1 is the fallback, to the expected value of perfect 
information when to is the fallback. This is equivalent to setting the consequences 
of designating a result as positive equal to the consequences of designating a 
result as negative and rearranging so the likelihood ratio or the slope of the ROC 
curve is the product of the ratio of prior probability of no disease and disease and 
the ratio of the net consequences of no disease and disease 72, 107, 137. 
The optimal dp/dq is simply the ratio of the expected costs offalse positive and 
false negative results and optimal test operation is similar to establishing technical 
efficiency in production by ensuring that the ratio of factor input prices is equal to 
the marginal rate of technical substitution between these inputs in production. 
Production will be technically efficient at a point of tangency between the isoquant 
(ROC curve) and the budget constraint (dp/dq). If the relative factor prices 
(expected cost of false positive and false negative results) change then the slope of 
the budget constraint (dp/dq) will change. The point of tangency with the 
isoquant (point on the ROC curve) will shift and the technically efficient factor 
input (optimal combination of sensitivity and specificity) also changes. 
Figure 2.3.3 
Equation (2.3.3c) shows that the optimal test operation is dependent on both the 
prior probability of disease and the value placed on health outcome. Figure 2.3.3 
illustrates how the range of prior probabilities from the first hurdle in figure 2.3.1a 
can be used to define the economically relevant portion of the ROC curve. The 
optimal points dp/dql and dpJdqo are based on the range of prior probabilities of 
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disease where the test is potentially cost-effective (fl and fo respectively). dp/dql 
and dpJdqo defines the economically relevant portion of the ROC curve. When f 
is low (at fo=0.38) the expected cost of false positive results is relatively high and 
the optimal point on the ROC curve will substitute reduced false positives for 
increased false negatives (dpoldqo=6.53). When fis higher (fl=0.905) the expected 
cost of false negatives is relatively high and optimal test operation will substitute 
reduced false negatives for increased false positives (dp/dql=0.42). 
This strategy makes it clear that it is unnecessary to evaluate the whole ROC 
curve and the first hurdle can be used to focus prospective research on the 
economically relevant range of test characteristics. Points on the ROC curve with 
a slope greater than dpoldqo or less than dp/dql are irrelevant because the 
diagnostic test will never be cost-effective when operated beyond these points. 
Phelps and Mushlin go on to define ROC challenge regions: the minimum 
combinations ofp and q which a new device must achieve to be cost-effective. 
The first hurdle then asks ifthere is any prospect of a new technology achieving a 
point within the challenge region, if not the test fails at the first hurdle. This 
approach also makes it clear that the optimal operation of diagnostic technology is 
dependent on specifying a value of health outcome. If economic criteria are used 
to evaluate a new technology then the same criteria must be used to establish how 
it should be operated before an economic evaluation can take place. The selection 
of lIg prior to the economic evaluation is unavoidable. 
2.3.4 Focusing Clinical Research 
The Phelps Mushlin strategy and their proposed hurdles can be constructed based 
solely on prior information about health outcomes, costs, prior probabilities of 
disease and a measure of the accuracy of the test. It can combine information 
which may already be available from a variety of sources. Health outcomes can be 
based on literature review and observation of current practice and health state 
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utilities can be elicited using established methods. Similarly, information on prior 
probabilities and the distribution of probabilities of disease can be based on 
published epidemiological studies. The costs of treatment can be estimated by 
observing current practice or may be readily available from routinely collected 
information. However the approach proposed by Phelps and Mushlin does not 
include any way to take into account the variable quality of information from 
different sources, and this issue will be addressed in chapters 4, 5, and 6 where 
prior distributions are assigned to the health outcomes and path probabilities. 
This strategy not only focuses clinical research by eliminating those proposed new 
technologies which will not be cost-effective, it also focuses prospective clinical 
research on potentially cost-effective devices, and on those variables where prior 
information is not available. The only information that will require prospective 
research is the accuracy of the new test, and if the test is non-invasive this can be 
done without patient selection and randomised design can be avoided. 
Furthermore if the diagnostic test allows a trade-off between sensitivity and 
specificity the first hurdle can define the economically relevant portion of the ROC 
curve and the clinical evaluation of the whole ROC curve will be unnecessary. It 
provides an approach to the economic evaluation of clinical information which can 
avoid randomised trial designs which include both the diagnostic and treatment 
process. This could substantially reduce the cost of research and development in 
terms of resources, the opportunity cost of delaying the implementation of cost-
effective technology (or providing evaluative evidence before an unproven 
diagnostic technology is widely implemented), and the opportunity costs to 
'individuals enrolled in less effective arms of a clinical trial. 
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Table 2.2 A Numerical Example 
Utilities Incremental Costs (Cij) Incremental Costs 
(Vij) Utilities (D.Uijk) (D.C ijk) 
U ll 6 D.UlIO 4 ClI £12,000 D.C 1IO £12,000 
UOI 8 D.UOOI 2 COl £8,000 D.COOI -£8,000 
U IO 2 CIO £0 
Uoo 10 Coo £0 
The characteristics of the proposed diagnostic test are: p=0.9, and q=0.2 
Figure 2.2.1 Decision Tree for the Fallback Decision 
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3.1 Introduction 
The approach to the economic evaluation of diagnostic information which was 
outlined in the previous chapter has a number of advantages and attractions: it is 
consistent with economic decision rules; it enables research to be focused on new 
diagnostic technologies which are potentially cost-effective; and it can combine 
information that is available from a number of different sources. However the 
presentation of the approach by Phelps and Mushlin and its application to a simple 
numerical example assumed that there is only one possible treatment for a given 
diagnosis. This is clear in figure 2.2.3 where the decision problem facing the 
clinician is simply whether to test and treat according to test results: where tl 
follows a positive test and to follows a negative test. Treatment following 
diagnosis is determined only by the test result and this implies that no other 
treatment alternatives are possible. The approach has simply added a diagnostic 
device to existing patient management strategies and clinical practice is changed 
only to the extent that the test changes the probability of assigning a patient to a 
particular diagnosis. 
However in most clinical decision problems there is a range of treatment 
alternatives (and other diagnostic processes) which are at least possible following 
the results of the test, even if these alternatives are currently not used as part of 
existing patient management. In these circumstances where there is more than one 
treatment alternative for a given diagnosis, diagnostic iIiformation may change 
patient management by changing the probability of assigning a patient to a 
particular diagnosis and by changing the optimal treatment choice. To establish 
the circumstances in which this strategy will be appropriate to these less restrictive 
decision problems the first step is to generalise the Phelps Mushlin strategy to 
accommodate more than one treatment for a given diagnosis and identify the 
assumptions that are required. The second step is to examine the consequences of 
violating these assumptions. 
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3.2 Generalising the Phelps l\lushlin Strategy 
In this section the approach is generalised and applied to the same numerical 
example but with an additional treatment option (t2). This treatment is less costly 
than tl but is less effective for those with the disease, although it has fewer side 
effects than t1 for patients with no disease. The details of this numerical example 
are reported in table 3.2.1. The decision problem facing the clinician before the 
test is introduced is to choose either to, t1, or t2 . Once the test is introduced the 
clinician can choose to test and treat with either tl or t2 following a positive result, 
and to following a negative result. This decision problem is illustrated in figure 
3.2.1. 
Table 3.2.1 
Figure 3.2.1 
Following chapter 2 it may be reasonable to assume that some information on the 
costs and health utilities of these three treatment alternatives will be available if 
- they are part of e~sting patient management before the test is introduced. 
3.2.1 Selecting the Fallback Strategy 
FolIo_wing the presentation of the previous section the first step is to establish the 
appropriate baseline or fallback strategy. The clinician must now decide whether 
to treat with either tl or t2 0r to select no treatment. The same decision rules from 
(2.2.2a) and (2.2.2b) can be applied to the choice between to and tl and t2• The 
equivalent deCision rule from (2.2.2d) can be expressed in terms of net benefits 
and tj 0=0, 1, 2) should be chosen rather than tk (k=O, 1, 2) if: 
3.2.la 
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This decision rule can also be expressed in terms of a treatment threshold for f and 
tj should be chosen rather than tk if f>~k where: 
3.2.1b 
There are now three treatment thresholds: f20, where the clinician is indifferent 
between to and t2; flO, where the clinician is indifferent between t1 and to; and f12 
where the clinician is indifferent between t1 and t2. These thresholds are illustrated 
for this numerical example in figure 3.2.2 and summarise the selection of optimal 
fallback strategies. 
Figure 3.2.2 
The treatment threshold flO is the same as in figure 2.2.2, but now t2 is also 
available to the clinician and in this numerical example f20~flO~f12. Efficient clinical 
practice is as follows: when f<f20 the clinician should select to; when f20<f<f12 the 
clinician should select t2; and when f>f12 the clinician should select t1• Although 
there are three treatment thresholds there are only two points where the clinician 
will be most uncertain about selecting the fallback strategy: when they are 
indifferent between no treatment and treatment (with either tl or t2); and when 
they are indifferent between the treatment options. A treatment threshold (£'*) can 
be defined as the minimum of flO and f20 (in this case f20~flO and £'*=f20) and the 
clinician will be uncertain about selecting treatment or no treatment at £'*=f20 and 
about selecting which treatment option at f=fI2. There are now two points where 
the value of clinical information may reach a maximum. 
Figure 3.2.2 also illustrates the relationship between the value of health outcome 
and efficient clinical practice. When l/g is low (in this case less than £1,500) 
f20=flO=fI2=1, and there is no value of f where either treatment would be efficient. 
to should be chosen in all circumstances. Figure 3.2.2 shows that when t2 is 
available it will be efficient to treat at lower prior probabilities of disease. When 
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1Ig=£4,000 the clinician will move from no treatment to treatment when freaches 
0.533 rather than 0.8 when only t\ is available. Indeed at this value of 1Ig, t\ is 
never part of current practice because f12= 1. t\ only becomes part of the fallback 
strategy when 1/g~£5,000 and ±;2<1. 
As the value placed on health outcome is increased the treatment thresholds fall 
and in the limit the thresholds collapse to purely clinical decision rules. In this 
particular numerical example f20=flO=f\2=1/3 when g=O and when a purely clinical 
decision rule is used t2 will not be part of the fallback strategy because when 
f< 113, to should be chosen but when f> 113, t\ should be chosen. If t2 is not part of 
existing patient management then information on the utilities and costs of the 
treatment will not be available by simply observing current practice. By making 
minor changes to this numerical example it can be shown that t2 will not be part 
of existing patient management even when economic rather than purely clinical 
decision rules are used. This poses a problem for Phelps Mushlin approach which 
will be examined in more detail in section 3.3 of this chapter. 
3.2.2 The Expected Value of Clinical Information 
The Expected Value of Clinical Information is the difference in expected net 
benefit between the test and the fallback strategies. The EVClhj can be defined for 
each combination of the three possible fallback strategies 0=0,1,2) and two 
possible testing strategies (h=l, 2) where the clinician can treat with t1 (h=l) or t2 
(h=2) following a positive test and 'to following a negative test. 
The EVClhj is equivalent to the EVClj (2.2.5c) when treatment with either t\ or t2 
is the fallback and the fallback treatment is the same as the treatment which 
follows a positive test result 0=h=1,2). 3.2.2a is equal to 2.2.5c whenj=h=l. 
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EVClhj = -f.(1-p).(b.U\jO-g.b.C\jo) 
+(l-f).( l-q).(b. Uoorg·b.COOj) 3.2.2a 
The EVClhj falls with f and (3.2.2b) is equal to (2.2.5d) whenj=h=1. 
aEVCIh/af= -(1-p).(b.U\jO-g·b.C1jO) 
-(l-q).(b.Uoorg.b.COOj) < 0 3.2.2b 
The EVClhj is equivalent to the EVClo (2.2.6c) when no treatment is the fallback 
strategy (j=0; and h=1,2) and (3.2.2c) is equal to (2.2.6c) when h=1. 
EVCIho = f.P·(b.UlhO-g·b.ClhO) 
- (I-f). q. (b. UOOh -g.b. CooJ 3.2.2c 
The EVCIhj rises with f and (3.2.2d) is equal to (2.2.6d) when h=l: 
aEVClhJaf = P·(b.UlhO-g·b.ClhO) 
+ q.(b.UOOh-g.b.COOh) > 0 3.2.2d 
Now that two treatments are available it is possible that the fallback strategy is to 
treat but the fallback treatment is not the same as the treatment which follows a 
positive test result (j",h=l, 2). The diagnostic device not only changes the 
probability of assigning a patient to a particular diagnosis but it can also change 
the optimal treatment choice for a given diagnosis. In these circumstances the 
. EVCIhj is not equivalent to the EVClj. 
EVCIhj = f.(P·(b.UlhO-g·b.ClhO)-(b.UljO-g·b.CljO» 
- (1-0·( q.(b. Uooh-g·b.CooJ-(b. Uoorg.b.Cooj» 3.2.2e 
The EVCIhj will fall with f if: 
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c3EVCIh/c3f= P·(~UlhO-g·~ClhO)+q·(~UOOh-g·~COOh) 
-((~UljO-g.~CljO)+(~Uoorg.~COOj)) < 0 3.2.2f 
If the c3EVCI1ic3f< 0 then the EVCI will reach a maximum at f20, but if 
c3EVCI12/c3f> 0 then the EVCI will reach a maximum at f12. The value of 
c3EVCI12/c3fis determined by the ~Uijk and ~Cijk from table 3.2.1, and the value of 
health outcome: when g=O the c3EVCI12/c3f>O and the EVCI reaches a maximum 
at f12, but when 1/g low then c3EVCI12/c3f <0 and the EVCI reaches a maximum at 
f20· 
3.2.3 Hurdle I: The Expected Value of Perfect Information. 
The EVPlhj is derived from the· expressions for the EVCIhj in the same way as in 
chapter 2 by setting p=1 and q=O. The EVPIhj when treatment is the fallback and 
the fallback and test/treatment strategies are the same G= 1 ,2; and h=j) is 
equivalent to the EVPIj (3.2.3a is equal to 2.3.1a when h=l), and from 3.2.2a: 
3.2.3a 
The EVPIhj falls with f and from 3.2.2b: 
3.2.3b 
The EVPlhj when no treatment is the fallback 0=0; and h= 1 ,2) is equivalent to the 
EVP10 (3.2.3c is equal to 2.3.1c when h=l), and from 3.2.2c: 
3.2.3c 
The EVPlhj rises with f, and from 3.2.2d: 
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3.2.3d 
If the fallback is to treat but the fallback treatment is not the same as the treatment 
following a positive test result U # h= 1 ,2) the EVPlhj will not be equivalent to the 
EVPJ. J. 
EVPlhj = f((dUlhO-g·dClhO)-(dUljO-g·dCljO)) 
- (l-f).(q.(dUOoh-g·dCoOh)-(dUoorg·dCooj») 3.2.3e 
The EVPlhj may rise or fall with fdepending on the values of llUij, llC;j, and 1/g, 
and from 3.2.2f: 
c3EVPlh/c3f= (llUlhO-g·llClhO) 
-( (ll Uljo-g.llCljO)+( II Uoorg·ll Coo)) 3.2.3f 
The first hurdle for this numerical example is constructed by calculating the EVPI 
for the full range of prior probability of disease and this is illustrated in figure 
3.2.3 where the EVPI has been rescaled into monetary values using 1/g=£4,000. 
Figure 3.2.3a 
The optimal treatment following a positive test result is t2. The EVPlhj reaches a 
maximum at f20 where the clinician is indifferent between to and t2 so when f<f20 
the fallback is not to treat, and from (3.2.3d) the EVPI20 rises with f. When £>f20 
the fallback is to treat with t2 and from (3.2.3b) the EVPIz2 will fall with f Now 
that tz is available, tl is not part of either the fallback or the test treatment strategy. 
If the cost of the test is £1,500 then it is potentially cost-effective when fo<f<f2. 
Figures 3.2.3b and 3.2.3c illustrate the relationship between the EVPlhj and the 
value of health outcome. The optimal treatment following a positive test is tl 
when 1/g is increased to £8,000 in figure 3.2.3b. The optimal fallback strategies 
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are as follows: when f<f20 the fallback is to and the EVPI rises with f; when f.>f\2 
the clinician should select t\ as both the fallback and test treatment strategy and 
the EVPI falls with f; however when f20>f.>f\2 the clinician should select t2 as the 
fallback but t\ as the optimal treatment following a positive test result. The 
EVPII2 falls with fwhen 1/g~£12,000 and it reaches a maximum at f20, but when 
1/g>£12,000 the EVPI\2 rises with fand it reaches a maximum at f12. So once 
again the value placed on health outcome determines the point at which 
information is most valuable, and the value placed on the information. 
Figure 3.2.3b 
Figure 3.2.3c 
Table 3.2.2 details the optimal fallback and testing strategies which lie behind 
these figures, and shows that t\ does become part of both the fallback and testing 
strategy when l/g is increased. The shaded area indicates the circumstances in 
which the fallback is to treat but the fallback and treatment strategies differ. This 
is where the test changes the optimal treatment for a given diagnosis as well as 
changing the probability of being assigned to a particular diagnosis. If a 
diagnostic test not only changes the probability of being assigned to a particular 
d.iagnosis but also the optimal treatment for a given diagnosis then it will not be 
appropriate to simply add a diagnostic device to existing (fallback) strategies of 
patient management. 
Table 3.2.2 
The first hurdle operates in the same way as in the previous chapter: if the cost of 
the test is greater then the maximum value of the EVPI (at f=f20, or f=f12) then the 
device will never be cost-effective; but if the maximum EVPI exceeds the cost 
then the proposed test is potentially cost-effective over some range of prior 
probability of disease. The population EVPI can be estimated and compared to 
the total costs of implementing the new technology. In figure 3.2.3a (1/g=£4,000) 
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the population EVPI from (2.3 .1 e) requires only minor amendment. The device is 
potentially cost-effective if: 
~ q q 
J EVPI20(f)cp(f)df + J EVPI2if)cp(f)df > g.C'te J cp(f)df + g,C te 3.2.3g 
r. 1\ ( 
In figure 3.2.3b when 1/g=£8,000 and the variable cost is C'Ic2 then the population 
EVPI requires further amendment. The device will be potentially cost-effective if: 
q q fa 
J EVPIlO(f)cp(f)df + J EVPI1if)cp(f)df + f EVPI11(f)CP(f)df 
r. fl f. 
fa 
> g.C'te2 J cp(f)df + g,C te2 
r. 
3.2.3h 
3.2.4 Hurdle II: The Expected Value of(Imperfect) Clinical Information. 
The second hurdle is constructed for this numerical example by calculating the 
EVClhj for the full range of prior probability of disease. This second hurdle when 
1/g=£4,000 is illustrated in figure 3.2.4a. The optimal treatment following a 
positive test result is t2. Treatment t1 is not part of either the fallback or the test 
treatment strategies. The EVCI20 rises with f and the EVCI22 falls with f so that 
the EVCI reaches a maximum at f20. If the cost of the test is C'lcl=£1,500 then it 
will be cost effective when fo>f>f2 in figure 3.2.4a. 
Figure 3.2.4a 
The relationship between the EVCI and the value placed on health outcome is 
illustrated in figure 3.2.4b and figure 3.2.4c. The optimal treatment following a 
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positive test result now changes with the prior probability of disease. In figure 
3.2.4b when 1/g=£8,000 the optimal strategy is to use t2 following a positive test 
when the prior probability of disease is less than 0.34, but to use t} when £>0.34. 
As the value placed on health outcome increases, the probability of disease where 
the clinician is indifferent between using t2 or t} as the test treatment strategy falls, 
because t} is more costly than but more effective than t2· 
Figure 3.2.4b 
Figure 3.2.4c 
Table 3.2.3 details the optimal fallback and test treatment strategies which lie 
behind these figures. Treatment t} only becomes both the optimal fallback and 
testing strategy at higher prior probabilities of disease and at higher values of l/g. 
Indeed t} becomes the optimal treatment following a positive test while t2 remains 
the optimal fallback strategy. In this case the test changes the optimal treatment 
for a given diagnosis and the circumstances where the diagnostic test can't simply 
be added to existing patient management are indicated by the shaded areas in table 
3.2.3: 
Table 3.2.3 
There are now four combinations of fallback and test/treatment strategy which 
make up the second hurdle and it is clear that a new diagnostic device can not 
-
simply be added to existing strategies of patient management. The test changes 
the optimal treatment for a given diagnosis when f:w>£>f12 and the optimal 
treatment following a positive test results also changes with the prior probability 
of disease. 
The second hurdle operates in the same way as in chapter 2 and if the cost of the 
test is greater than the maximum value of the EVeI then there is no range of prior 
probability of disease where the test will be cost-effective and it should be 
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rejected. If the maximum value of the EVCI exceeds the cost of the test then 
there will be a range of prior probability of disease where the test will be cost-
effective. In the example illustrated in figure 3.2.4b the EVCI12 falls with [ when 
1/g=£8,OOO and the EVCI reaches a maximum at [20' however when 1/g~£12,OOO 
the EVCII2 rises with f and the EVCI reaches a maximum at f12. The population 
EVCI can be calculated in the same way as the population EVPI (but taking 
account of the changes in the test treatment strategy) and compared to the total 
cost of implementing the new technology. 
The preceding example illustrates how the Phelps Muslin strategy can be 
generalised to take account of more complex clinical decision problems where 
there is more than one treatment for a given diagnosis, and both hurdles can be 
constructed. However once more than one treatment for a given diagnosis is 
available a new diagnostic device cannot simply be added to existing patient 
management. Diagnostic information can now change patient management not 
only by changing the probability of assigning a patient to a particular diagnosis but 
also by changing the optimal treatment for a given diagnosis. 
Once an alternative treatment is available it is not necessarily the case that the 
treatment which may be optimal once the diagnostic device is in place will be part 
of existing patient management. In this example when lIg<£5,OOO tl is not part of 
existing patient management. Similarly when a purely clinical decision rule is used 
t2 will not be part of the fallback strategy and with minor changes to this numerical 
example t2 will never be part of current practice even when economic criteria are 
used to select current practice. If a treatment is not part of the fallback strategy 
then information on the Uij and Cij will not be available from observing current 
practice. The investigator may be forced to consider an experimental design 
which includes both the diagnostic test and the subsequent treatment choices. In 
these circumstances random allocation may be unavoidable. This generalisation 
has imposed a number of assumptions which are unlikely to hold in many clinical 
settings. These assumptions are discussed in more detail in the next section of this 
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chapter and the implications of violating these assumptions are illustrated using 
the same numerical example. 
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3.3 Consistency in the Evaluation of Diagnostic Information 
Although the strategy of economic evaluation proposed by Phelps and Mushlin 
can be generalised to more complex decision problems it depends critically on two 
assumptions: 
Firstly, as already noted in chapter 2, it is assumed that the decision problem 
facing the clinician prior to the introduction of the test must be identical to the 
decision problem when the test is introduced and the test results are known. The 
utilities and costs for a particular disease state and treatment alternative are 
identical before and after the test is introduced. This assumption enables the prior 
information about the Uij and Cij from current practice to be used to estimate the 
EVPI and EVCI. This assumption may be violated if: (a) the test also provides 
prognostic information; (b) the test results are required to direct treatment (for 
example coronary angiography prior to coronary artery surgery); or (c) if the 
results of the proposed diagnostic test are not conditionally independent of other 
diagnostic tests which may be part of current practice. 
Secondly any approach to economic evaluation which accepts current practice as 
an appropriate baseline (or relevant alternative) to evaluate a new diagnostic 
device implicitly assumes that the existing strategies of patient management are 
correct. In the context of an economic evaluation this means that existing . 
strategies of patient management must be cost-effective at the critical cost-_ 
effectiveness ratio (value ofheaIth outcome) selected to evaluate the new device. 
Current practice will only be the relevant alternative if there is consistency 
between the value of health outcome which is implicit in the selection of current 
practice (1/g) and the value of the critical cost-effectiveness ratio (CCER) which 
will be used to decide if the new technology will be cost-effective. 
This assumption is unlikely to hold because the appropriate critical cost-
effectiveness ratio (the shadow price of the budget constraint) is uncertain (due to 
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incomplete information on competing programmes within the budget) and depends 
crucially on the perspective of the evaluation which determines the budget that is 
regarded as relevant 16, 108, 141. There are a number of reasons to believe that the 
value of health outcome implicit in existing patient management may be greater 
than a CCER selected by an analyst. For example: clinicians may only consider 
clinical effectiveness or have a higher (infinite) implicit value of health outcome~ 
they may not perceive all the costs of the alternative patient management 
strategies~ or they may not have full information about the budget constraint they 
face and the competing programmes within the budget. 
If the value of health outcome implicit in the selection of current practice is 
greater than the CCER then an analysis which uses current practice as a baseline 
to value a new diagnostic device may overestimate the value of diagnostic 
information because it will be compared to an inefficient fallback strategy. Ifboth 
the fallback and the test/treatment strategy are selected using a value of health 
outcome which is inconsistent with the CCER then the analysis can be subject to 
two types of errors at each of the two hurdles. The value of clinical information 
can be overestimated and a diagnostic technology which is not cost-effective may 
be accepted. In addition a second type of error will be made when the value of 
clinical information is underestimated and a potentially cost-effective diagnostic 
technology is rejected. These potential biases are illustrated using the same 
numerical example and are discussed in detail below. 
3.3.1 Errors at the First Hurdle 
At the first hurdle a new diagnostic test is potentially cost-effective if the 
maximum EVPI is greater than the cost of the new test and from section 3.2 it can 
be seen that the EVPI will reach a maximum at either f20 or f12. If the fallback 
strategy is selected using an implicit value of health outcome which is inconsistent 
with the CCER selected to evaluate the new diagnostic device then the value of 
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information will be overestimated and the point at which the EVPI reaches a 
maximum will also be biased. This is illustrated in figure 3.3.la where the CCER 
is £4,000 but the value of health outcome implicit in the selection of the fallback 
strategy is £20,000. 
Figure 3.3.la 
This inconsistency in the decision rules used to select current practice and to 
evaluate a new diagnostic device leads to an overestimation of the value of perfect 
information because the optimal testing strategy is compared to an inefficient 
alternative. When the CCER=I/g=£4,000 the test treatment strategy is t2 and the 
optimal fallback is to when f<0.54 and t2 when f~0.54. However when 
l/g=£20,000 current -practice differs from the optimal fallback strategy in a 
number of important respects and the value of perfect information is 
overestimated. When 0.36<f<0.46 the EVPI22 overestimates the EVPI20 and when 
f~0.46 the EVPI21 overestimates the EVPI22• The EVPI reaches a maximum at 
f
12
=0.46 rather than f20=0.54. The EVPI is seriously overestimated because the 
test is not being compared to the relevant alternative (the optimal fallback at the 
CCER). The discontinuities in the EVPI are due to the fact that the alternatives 
have been selected using one decision rule (1Ig=£20,000) but then valued using 
another (CCER=£4,000). There is a danger that a diagnostic test which cannot be 
cost-effective will pass the first hurdle. A diagnostic test which costs between 
£9,300 and £3,000 will pass this first hurdle but at a CCER of £4,000 it is not 
potentially cost-effective and should be rejected. If the cost of the test was less 
than £3,000 the range of prior probability of disease where it will be regarded as 
potentially cost-effective will be overestimated, biasing estimates of the population 
EVPI. 
Figure 3.3.1b 
The first hurdle is very sensitive to the way in which current practice is selected 
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and figure 3.2.2b illustrates the errors that will be made if the value of health 
outcome implicit in the selection of current practice is greater than the 
CCER=£4,000. Even when 1/g=£5,000 the maximum EVPI will be overestimated. 
The consequences of these overestimates is that a test may pass the first hurdle 
when it is not potentially cost-effective and research and development resources 
will be wasted. 
Ifboth current practice and the treatment which will follow a positive test result 
are selected using an implicit decision rule which is inconsistent with the CCER 
then two types of errors can be made at the first hurdle. The first type of error 
will occur when the value of information is overestimated but now a second type 
of error can also be made where the value of information is underestimated and a 
potentially cost-effective test may be rejected at the first hurdle. 
Figure 3.3.2a 
These errors are illustrated in figure 3.2.2a where the CCER=£4,000 but the value 
of health outcome implicit in the selection of the fallback and the testing strategy 
is £4,000, £5,000 or £20,000. As before the EVPI may be overestimated if 
current practice is not the optimal fallback strategy but now the treatment that 
follows a positive test results will not necessary be optimal at the CCER. In figure 
3.3.2a when 1/g=£20,000 and when 0.36<f<0.46 the EVPI12 overestimates the 
EVPI20, and when £>0.46 the EVPIll overestimates the EVPI22 . But now when 
f<0.36 the EVPIIO underestimates the EVPI20, because although the fallback to is 
optimal, the testing strategy is inefficient and the value of information will be 
underestimated. 
This second type of error is more clearly illustrated when l/g=£5,000 and the 
maximum EVPI is underestimated because although current practice is optimal, 
the testing strategy selected is inefficient. When f<0.5 the EVP110 underestimates 
the EVPI20 and when 0.5:d<0.98 the EVPI12 underestimates the EVPI22 . The 
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range of prior probability of disease where the test is potentially cost-effective will 
be underestimated and estimates of the population EVPI will be biased. In these 
circumstances it is possible that a potentially cost-effective diagnostic test will be 
rejected at the first hurdle. 
Figure 3.3.2b 
When both the testing and fallback strategies are selected using an implicit value 
of health outcome which is inconsistent with the CCER the first hurdle is very 
sensitive to differences in these decision rules. The errors which will be made in 
estimates of the EVPI are illustrated in figure 3.2.2b and in this example one of 
the two types of error will be always be made if l/g>CCER. 
3.3.2 Errors at the Second Hurdle 
Similar errors can occur at the second hurdle but now the consequences are more 
serious because if the EVCI is overestimated then there is a danger that a 
diagnostic device which is not cost-effective will pass the second hurdle and will 
become accepted as part of efficient clinical practice, incurring the opportunity 
cost of the greater health benefits which could be gained from an alternative use of 
these resources. 
Figure 3.3.3 
Figure 3.3.3 iIIustrates the way that the EVCI will be overestimated when current 
practice is selected using an implicit value of 1/g=£20,OOO. The errors follow the 
same pattern as at the first hurdle because the errors are due to an inefficient 
fallback strategy being selected rather than differences in the testing strategy. Just 
as at the first hurdle the EVCI12 overestimates the EVCI2o, and the EVCI21 
overestimates the EVCI22 · A diagnostic test with an estimated cost between 
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£8,400 and £2,000 will pass this second hurdle and become part of what is 
regarded as efficient clinical practice. However at a CCER of £4,000 it is not cost-
effective and should be rejected. A test which costs less than £2,000 is cost-
effective but the range of f where the test should be used will be overestimated, 
biasing estimates of the population EVCI. 
Figure 3.3Aa 
Figure 3.3 Ab 
Ifboth the fallback and the testing strategies are selected using an implicit value of 
health outcome which is inconsistent with the CCER then the EVCI may be under 
or overestimated and there is now a possibility that either a cost-effective test will 
be rejected or an inefficient test will be accepted. This is illustrated in figure 
3.3.4a. When the implicit value of health outcome is £20,000 then the EVCl lO 
underestimates the EVCI20 when 0.12!'>f!'>0.36; the EVCI12 underestimates the 
EVCI20 when 0.36<f<0.46; and when f~0.46 the EVCIll underestimates the 
EVCI22 . Similarly when the value of lIg implicit in the selection of the alternative 
strategies is £5,000 the EVCI22 will be underestimated by the EVCI12 when 
0.84<f<0.98. 
The second hurdle is sensitive to the decision rule that is used to select the 
alternatives which are compared in the economic evaluation. If there is an 
inconsistency in the decision rule implicit in the selection of these alternatives and 
the decision rule which will be used to decide whether the new test is cost-
effective then the estimates of the value of information will be biased. There is a 
danger that one of the two errors could be made at the second hurdle. These 
errors in the estimates of the EVCI are also illustrated in figure 3.3.4b for a range 
of values of l/g. This shows that for this numerical example there will be some 
range of f where the value of information will be either under of over estimated if 
there is any discrepancy in the value of l/g used to select alternatives and the 
CCER selected by the analyst to evaluate the new device. 
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3.4 Implications for Focusing Clinical Research 
Section 3.2 demonstrated that the Phelps Mushlin approach can be generalised to 
more complex decision problems, but when more than one treatment is available 
for a given diagnosis the optimal treatment following the test result may not be the 
same as the optimal treatment choice without the test. This demonstrates that 
simple measures of accuracy, including the area under the ROC curve, which only 
measure the ability of a test to assign patients to a particular diagnosis, will be 
inappropriate because they do not measure the impact of information on changing 
the optimal treatment for a given diagnosis. Similarly other intermediate output 
measures from a diagnostic process which are based on measures of accuracy or 
assignment, such as the number of cases found, and assignment strength or 
assignment potential, will not reflect these changes in patient management and 
may lead to an underestimate of the value of the diagnostic information. 
However the generalisation of the Phelps Mushlin strategy relies on the 
assumption that current practice (or the fallback strategies) are correct which in 
this context means that they are t~e most cost-effective strategies at the CCER 
which will be used to evaluate the new test. The numerical example in section 3.3 
demonstrates that the value of diagnostic information will be overestimated when 
the existing fallback strategies are not optimal at the CCER, and will be 
underestimated when the fallback is optimal but the test treatment strategy is 
inefficient at the CCER. These are examples of the errors generated when the 
alternatives compared in an economic evaluation are not the relevant or efficient 
alternatives. Clearly almost any proposal can appear to be cost-effective if it is 
compared to an alterative which is sufficiently inefficient. 
This demonstrates that the selection of relevant alternatives depends crucially on 
the value of the CCER and that relying on the alternatives currently selected by 
existing clinical practice will introduce bias unless the value of health outcome 
implicit in current practice is consistent with the CCER. This consistency requires 
60 
that in existing clinical practice all competing projects are already allocated 
efficiently within the budget. This implies that decision-makers have full 
information about the budget constraint the costs and benefits of all competing 
programmes; and make consistent decisions using the shadow price of the budget 
constraint. These are conditions which are unlikely to hold in most clinical 
settings. 
There are good reasons to believe that the value of health outcome implicit in the 
selection of current practice may be greater than the CCER. In these 
circumstances any approach to economic evaluation which accepts current clinical 
practice as a relevant alternative may introduce bias into the analysis. This is an 
example of "second best" 129 where by applying first best rules (assuming existing 
clinical practice is efficient and l/g=CCER) in a second best world (where clinical 
practice is not necessarily efficient and 1/g>CCER) will bias the results of any 
evaluation and lead to a further inefficient allocation of resources when a cost-
effective test is rejected and an inefficient test is accepted. 
In a second best world existing clinical practice cannot be used to identify which 
alternatives are relevant in an economic evaluation. The alternatives which should 
be regarded as relevant depends on the decision rule which will be used to 
evaluate the new technology. In the simple decision problem considered in this 
chapter there are three fallback and two testing strategies giving six possible 
comparisons between the test and no test alternatives. In this numerical example 
when the prior probability of disease is 0.6 then there are 4 comparisons involving 
five alternatives which will become relevant at different values of 1/g. In 'table 
3.2.3: when l/g~£3,OOO to is the relevant fallback and t2 is the relevant testing 
strategy; when £4,OOO~ 1/g~£5,OOO t2 is the relevant fallback and t2 is the relevant 
testing strategy; when £6,OOO~ l/g~£10,OOO t2 is the relevant fallback and t\ is the 
relevant testing strategy; and when 1/g~£11,OOO t1 is the relevant fallback and t1 is 
the relevant testing strategy. There are four comparisons generating four different 
cost-effectiveness ratios for this new diagnostic test. The correct ratio which 
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compares relevant alternatives depends on the value of health outcome which will 
be used to decide if the test is cost-effective IS, 16, 78. This poses the problem of 
which ratio should be placed in a league table of cost-effectiveness ratios of 
competing programmes 47,61. The implications of this issue for the traditional 
approach to priority setting and decision making using cost-effectiveness and cost 
utility ratios is discussed in chapter 7. 
It has been argued that the value of health outcome implicit in exiting patient 
management is likely to be greater than a CCER selected by an analyst. A less 
effective but less costly alternative treatment may exist which would be optimal at 
the CCER but may not be part of current practice and it can no longer be assumed 
that treatment alternatives which are optimal following the new test will be part of 
existing patient management. In this numerical example when a purely clinical 
decision rule is used to select current practice (g=O) t2 will never be selected. 
However if the analyst used a CCER of £4,000 to evaluate the new technology t2 
would be the optimal treatment which should follow a positive diagnostic test 
result. Not only will the EVPI and the EVCI be overestimated if current practice 
is used as a baseline, but there will be no information about t2 by simply observing 
current practice. It will not be possible to estimate the EVPI or the EVCI based 
on existing information. The investigator may be forced to consider an 
experimental design which includes both the diagnostic test and the subsequent 
treatment choices, to establish the value ofUij and Cij. In these circumstances 
random patient allocation in a clinical trial may be unavoidable even if the 
diagnostic test is non-invasive. 
The Phelps Mushlin approach to evaluating diagnostic information and focusing 
clinical research is likely to fail when it is generalised to more complex decision 
problems because: (a) the key assumption of consistency between the value of 
health outcome implicit in current practice and the CCER is unlikely to hold; (b) 
when this assumption is violated the values of both the first and second hurdles 
will be biased; and (c) it is not necessarily the case that information about current 
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practice before the test is introduced will be sufficient to construct the first hurdle. 
This poses some practical and methodological problems for the economic 
evaluation of sequential clinical decision problems and for clinical research. If 
valid inferences cannot be based on observing current clinical practice, but the 
prospective evaluation of all possible alternatives in a sequential clinical decision 
problem is not possible, efficient, or ethical then: (a) how should information of 
different quality from different sources be combined consistently and explicitly; (b) 
which clinical decision problems will be worth evaluating in a clinical trial; (c) if a 
clinical decision problem is worth evaluating which of the competing alternatives 
should be compared in a clinical trial; and (d) what is the optimal scale of this 
prospective research? These are questions about how to establish technical 
efficiency in clinical and economic research design, and how to achieve allocative 
efficiency in clinical research across clinical decision problems and between 
research and service provision. It is these questions which are addressed in the 
following chapters of the thesis. 
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Table 3.2.1 A Numerical Example 
Utilities Incremental Costs (C i) Incremental Costs 
(Uij) Utilities (t1 Uijk) (~Cijk) 
Ull 6 ~UllO 4 Cll £12,000 ~Clto £12,000 
UOl 8 ~UOOI 2 COl £8,000 t1COOI -£8,000 
U IO 2 ~U1l2 2 CIO £0 ~C112 £9,600 
Uoo 10 ~U120 2 Coo £0 t1C 120 £2,400 
U l2 4 ~Ul2l -2 Cl2 £2,400 L\C l2l -£9,600 
U02 9 L\Uoo2 1 CO2 £2400 L\COO2 -£2,400 
The characteristics of the proposed diagnostic test are: p=0.9, and q=0.2 
Figure 3.2.1 Decision Tree for the Test Treatment Decision 
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Table 3-2-3 Optimal Strategies with Clinical Information 
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4.1 Introduction 
The analysis in the previous chapter demonstrated that a clinical trial may be 
unavoidable even in the evaluation of a non invasive diagnostic technology. This 
poses the problems of allocative efficiency across clinical research and technical 
efficiency in research design which were raised at the end of chapter 3. In this 
chapter it is argued that the traditional approach to clinical trial design is 
inconsistent with concepts of efficiency, leads to either infinite or arbitrary sample 
sizes, and cannot address the issues of allocative or technical efficiency in clinical 
research. 
The methods developed in this chapter address these problems by constructing 
two hurdles that proposed research must overcome before it can be considered 
cost-effective. The first hurdle asks if the cost of proposed research exceeds the 
maximum possible benefits. If the cost does not exceed the maximum benefit then 
it is potentially cost-effective. Whether the proposed research is actually cost-
effective can be established by constructing the second hurdle which explicitly 
considers the marginal cost and marginal benefits of sample information. The 
second hurdle ensures that the research is conducted at the technically efficient 
scale and provides a measure of the net present value of the proposed research. 
This approach is illustrated by considering the simple single-stage fallback 
treatment decision which was discussed in chapter 2. The approach is generalised 
to the more complex two and four-stage testltreatmenLdecisions in chapter 5. 
4.1.1 The Traditional Approach to Trial Design 
The problems encountered when running an economic evaluation alongside a 
clinical trial are well documented 1,21,42,43,45. However, more fundamental is the 
fact that the traditional approach to the design of pragmatic clinical trials is 
inconsistent with concepts of efficiency, because an infinite value is implicitly 
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placed on the benefits of sample information. Furthermore, the traditional 
approach does not directly address the decision problem faced by clinicians, 122, 123 
and cannot incorporate prior information explicitly and consistently. The purpose 
of this chapter is to show how the principles of economic evaluation can be used 
to develop a consistent approach to trial design and research priority-setting. 
In the traditional approach (assuming a fixed sample design, where all the results 
are available at the same time at the end of the trial), the key design issue is the 
number of patients to recruit. Optimal sample size (n*) is determined by the 
reference improvement (or), the working significance level (ex), the power of the 
test (l-P), and the variance of population differences in effectiveness between 
interventions (a2). 
n*= (y Ie)! e = effect size = or la y = f(P, ex) 4.1.1 
Sample size is very sensitive to the reference improvement, and if the selection of 
or is not well defined or is chosen in an arbitrary way, then sample size will also be 
arbitrary. The clinical reference improvement has been defined as the smallest 
worthwhile difference in effectiveness 84. Very small improvements in effectiveness 
should be worthwhile, but as or approaches zero, sample size tends to infinity. 
The justification given for or substantially greater than zero (and finite sample 
size) is that practitioners require a large clinical difference before they can be 
convinced that the experimental treatment will improve health outcome, and that 
incurring the additional costs of the experimental treatment will be worthwhile. 
These are two separate issues. If practitioners are sceptical of improved 
effectiveness then an appropriate response is to increase the level of significance 
and power by increasing sample size at each level of or. The minimum 
improvement in effectiveness required to offset the additional costs of a new 
treatment can be established by rescaling the incremental costs into health 
outcome using the critical effectiveness-cost ratio 86,108,140 (this is the effectiveness-
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cost ratio of the marginal project which will be displaced by the new treatment). 
The costs of treatment are now included in the analysis and the appropriate 
reference improvement is the minimum improvement in efficiency (rather than 
effectiveness) that is considered worthwhile. But a reference improvement in 
effectiveness which would just offset the incremental cost will lead to a reference 
improvement in efficiency of zero, and sample size will again tend to infinity. 
Although the costs of treatment can be taken into account when designing a 
clinical trial there is no consideration of the marginal cost of obtaining sample 
information. Any improvement in either effectiveness or efficiency will be worth 
detecting if it is assumed that the marginal cost of detecting such a difference is 
zero. An infinite value is implicitly placed on the benefits of sample information, 
leading to either infinite or arbitrary sample sizes. The approach is inconsistent 
with concepts of efficiency and with the original rationale for considering the cost 
of treatment alongside the trial. 
It has been recognised for some time that the traditional approach to trial design 
does not directly address the decision problem facing clinicians. A minimum 
combination of ex and P is stipulated which should be applied in all clinical settings 
irrespective of the relative costs of type I and type II errors. Schwartz and 
Lellouch (1967) have argued that in a pragmatic clinical trial type I errors impose 
no costs and are irrelevant 121,122. A type I error will be made if the clinician 
concludes that there is a difference between treatments when no difference 
actually exists. In this case, since the treatments are equivalent, it does not matter 
which treatment is chosen, and the level of significance is irrelevant. It is the 
probability of making the wrong decision by concluding that the experimental 
treatment is superior to the control when the reverse is true (the probability of a 
type III error) which should be the issue of concern. 
Finally, the traditional approach to clinical trial design is founded on the view that 
probability represents the relative frequency of repeated events. There is no 
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explicit role for prior information, although in practice it is implicit at each stage 
of design 14,31 (including the choice of alternatives to be compared; and the 
selection of or, ex, and P), and during data monitoring in sequential trials 52,53,54,55, 
59,76, 113, 126. Because the role of prior information is not explicit, it cannot be 
handled consistently and is not open to criticism, alternative formulation and 
empirical falsification. 
4.1.2 A Decision-Analytic Approach to the Value oflnformation 
An approach to trial design is required which directly addresses the decision 
problem faced by clinicians; which takes account of the marginal costs and 
marginal benefits of sample information; which uses all of the information 
available prior to prospective research and can address the issue of allocative 
efficiency across clinical research; and technical efficiency in research design. 
The decision-analytic approach presented in this chapter combines a Bayesian 
view of probability with a framework for decision-making which explicitly takes 
into account the consequences of making a type III error. The approach abandons 
traditional significance testing, confidence intervals,s8, 114 and their Bayesian 
counterparts 60, 127, 128 in favour of minimising the expected costs of making the 
wrong decision. 
There have been a number of contributions to the literature which have proposed 
a decision-analytic approach to sequential clinical trial design 5, 6,29,30, 149. These 
contributions have focused on clinical measures of efficacy rather than efficiency, 
and have been criticised 7,27 because predicted sample sizes may become very 
large. There have been a number of contributions which have proposed data-
dependent allocation, normal loss functions, and an explicit patient horizon to 
establish the optimal allocation of patients as a sequential trial progresses 7,8,9, 12, 
13. These approaches focus on clinical outcomes in sequential trial designs without 
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explicit consideration of economic criteria or the resource costs of obtaining 
sample information. 
The following example illustrates the use of a decision-analytic approach when 
considering the more fundamental problem of a fixed sample design where the 
problems of optimal sequential allocation and optimal stopping do not arise 116, 11S, 
121. It explicitly includes economic criteria at all stages of the design, including the 
costs of treatment and sampling, \08 and the timing of costs and benefits. This 
approach uses the same decision rules for cost-effectiveness and efficiency which 
are increasingly used to set priorities in service provision 146. The objective is to 
promote consistency in decision-making and priority-setting between research and 
service provision. 
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4.2 A Single-Stage Clinical Decision Problem 
The approach is illustrated using the simple numerical example of the fallback 
treatment decision considered in chapter 2. The example considers a fixed sample 
design of a pragmatic or phase III clinical trial for this single stage decision 
problem. The clinician faces a choice between two alternatives (tj' j=O, 1) where 
to is current practice (no treatment), and tl can be regarded as the experimental 
treatment for a well-defined patient population. This single-stage problem is 
illustrated in figure 4.2.1 and is identical the problem which was illustrated in 
figure 2.2.1. There are two disease states; no disease (i=O), and disease (i=I), 
with a prior probability of Pi. The health utilities (outcomes) can be regarded as 
measures ofheaIth related quality of life (Uij), and the resource costs (Cij) also 
depend on disease state and treatment. 
Figure 4.2.1 
Table 4.2 
The prior mean and variance of the health utilities, probabilities and costs for the 
example are reported in table 4.2. It is assumed that the utilities and the 
probabilities are independent and normally distributed so the prior variance (Varo) 
ofE(U): 
Varo(E(U)) = E(P/).E(UI/)-E(P1fE(UI/ 
+E(P 02).E(Uo/)-E(P 0)2.E(Uo/ 
E(P/) = E(P/ +Varo(Pj ) 
E(U/) = E(Uij)2 +Varo(Uij) 
4.2.1a 
To simplity the example further it is assumed that each element of cost C· and the 
II 
value of g are known, but expected cost (E(C)) is normally distributed because of 
the prior variance of the probability of disease. 
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4.2.lb 
These assumptions can be relaxed without loss of generality. 
4.2.1 Hurdle I: The Expected Value of Perfect Information 
Without sample information the decision-maker must choose between t\ and to 
using only prior information. If prior expected costs are rescaled to units of health 
outcome (using g, the critical effectiveness-cost ratio), 108,140 the decision-maker 
should choose t\ if the prior incremental net benefit oft\ (50) is positive. 
-
50(2) = (E(Ult\)-g.E(Clt\»-(E(Ulto)-g.E(Clto)) 4.2.2a 
The prior net benefit can also be rescaled to monetary units (using IIg, the critical 
cost-effectiveness ratio) so the decision-maker should choose t\ when k\.50>0 
(where k\=lIg), and should choose to when 1<0.50>0 (where ko= -l/g). The 
decision-maker will be indifferent between t\ and to when 00 is equal to its break-
even value (5b=0). An alternative approach is to minimise the expected 
opportunity loss. Opportunity loss is the difference in incremental net benefit 
between the best choice and the alternative actually chosen (opportunity loss 
=lk1-kol.15o-5b l= K..150-5blwhere K.=2/g). The loss functions for to and t\ are 
illustrated in figure 4.2.2. 
Figure 4.2.2 
The opportunity loss is minimised by choosing t\ when 5o>5b, and by choosing to 
when 50<5b· However, the incremental net benefit oft1 has a prior probability 
distribution with a prior mean of 50 and a prior variance of 0 02• Given the 
assumptions of normality and independence: 
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0 0
2 = Varo(E(Ultl»+Varo(g·E(Cltl» 
+Varo(E(Ulto»+Varo(g·E(Clto») 4.2.2b 
There is a probability that a decision based on the prior mean will be wrong, and 
opportunity losses will be incurred. The expected opportunity loss is the expected 
cost of the uncertainty surrounding the decision problem: this is the Expected 
Value of Perfect Information (EVPI). 
The EVPI is determined by three factors: the slope of the loss function (~ = 2/g), 
which determines the value of opportunity losses; the distance of the prior mean 
from break-even (100 - ObI) and the spread of the prior distribution (00), both of 
which determine the chances of incurring opportunity losses. The expected 
opportunity loss (EVPI) is calculated based only on prior information and the unit 
normal loss integral 116, 121. 
EVPI = ~.oo.L(Do) 
Do = (00 -Ob)/°O 
00 = prior incremental net benefit 
0 0 = prior standard deviation of 00 
4.2.2c 
(4.2.2c) gives the EVPI when faced with a choice between t) and to for an 
individual patient. ·However, a decision-maker will face this same decision 
problem for a num?er of patients over a period of time. Given an estimate of the 
incidence of patients entering the decision problem in figure 1 in each period (h), 
the population EVPI can be calculated. ·The incidence in each period can be 
discounted at rate r to provide the present value of the population EVPI. 
H 
Population EVPI= L (EVPLIncidence(h)" 1/(1 +r)h) 
h=l 
4.2.2d 
This is the maximum benefit that could be provided by additional information, and 
the maximum return to research effort in this area. This gives a method for 
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focusing research priorities. It can be used to identify those clinical decision 
problems (or areas of clinical research) where the costs of uncertainty are highest, 
and where the information from research will be most valuable. If the fixed costs 
of research are known, the EVPI can be used as an effective hurdle to eliminate 
proposals (where the costs exceed the EVPI) which will not be cost-effective. 
The EVPI can also be used in the same way to identify priority areas for scientific 
reviews and Meta-analysis: clinical decision problems where the costs of 
uncertainty are greatest derive the most benefit from a review of existing research. 
The EVPI is a powerful tool for identifying research priorities in support of a 
move towards evidence-based medicine 49, 119,120. Indeed this approach can set the 
limits to evidence based medicine and provide a framework within which it can be 
1· d . tl 40 41 app Ie conslsten y , . 
The expected value of perfect information can be calculated for any decision 
problem based only on prior information, including evidence from previous 
intervention and observational studies, but it can also include expert judgements. 
The decision-analytic framework focuses attention on those variables where 
evidence or judgement is required (in this example on the health outcomes, costs 
and path probabilities illustrated in figure 4.2.1 and shown in table 4.2). By 
making prior information and judgements explicit they are open to criticism, 
alternative formulation and empirical falsification. This is not necessarily the case 
in input/output models for assessing payback in clinical research 36, 48. Delphic 
studies in research foresight which elicit preferences over research priorities 3,4,95, 
102, 147 use expert judgements which are not open to criticism or empirical testing 
because assumptions about outcomes, costs, path probabilities and decision rules 
remain implicit. 
Where expert judgements are used to establish the EVPI, the level of confidence 
in this prior information will be reflected in a higher prior variance. Prior 
information can be regarded as a quasi sample with a quasi sample size of flo <flo= 
ratio of population to prior variance), where a smaller flo indicates a more sceptical 
74 
prior. This index of confidence is used in this example and is reported in table 4.2. 
The quasi sample size is higher for the utilities and probabilities associated with to, 
and this reflects the assumption that there may be more confidence in the prior 
information about current practice. This framework makes these judgements 
explicit and allows prior evidence form a variety of sources to be combined, and 
handled consistently using Bayes Theorem 67, 116, 121. 
Value ofllealth Outcome 
An example of the relationship between the EVPI and the value of 1/g (the critical 
cost-effectiveness ratio; the value of health outcome) is shown in figure 4.2.3, and 
this demonstrates the fact that the value of information is crucially dependent on 
the value of health outcome used to set priorities in service provision. 
Figure 4.2.3 
The slope of the loss function or loss constant (K,=2/g) determines the value of 
opportunity losses when they occur. If the value of health outcome is greater the 
opportunity costs of making the wrong decision are valued more highly. This 
suggests a positive relationship between EVPI and value of health outcome. 
However the prior variance of 50 partly determines the probability of incurring 
these opportunity losses, and 0 0 will fall as 1/g increases ( 4.2.1 b). The probability 
of incurring opportunity losses is also determined by 150 - 5bl. When the prior 
cost-effectiveness ratio oftl (£6,500) is equal to 1/g the decision maker will be 
indifferent between tl and to. At this point 50 = 5b = 0 and the decision maker is 
most uncertain. The standardised distance (Do in 4.2.2c) is equal to zero in figure 
4.2.4a and L(Do) reaches a maximum in figure 4.2.4b. In this example the EVPI 
reaches a peak in figure 4.2.3 when l/g=£6,500 and the clinician is most uncertain 
about the treatment decision. 
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Figure 4.2.4a 
Figure 4.2.4b 
The decision maker will choose to when 1Ig <£6,500, an increase in 1/g will 
reduce 100 - obi and Do in figure 4.2.4a, and the probability of incurring 
opportunity losses will increase. Both L(Do) in figure 4.2.4b and Kt will rise with 
1/g, and the EVPI will increase up to the point where 1/g=£6,500. The decision 
maker will choose tl when 1/g>£6,500, but now an increase in 1Ig will increase 100 
_ obi and Do in figure 4.2.4a and reduce the probability of incurring opportunity 
losses. L(DO) falls in figure 4.2.4b with a rise in 1/g, and the EVPI will fall if this 
off-sets the effect of the increase~. This occurs in figure 4.2.3 when 1Ig is 
increased from £6,500 to £11,000 per unit of health outcome gained. 
The value of 1Ig is determined by the budget constraint faced by clinical 
practitioners in service provision. If the budget constraint is relaxed then more 
costly but effective health services can be provided, the cost-effectiveness ratio of 
the marginal service will increase, and the EVPI will rise (because the cost-
effectiveness ratio of the new marginal service will always be greater than 1Ig 
before the increase in the budget). If the budget is tightened the cost-effectiveness 
ratio of the marginal project will fall, service providers will be unable to take 
advantage of the information provided by clinical research, and the value placed 
on this information will diminish. The value of information, research priorities and 
the optimal level of research and development e~penditure are all dependent on 
the budgetary constraint on the provision of health services. 
The EVPI is also determined by the quality or confidence in the prior information. 
The confidence in the prior information is represented by the prior quasi sample 
size no where a smaller quasi sample represents a more sceptical prior and less 
confidence in the prior mean. The impact on the EVPI of considering more or less 
sceptical prior is illustrated in figure 4.2.5. This demonstrates that when there is 
less confidence in the prior information (no=2) the EVPI is higher because there is 
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more uncertainty surrounding a decision based only on prior information. 
Similarly when the prior is less sceptical (no=18) the decision will be less uncertain 
and the EVPI is lower. The point at which L(Do) reaches a maximum where the 
clinician is indifferent between to and t1 does not change and the EVPI either 
reaches a peak or there is a discontinuity when 1/g=£6,500. 
Figure 4.2.5 
4.2.2 Hurdle II: The Expected Net Benefit of Sample Information 
Proposed research which passes the first hurdle can be regarded as potentially 
cost-effective. To demonstrate that it will be cost-effective the optimal scale of 
the research (in this case sample size) must be established. Sample size will be 
optimal where the marginal benefit of additional sample information is equal to 
the marginal cost of sampling. 
The expected benefit of sample information is measured by the reduction in 
expected opportunity loss, and this is given by the Expected Value of Sample 
Information (EVSI(n») 25,26. This can be calculated for a particular sample size 
from the prior information already used to establish the EVPI and an estimate of 
the sample variance of the incremental net benefits oft1 . 
EVSlln = Kt • .;vn .00.L(Dln) 
Din = (oo-ob)1 .;vn 
.jVn = 0021 (002+0/) 
00 = prior incremental net benefit of t1 
0 02 = prior variance of 00 
4.2.3a 
On2 = sample variance of the incremental net benefit oft1 with sample size n 
The EVSlln is determined by four factors: the slope of the loss function; the prior 
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mean; the prior variance; and the variance fraction (ffn). The variance fraction 
is determined by sample size and ..;vn approaches 1 as the sample size is 
increased. The EVSlln approaches the EVPI as sample size tends to infinity, and 
this confirms the interpretation placed on the EVPI that it represents the maximum 
benefit that sample information can provide. 
The population EVSI measures the benefits of sample information for current and 
future patients, and can be calculated for a particular sample size given an estimate 
of the incidence of patients entering the decision problem in each period. 
H 
Population EVSlln = L (EVSlln.Incidence(h)" 1/(1 +r)h) 
h=1 
The Costs of Sampling 
4.2.3b 
The cost of obtaining a sample of size n (Cs\n) takes the following simple form 
with fixed cost (Cf) and constant marginal cost (Cm) 
4.2.3b 
The marginal cost of sampling includes the additional cost of treatment when 
patients entering the trial are allocated to the experimental treatment. In this 
example patients are allocated equally between the control and experimental arms 
of the trial (an optimal allocation of patients in a fixed sample design is possible 
using dynamic programming techniques and is discussed in chapter 6) so in this 
example each observation on the incremental net benfit of tl requires two patients 
to enter the trial with each allocated to either tl or to to. The marginal costs of 
observing and recording the results of treatment are assumed to be negligible, and 
the marginal cost of an additional trial entrant is half the incremental cost of t1. 
4.2.3c 
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The maximum sample size that should ever be considered can now be established, 
because when n = (EVPI-Cf)/Cm the cost of the research will be exactly equal to 
the maximum possible benefits. 
Expected Net Benefit of Sampling and Optimal Sample Size 
The Expected Net Benefit of Sampling (ENBS\n) is the difference between the 
total benefit and the total variable cost for a particular sample size. 
ENBS\n = EVSI\n - Cs\n 4.2.3d 
Sample size will be optimal (n*) when ENBS\n is positive and at a maximum. The 
relationship between sample size and ENBSln is shown in figure 4.2.6a. 
Figure 4.2.6a 
In figure 4.2.6a l/g=£4,000 and Do>O. The decision-maker initially prefers the 
control treatment to. Small amounts of sample infonnation are unlikely to change 
this decision, so that ENBS\n<O when sample sizes are very small. However there 
is a range of sample size where EVSI\n-Csln>O and the ENBSln reaches a 
maximum when n*=92. At this point clEVSIIan = Cm' and sample size is optimal. 
The EVSIln initially increases at an increasing rate with n, but ultimately declines 
because as n tends to infinity the EVSI approaches the EVPI. The variable costs 
of sampling continue to rise at rate em, and the optimal sample size will be finite. 
The problem of potentially infinite sample size associated with the traditional 
approach is avoided. 
A second hurdle for potentially cost-effective research can now be constructed. 
The EVSIln* represents the maximum that those commissioning research should 
be willing to pay given the budget constraint on service provision. In figure 
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4.2.6a, EVSlln*= £1,202,021. If the total cost of the research is less than this 
amount then it is cost-effective and should be implemented. The ENBSln* is the 
expected net present value of research. In figure 4.2.6a, EVSlln*-Cm.n* = 
£723,621, and this is the maximum fixed cost of research which could be incurred 
if the research is to remain cost-effective. ENBSln* can be used to prioritise 
research proposals. By implementing first those proposals with highest net 
present value, the maximum benefit can be obtained for a given research and 
development budget. The optimal level of research and development expenditure 
is given by the cost of implementing all proposals with a positive net present 
value. At the margin, ENBSln* is zero. 
The ENBSln* also represents the opportunity cost of failing to implement cost-
effective proposals. For example, if the fixed cost of this research proposal was 
estimated to be £100,000, the expected net benefit is £623,621, and it would pass 
the second hurdle. However, if this proposal was rejected on the grounds of 
medical ethics then the implicit opportunity cost of this ethical position is 
£623,621: equivalent to 156 units of health outcome (using 1/g=£4,000 per unit of 
health outcome gained). Consideration of medical ethics is an essential element in 
trial design and data monitoring, but this approach makes it possible to estimate 
the opportunity cost (to society as a whole) of particular concerns for the 
individuals involved in a clinical trial. In this way the inevitable trade-off between 
individual and collective ethics can be made explicit 38,79,91, 143, 144, 145. If these 
trade-offs are explicit they can be made consistently, and be open to criticism and 
debate. 
Value of Health Outcome 
The expected net benefit of sampling and the optimal sample size are dependent 
on the budgetary restrictions on service provision or the value of health outcome. 
In this example when the value of health outcome is higher, at £10,000, the 
expected net benefit and optimal sample size is also higher. The ENBS, EVSI and 
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the variable costs of sampling are illustrated in figure 4.2.6b for a range of 
possible sample sizes. The ENBS reaches a maximum of £5,040,755 at and 
optimal sample size of 188. At this value of health outcome the clinician should 
choose t 1. based only on prior information. The probability that this will be the 
wrong decision is higher than when 1/g=£4,000 (because L(Do) when 
l/g=£10,000 is greater than L(Do) when l/g=£4,000 in figure 4.3.4b) and the 
value placed on opportunity losses is also higher so the value of sample 
information is also higher 
Figure 4.2.6b 
The expected net benefit of sampling when the value of l/g is increased to 
£20,000 is illustrated in figure 4.2.6c. The ENBS reaches a maximum of 
£5,425,760 at an optimal sample size of246. The optimal sample size and the 
value of sample information is higher because although the prior decision to treat 
with tl is less uncertain (L(Do) when 1/g=£20,000 is less than L(Do) when 
1/g=£10,000 in figure 4.3.4b) the value placed on opportunity losses is higher, and 
in this case the value of sample information is also higher. This demonstrates that 
the value of sample information and the technically efficient scale of clinical 
research is dependent on budgetary constraints on service provision and the issues 
of allocative and technical efficiency cannot be addressed before health outcome 
has been valued in monetary terms. 
Figure 4.2.6c 
In this example the optimal sample size increases with the value placed on health 
. outcome and this is illustrated in figure 4.2.7. The relationship between optimal 
sample size and the value of l/g for a more sceptical (no=2) and a less sceptical 
prior (no=18) is also illustrated in figure 4.2.6c. When the value of health outcome 
is low the optimal sample size is zero and the decision should be based only on 
prior information. In these circumstances the prior decision will be to reject the 
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experimental treatment and not treat without conducting a clinical trial. If there is 
less confidence in the prior information then sampling becomes optimal at a lower 
value of 1/g (ifno=2 then n*=O when 1/g<£2,000, but ifno=18 then n*=O when 
1/g<£5,000) because the prior decision not to treat is le~s certain and sample 
infonnation is more valuable. 
Figure 4.2.7 
Figure 4.2.7 also shows that when the prior is less sceptical (no=18) and the value 
of health outcome is high (1/g>£12,000) then the optimal sample size is zero. 
Decisions should once again be based only on prior information which is now to 
treat using the experimental treatment t1· This suggests that there may be 
circumstances in which a new treatment should be adopted without gathering 
sample information through a clinical trial. If the prior incremental net benefit of 
the new treatment is sufficiently high and if there is sufficient confidence in this 
prior information, it will not be worth incurring the costs of a trial because these 
resources could be better used elseware, either in service provision or other areas 
of clinical research. This demonstrates that a decision-analytic approach can be 
used to set rational limits to evidence based medicine and provide a framework 
where new treatments of potentially great benefit 80, \34 can be adopted without 
incurring the cost (including the opportunity cost of the delay before the results 
are available) of a clinical trial. 
Once the optimal sample size has been established the relationship between the 
value of 1/g and the maximum value of the ENBSln can be considered. This is 
illustrated in figure 4.2.8 for three different priors. These estimates of the 
ENBSln* represent the value of the second hurdle and show that the second 
hurdle is sensitive to both the value of health outcome and the strength of prior 
information. The ENBSln* reaches a peak or shows a discontinuity when 
1/g=£6,5000 because this is the prior cost-effectiveness ratio for this decision 
problem. At this point the prior decision is most uncertain, Do=O in figure 4.2.3a, 
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and small amounts of sample information is valuable. 
Figure 4.2.8 
Decision Rules 
Once a proposal has passed both hurdles the decision rule which should be 
applied to the information provided by the sample must be established. The 
objective is to minimise the expected opportunity loss (maximise expected net 
benefits). 
Before sample information is available the treatment decision can only be based on 
prior information. Once sample information is available this must be combined 
with prior information to produce a posterior distribution with mean 01 and 
variance ot The posterior mean is a weighted average of the prior and sample 
information with the weights representing the informational content of each 87, 
01 = (Io·oo+I".OJ/{Io+IJ 
Ox = sample mean 
10 = 1/002 
I" = 1/(00 • 2) 
4.2.4a 
A decision rul~ which will minimise opportunity loss once sample information is 
available is to choose to when 01<0, and choose t1 when 01>0. The decision-
maker will be indifferent when 01=Ob=0. An equivalent decision rule based on 
sample results can be established by defining a critical value for the sample mean 
(ox.) which gives 01=Ob=0. 
4.2.4b 
If the sample mean is less than ox. then 01<0 and the decision maker should 
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choose to. In this example when IIg =£4,000 and 60= -1, to will be chosen on the 
basis of prior information alone. With an optimal sample size of92, 6".=0.504. A 
sample mean of at least 0.504 units ofheaIth outcome would need to be observed 
before the decision would be changed. 
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4.3 Conclusions 
The traditional approach to clinical trial design is inconsistent with concepts of 
efficiency even when the cost of the treatment alternatives are considered 
alongside the trial. The traditional approach implicitly places an infinite value on 
the benefits of sample information, leading to either unbounded or arbitrary 
sample sizes. Because the marginal cost of acquiring sample information is not 
.. considered it is unable to provide a framework for setting priorities in clinical 
research or establishing efficient research design. It is not able to address the 
problems which were posed at the end of chapter 3. 
A decision-analytic approach can provide practical tools for research priority-
setting. The information generated by clinical research is valued in a way which is 
consistent with concepts of efficiency, and with the methods used to set priorities 
in service provision. The prior information, which is implicit in the traditional 
approach, is identified and handled consistently so that it is open to criticism, 
. alternative formulation, and empirical testing. It is able to combine information 
from a variety of sources taking into account the variable quality of this 
information. 
The simple example of a fixed sample phase III trial shows that these techniques 
can be used to identify areas of clinical practice where the cost of uncertainty is 
high, and where the potential benefits of clinical research will also be high. 
Estimates of the EVPI and the EVSlln* can be used to construct two hurdles 
which proposed research must overcome before it can be considered cost-
effective. 
Hurdle I EVPI> Cr 
The first hurdle is based only on prior information, and asks if the EVPI (the cost 
of uncertainty or the maximum value of sample information) is greater than the 
85 
costs of the proposed research. This hurdle can eliminate proposed research which 
will not be cost-effective before issues of research design must be addressed. 
Those proposals which pass the first hurdle can be regarded as potentially cost-
effective and can be considered at the second hurdle. 
Hurdle II EVSIln* - Csln* = ENBSln* > 0 
The second hurdle ensures that the design of potentially cost-effective research is 
technically efficient, and that it will be cost-effective when conducted at the 
optimal scale. The ENBSln* represents the value of the proposed research to the 
providers and consumers of health services. It also represents the opportunity 
cost of rejecting cost-effective research proposals. Estimates of the expected net 
benefit of research can be used to rank proposed research. By implementing 
proposals with higher net benefit first, the maximum health benefits can be gained 
for limited research and development resources. This approach provides a means 
to decide which clinical decision problems are worth evaluating in a clinical trial 
and what is the technically efficient scale of this research. 
All but one of the problems posed at the end of chapter 3 have been addressed 
using these techniques. However two substantial problems remain. In chapter 2 
and 3 it was argued that many clinical decision problems are sequential and 
involve a choice between many competing alternative strategies. The approach 
has been illustrated using a single-stage decision problem and will be generalised 
to the two and four-stage sequential test/treatment decision problems in the next 
chapter .. The second problem is the selection of relevant alternatives which should 
be compared in a clinical trial. This problem did not arise in this simple single-
stage decision but this issue is considered in chapter 5 and will be addressed in 
detail in chapter 6. 
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Figure 4.2.1 Decision Tree for the Single-Stage Decision Problem 
Utilities Costs 
Uij Cij 
Disease Ull ell 
Treatment 
UOI COl 
Disease UIO CIa 
Uoo Coo 
Table 4.2 
Numerical Example for the Single-Stage Decision Problem 
Prior Prior Population Quasi prior 
Mean SD SD sample size (110) 
Ull 6 0.5164 1.2649 12 
UOI 8 0.5164 1.2649 12 
UIO 2 0.2582 0.8942 6 
Uoo 10 0.2582 0.8942 6 
Cll £12,000 
COl £8,000 
CIO 0 
Coo 0 
pCD) 0.6 0.1 0.4899 24 
pCD) = prior probability of disease 
In this example 1000 patients enter the decision problem in one year. 
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5.1 Introduction 
In the last chapter a decision analytic approach was applied to the simple single-
stage decision problem of choosing between treatment (t1) and no treatment (to). 
This single-stage problem is the choice between the fallback strategies which was 
discussed in chapter 2. However it was argued in chapter 2 that many clinical 
decision problems are sequential and involve a number of contingent decisions 
concerning diagnostic and treatment strategies. This chapter will demonstrate that 
the approach that was used in chapter 4 can also be applied to sequential clinical 
decision problems. 
In section 5.2 this approach is applied to the test-treatment decision problem 
where the clinician faces a choice between using a diagnostic test and treating 
according to test results, or choosing not to test and selecting either t1 or to' This 
is the same two-stage decision problem which was used to illustrate the strategy 
for the economic evaluation of diagnostic information proposed by Phelps an 
Mushlin in chapter 2 and the same numerical example is used to construct the first 
and second hurdles for proposed research. In section 5.3 this approach is also 
applied to the four-stage decision problem which was used to generalise the 
Phelps Mushlin strategy in chapter 3. 
The value of perfect information (the cost of uncertainty) for these more complex 
decision problems can be established and this is used as the first hurdle that 
proposed research must overcome before it can be considered potentially cost-
effective. If the expected value of perfect information exceeds the estimated fixed 
cost of proposed research the research is potentially cost-effective. The cost of 
uncertainty at particular points in a sequence of decisions can also be identified. 
Those contingent decisions where the cost of uncertainty is highest will be the 
points where additional information will be most valuable and this approach can be 
used to set priorities in acquiring information to inform particular contingent 
decisions. 
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The value of sample information at each point in the sequence of decisions can be 
established and compared to the cost of sample information. By establishing the 
expected net benefits of sample information at each stage in a sequential decision 
problem the optimal sample size entering the initial decision node can be 
identified, and the expected net benefit of prospective clinical research can be 
estimated. This can be used as the second hurdle that proposed research must 
overcome before it can be considered cost-effective. It provides a means of setting 
priorities in research and development across sequential clinical decision problems. 
The analysis in this chapter (like chapter 4) assumes a fixed and equal allocation of 
trial entrants between the different arms of the trial at each decision node. This 
assumption will be relaxed in chapter 6 where a dynamic programming approach 
is used to allocate patients efficiently. 
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5.2 A Two Stage Sequential Clinical Decision Problem 
The same methods which were applied to the single-stage decision problem in 
chapter 4 can be applied to the two-stage sequential decision problem which is 
illustrated in figure 5.2.1. This is the same decision problem which was used to 
illustrate the approach to the economic evaluation of diagnostic information 
proposed by Phelps and Mushlin in chapter 2, but it has been structured following 
the correct chronology and includes Bayesian probability revisions. This chapter 
also uses the same numerical example but with a prior distribution for each of the 
health outcomes and path probabilities. The prior distributions reflect the quality 
of prior information or confidence in the prior mean. In this example the quasi 
prior sample (Ilo) is higher for current practice (to) where more prior information 
-
may be available. The values of the prior mean and variance and population 
variance for these variables are reported in table 5.2. The assumption of 
normality and independence, which was also made in chapter 4, allows normal loss 
functions to be used and covariance terms to be zero when calculating the 
variance of expected net benefits at different stages. 
Figure 5.2.1 
Table 5.2 
Figure 5.2.1 illustrates the decision problem facing the clinician. If the clinician 
decides not to use the diagnostic test then at the second stage the decision 
problem is to choose to treat with t1 or not to treat (to). This is identical to the 
single-stage decision problem in chapter 4, but it is now a contingent treatment 
decision because a diagnostic device is available. The initial decision at the first 
stage is to choose to test and treat according to test results, with t1 following a 
positive test and to following an negative result, or to not test and follow the 
contingent treatment decision at the second stage. 
The problem is to establish the value of perfect information for this sequential 
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decision problem to construct the first hurdle and then to estimate the expected 
net benefits of sampling and optimal sample size so that the second hurdle can be 
constructed. This will allow an efficient allocation of research and development 
resources between technically efficient research designs. 
5.2.1 Hurdle I: The Expected Value of Perfect Information 
The clinician must make a decision at two points in this model. Without any 
additional infonnation this choice can be based only on the prior infonnation. The 
clinician should choose the alternative with the highest prior net benefit, but when 
estimates of net benefit are based on prior information there is a possibility that 
this decision will be wrong and opportunity losses will be incurred. Following the 
intuition of chapter 4, the expected value of opportunity losses is the expected 
cost of uncertainty surrounding the decision problem, or the Expected Value of 
Perfect Infonnation. In general the EVPI for a sequential decision problem with S 
stages and a choice between two alternatives at each stage (s=l, .. ,S), is the sum of 
the EVPI(s) at each stage or at each point where the clinician faces an uncertain 
decision. 
s 
EVPI:: :E ~VPI(S) 
s=1 
EVPI(9) = ~.oO(s).L(Do(s») 
Do(s) = (oO(S) -ob)/oo(s) 
oO(S) = prior incremental net benefit at stage (s) 
0 0(5) = prior standard deviation of 00(9) 
5.2.1a 
5.2.1b 
The decision problem in figure 5.2.1 indicates that the clinician will face an 
uncertain choice at two points: firstly when either test or no test must be selected 
and secondly where t1 or to must be selected (contingent on choosing not to test), 
so in this decision problem (s=1, 2) and the EVPI(s) must be estimated at both 
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stages. 
EVPI at Stage 2 
The clinician must make a decision at stage 2 of whether to treat with tl or to 
given that it has been decided not to use the test. This contingent decision is 
based on the prior incremental net benefit of tl (00(2») and must be made before the 
initial diagnostic decision can be taken at stage 1. The decision problem at stage 2 
is identical to the decision problem considered in chapter 4 and the EVPI(2) at 
what is now a contingent treatment decision in this larger sequential problem is 
identical to that reported in chapter 4 where: 
5.2.2 
EVPI at Stage 1 
At the initial diagnostic decision the clinician must choose between testing and 
treating according to test results and not testing and following the contingent 
treatment decision at stage 2. This decision will also be based on prior information 
and there is a chance that choices based on the prior incremental net benefit of 
testing at this first stage will be wrong and opportunity losses will be incurred. 
The expected opportunity loss at stage 1 (the EVPI(I») is in addition to the 
expected costs of uncertainty at stage 2 (EVPI(2)) and the EVPI for the full 
decision problem will include both the EVPI at the contingent treatment decision 
and at the initial diagnostic decision. The EVPI(I) at the initial decision is 
calculated in the same way as stage 2 but now 00(1) is the prior incremental net 
benefit of testing. This is the difference between the prior net benefits of testing 
(E(Ultc)-g.E(C!tc)) and not testing and selecting either t1 or to at stage 2. When 
1/g>£6,500 tl is selected at stage 2 and: 
5.2.3a 
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But when 1/g<£6,500, to is selected at stage 2: 
S.2.3b 
EVPI for the Two-Stage Problem 
The EVPI for this sequential decision problem is illustrated in figure 5.2.2 and is 
the sum of the EVPI at stage 1 and stage 2. The EVPI rises with the value of 
health outcome because the value placed on opportunity losses (the slope of the 
loss function (~=2/g» increases with 1/g, but there are now two discontinuities in 
this relationship which are due to discontinuities in the EVPI(l) and EVPI(2). The 
discontinuity in the EVPI(2) occurs when the clinician is indifferent between tl and 
to, at I/g=£6,500. The EVPI(2) reaches a peak at this point because DO(2)=O in 
figure 5.2.3a and L(D0(2» reaches a maximum in figure 5.2.3b in exactly the same 
way as in chapter 4. 
Figure 5.2.2 
The EVPI(I) at the initial decision rises with the value of health outcome but there 
are two discontinuities in this relationship. The first also occurs when the clinician 
is indifferent between tl and to, because when 1/g<£6,500 the clinician compares 
the net benefit of testing with the net benefit of to (oo(I)=5.2.3b) but when 
I/g>£6,500 the net benefit of testing is compared to the net benefit oftl 
(00(1)=5.2.3a). The second discontinuity in the EVPI(l) occurs when the clinician is 
indifferent between the test and no test alternative at stage 1. In this numerical 
example it is when 1/g=£11,800 and at this point the clinician is indifferent 
between testing and treatment t1. This where the initial decision is most uncertain 
and DO(I)==O in figure 5.2.3a and L(DO(l) reaches a maximum in figure S.2.3b. As 
the value of Ilg increases the clinician will prefer testing (00(1) >0) and the prior 
incremental net benefit of testing will increase (Do(l) increases), reducing the 
probability of incurring opportunity losses (L(DO(I» falls). This is offset by the 
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increase in value placed on opportunity losses when they occur (Kt=2/g rises) and 
the EVPI(I) increases with IIg. 
Figure 5.2.3a 
Figure 5.2.3b 
It was argued in chapter 2 and chapter 3 that many clinical decision problems are 
sequential and involve a choice between a number of competing strategies. This 
example shows that the EVPI can be established for sequential clinical decision 
problems by estimating the cost of uncertainty at each stage of the decision 
problem. The estimates of the EVPI in figure 5.2.2 can be used in the same way as 
in chapter 4 as a first hurdle that proposed clinical research must overcome. If the 
estimated cost of research is less than the EVPI then the proposed research is 
potentially cost-effective. Estimates of the EVPI can be used to set priorities 
across different sequential clinical decision problems by identifying those decision 
problems which may benefit most from information generated by prospective 
research as well as systematic reviews of existing literature and non-experimental 
research designs 40, 41, 119, 120. 
This numerical example also illustrates that the first hurdle may be very sensitive 
to the value of health outcome and in this example doubling the value of l/g leads 
to an approximately four-fold increase in the EVPI. This simply demonstrates that 
the value of information depends on the value placed on opportunity losses when 
they occur, which is double the value of health outcome (Kt=2/g). Just as in 
chapter 4 the relationship between the EVPI and 1/g demonstrates that the value 
of information and research priorities cannot be separated from the budgetary 
restrictions on service provision. If the budget is relaxed then the cost-
effectiveness ratio of the marginal project (l/g) will increase and the value of 
information will increase. Similarly if the budget for service provision is tightened 
then the cost-effectiveness ratio of the marginal project (1/g) will fall and the 
EVPI will fall. 
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The example also demonstrates that the cost of uncertainty for a clinical decision 
problem will be underestimated if some alternatives are ruled out as not relevant 
and a sequential decision problem is simplified to a single-stage problem. This is 
because the EVPI for the whole decision problem will be the sum of EVPI at each 
of the contingent decisions and at the initial decision. An analysis which simplified 
this sequential clinical problem to a single-stage problem by excluding the 
diagnostic process as not relevant (because it is not cost-effective when 
1/g<£11,800) would underestimate the EVPI because the process of 
simplification excludes some alternatives which are feasible and relevant and in 
certain circumstances could become the preferred strategy. 
Finally it demonstrates that by calculating the EVPI at each stage of a sequential 
decision problem, those points in the sequence of decisions where the cost of 
uncertainty is highest can be identified. This is not necessarily the case with 
conventional sensitivity analysis 18, 19 because the prior distributions for the key 
variables and the value placed on opportunity losses at sensitive decisions are not 
necessarily taken into account. This can be illustrated in figure 5.2.2. If 
1/g=£7,000 a traditional approach may regard the treatment decision at stage 2 to 
be more sensitive than the diagnostic decision at stage 1 because this value of 1/g 
is very close to the prior cost-effectiveness ratio at stage 2 (£6,500) and small 
changes to the key variables could change the treatment decision. The prior cost-
effectiveness ratio at stage 1 (£11,800) is further from this value of 1Ig and the 
decision not to use the diagnostic test at stage 1 may be regarded as less sensitive. 
However even when 1/g=£7,000 the EVPI(l) at the initial diagnostic decision is 
greater than the EVPI(2) at the contingent treatment decision. The cost of 
uncertainty at stage 1 is greater than at stage 2, demonstrating that simple 
measures of sensitivity may be misleading particularly if they are used to identify 
those points where information may be most valuable 
Figure 5.2.4 
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The relationship between the EVPI for the full decision problem and the quality of 
or confidence in, the prior information is illustrated in figure 5.2.4. The level of 
confidence is measured by flo, which is the ratio of population to prior variance 
(the quasi sample size of prior information). When the confidence in prior 
information is reduced from no=6 to flo=2 the EVPI increases because there will be 
more uncertainty surrounding a decision based on prior information. As the 
confidence in prior information is increased (flo= 18) the EVPI falls because the 
probability of incurring opportunity losses will decline. Clearly the first hurdle is 
sensitive to strength of the prior, and in this example a three-fold increase in the 
strength of prior information leads to an approximately three-fold decline in the 
EVPI. 
5.2.2 Hurdle II: The Expected Net Benefits of Sample Information 
If the EVPI exceeds the estimated fixed costs of prospective research then 
research is potentially cost-effective. The next step is to estimate the benefit of 
sample information and the marginal cost of acquiring sample information to 
establish the expected net benefits of sampling. The scale of proposed research 
will be technically efficient and sample size will be optimal when the ENBS 
reaches a maximum. The ENBS is the second hurdle that proposed research must 
overcome before it can be regarded as cost-effective. It operates in the same way 
as the second hurdle for the single-stage decision problem in chapter 4 and 
proposed research will be cost-effective if the ENBS at the optimal sample size 
exceeds the fixed cost of research .. 
The sequential clinical decision problem in figure 5.2.1 provides two points where 
trial entrants will be allocated to the different arms of this trial. At stage 1 in 
figure 5.2.1 the trial entrants (n(I») are allocated equally to the test and no test 
arms of the trial, so that n(1/2 patients will be assigned to the test arm of the trial, 
(n(l/2).p(t/) will receive tl following a positive test and (n(I/2).p(tc") will receive to 
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following a negative test result. The patients enrolled in the trial who are assigned 
to the no test arm at stage 1 will enter stage 2 (n(2)=n(l/2) and will be allocated 
equally between tl and to· Other optimal allocation rules are considered in chapter 
6. 
The Expected Value of Sample Information is calculated using the same methods 
which were described in chapter 4, but now in a sequential decision problem there 
are benefits from sample information at each stage (s) given the sample sIze 
entering and allocated at that stage (n(S» 
&0(5) = prior incremental net benefit at stage s 
0 0(8)2 = prior variance of &O(S) at stage s 
on(s)2 = sample variance of &(s) with sample size n(s) at stage s 
S.2.4a 
The marginal cost of a sample entering stage s (Cm(s» is the additional treatment 
costs (compared to current practice) of allocating patients to the alternatives at 
that stage. The expected net benefits given a sample of n(S) at stage s is the 
difference between the expected benefits (EVSI(s)in(s») and the total variable cost of 
sampling (Cm(S)·n(S»)· 
5.2.4b 
The ENBS for the decision problem is the sum of the ENBS(S) at each stage: 
s 
ENBSin= L ENBS(s)in(s) 
5:1 
5.2.4c 
98 
Sample size will be optimal (n·) when the ENBSln reaches a maximum. If the 
fixed cost of research is less than the ENBSln· then the research is cost-effective 
at this technically efficient scale. The difference between the ENBSln· and the 
fixed cost of research can be used to set priorities in research and development 
and those proposals where the additional net benefits of research are greatest 
should be implemented first. In this way allocative efficiency in research and 
development across different sequential clinical decision problems can be 
achieved. The second hurdle for the two-stage decision problem in figure 5.2.1 
can be constructed using the approach detailed above. The problem is to establish 
the EVSI and ENBS at stage 2 and stage 1 for a range of possible sample sizes, 
and then select the sample size entering the trial at stage 1 which will generate the 
maximum expected net benefits of sampling. 
EVSI at Stage 2 
The EVSI at stage 2 is calculated for the number of patients entering the trial at 
stage 1 who are assigned to the no test arm and enter stage 2 (n(2) = (n(l/2)). The 
EVSId n(2) is calculated in the same way as the single-stage decision problem in 
chapter 4, and the from 5.2.4a 
5.2.5a 
The prior incremental net benefit oftl (00(2») is the difference between the prior net 
benefit of tl and the prior net benefit of to. 
5.2.5b 
Cost of Sampling at Stage 2 
The marginal cost of sampling at this point is the additional costs of assigning half 
the trial entrants who enter stage 2 to tl rather than current practice (to). 
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5.2.5c 
As before it is assumed that the marginal reporting cost are negligible and initially 
the fixed cost of research are zero because the fixed element will have no impact 
on optimal sample size. The expected net benefits of sampling given a sample of 
n(2) entering stage 2 (ENBS(2)ln2) is simply the difference between the expected 
benefits and the total variable costs of sampling, and is identical to the single stage 
problem considered in chapter 4: 
5.2.5d 
EVSI at Stage 1 
The benefits of sampling at the initial diagnostic decision cannot be separated from 
the sample which enters stage 2 because the fixed allocation rule means that a 
sample of n(l) at stage 1 will generate a sample of n(2) = n(I/2 at stage 2, with n'(2/2 
allocated to tl and flc.2/2 allocated to to· So the ENBS(l)lflc.l) cannot be calculated 
simply based on prior mean and variance at stage 1 because this would assume 
that those allocated to the no test arm would not be allocated between tl and to at 
stage 2 but would all be allocated to either tl or t2. A sample at stage 1 implies 
acquiring information about the contingent treatment decision at stage 2 and this 
will change the prior information about the no test alternative at stage 1. It will 
change the expected prior net benefits of not testing and reduce the uncertainty 
surrounding the initial diagnostic decision because more will be known about the 
no test alternative. 
This problem can be solved by making contingent sampling decisions at stage 2 
before calculating The ENBS at stage 1. Considering a sample of n1 at stage 1 
implies a sample of n(2) =n(1/2 at stage 2, and the expected net benefit and 
posterior variance from stage 2, with sample of n(2)' is used as the prior mean and 
variance of the no test alternative at stage 1. Both the expected net benefits and 
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posterior variance from stage 2 depend on the size of the sample entering stage 2 
and this approach is consistent with the principles of backward induction, where 
contingent sampling decision must be solved at stage 2 and expected posterior 
values calculated, before the value of sampling at stage 1 can be estimated. From 
5.2.4a the EVSI(l)lI\l) can be calculated as follows: 
5.2.6a 
The prior incremental net benefit at stage 1 (00(1» is the difference between the 
prior net benefit of testing (E(Ultc)-g·E(qtc)) and the expected net benefit of not 
testing (E(Ulntc)-g·E(Clntc», which is dependent on sample size. 
00(1) = (E(ultc)-g·E(Cltc» - (E(Ulntc)-g.E(Clntc» S.2.6b 
Prior Net Benefit at Stage 1 
The value ofE(Ulntc)-g·E(Clntc) is dependent on the sample size at stage 2, 
because there is a chance that a sample of n(1) which implies a sample n(2)=n(lj2 at 
stage 2 will generate a posterior mean net benefit which will lead to t1 being 
selected with net benefits ofE(Ult1)-g·E(Clt1). There is also a chance that the 
same sample may generate a posterior mean which will lead to to being selected 
with net benefits ofE(Ulto)-g·E(Clto)· The expected net benefits of not testing 
depends on the posterior values at stage 2 which are a combination of prior and 
sample information. In general a posterior mean at stage s (Ol(S» is simply a 
weighted average of the prior (oO(S» and sample mean (OX(s» with the weights 
representing the informational content of each. 
01(5) = (I0(5)' 00(5) + Ix(s)' ox(s»/(IO(s) + Ix(s» 
10(5) = 1/00(5/ 
Ix(s) = I/on(5)2 
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S.2.7a 
Before sample information is available and when oO(s)<Ob the clinician should select 
to based on the prior mean, but once sample information is available the clinician 
should change this prior decision and select tl if OI(s?Ob . The critical value of the 
sample mean (OX(S)-) is the sample mean which generates a posterior mean that 
changes the prior decision. This can be found by setting al(s)=ab and ax(s)=ax(S)* 
and rearranging 5.2.7a: 
5.2.7b 
If the sample mean is greater than this critical value (ox(s?aX(S) *) the posterior 
mean will be greater than 0b and the clinician should select tl at stage 2, but when 
o <0 ( )* the posterior mean is less than 0b and the clinical should select to. 
xes) x s 
When a sample enters stage 2 there is a probability that the sample mean will lead 
to tl being selected (P(OX(2) >aX(2)-»)' with prior net benefits ofE(Ultl)-g·E(Clto). 
There is also a probability that the same sample will lead to to being selected (1-
P(OX(2»aX(2)·)) with prior net benefits ofE(Ulto)-g.E(Clto)' The expected net 
benefits of not testing given a sample of n(2) at stage 2 is the prior net benefits of 
the no test arm of the trial at stage 1, and in 5.2.6b: 
E(Ulntc)-g·E(Clntc) = p( OX(2) >ox(2)·).(E(Ult l)-g.E(Clt l) 5 .2.8a 
+ 1-P(OX(2) >oX(2)·).(E(Ulto)-g·E(Clto» 
Since the choice of sample size must be made before any sample information is 
available the null hypothesis is that the sample mean is normally distributed, 
centred on the prior mean, with sample variance of On(2/: 
5.2.8b 
Prior Variance at Stage 1 
Sampling at stage 1 generates sample information at stage 2 which will reduce the 
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uncertainty surrounding the no test alternative at stage 1. The prior variance at 
stage 2 does not reflect this additional information and it is the posterior variance 
from stage 2 which is used to establish the prior variance of the expected net 
benefits of not testing at stage 1. Posterior variance is a combination of prior and 
sample variance and will be less than either the prior variance or the sample 
variance. The uncertainty surrounding the no test alternative is reduced by taking 
the sample information generated at stage 2 into account in this way. In general 
the posterior variance (0 1(S)2) with a sample of n(5) is a combination of prior (00(5)2) 
and sample variance (On(s)2): 
5.2.9 
The prior variance ofE(ulntc)-g·E(Clntc) at stage 1 is a combination of the 
posterior variance ofE(Ult1)-g·E(Clt1) and E(Ulto)-g.E(Clto) given a sample of 
I1c2)=n(1/2 entering stage 2 with n(d2 allocated to tl and n(2/2 allocated to to. This 
approach ensures that the information generated at stage 2 is taken into account 
when calculating the benefits of sampling at stage 1. The population variance of 
E(U!ntc)-g.E(Clntc) is also dependent on the sample entering stage 2 because this 
determines the value of P(OX(2»OX(2)·) which is regarded as a constant when 
calculating the population and the prior variance of E(Ulntc)-g.E(Clntc) at stage 1. 
The EVSI(I)ln(l) from 5.2.6a can now be established taking into account the 
relationship between the sample considered at stage 1 and sample information it 
will generate at stage 2. It measures the additional value of sample information at 
this initial decision given that a sample of n(l) at stage 1 will generate a sample of 
n(2) at stage 2, which will reduce the uncertainty surrounding the no test alternative 
and will also change the expected prior net benefits of choosing not to test. 
Increasing the sample considered at stage 1 will change the expected net benefits 
of not testing from stage 2 and therefore change 00(1) • It will also reduce the 
posterior variance from stage 2 and therefore reduce the prior variance at stage 1. 
So unlike the single-stage decision problem, the prior mean and prior variance for 
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the initial decision is not independent of the sample size considered. 
Cost of Sampling at Stage 1 
The marginal cost of sampling at stage 1 is the additional treatment costs of 
allocating trial entrants to the testing arm of the trial. The marginal cost of 
allocating a trial entrant to the no test arm at stage 1 is zero because the 
additional treatment cost of assigning patients to tl at stage 2 has already being 
taken into account in the calculation of the ENBS(2)in(2). So the marginal cost of 
sampling at the initial diagnostic decision is the additional cost of assigning half 
the entrants to the test alternative: 
5.2.10 
The expected net benefit of sampling at the initial diagnostic decision is simply the 
difference between the expected benefits and the total variable cost of sampling: 
5.2.11 
The ENBS(l)in(l) is the net benefit of comparing the testing strategy to the no test 
strategy using sample information, given that a sample at stage 1 will generate a 
sample of "<2) at stage 2. The sample generated at stage 2 will provide net benefits 
from comparing tl to to using sample information and this is measured by 
ENBSdn(2)' but sampling at stage 2 will also provide information about the net 
benefit of the no test alternative at stage 1. The methods outlined above ensures 
that the ENBS for the full decision problem can be estimated by the sum of 
ENBS(l)in(l) and ENBS(2)in(2) without the danger that the benefits of sampling will 
be overestimated by double counting benefits at stage 1 and 2, or underestimating 
the benefits of proposed research by simplifying this two stage problem to a single 
stage problem and only comparing the testing strategy to either tl or to. 
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ENBS and Optimal Sample Size 
The ENBS for both stages of this decision problem is illustrated in figure S.2.Sa 
when the value of 1/g=£4,000 and for a range of possible sample sizes entering 
stage 1. The ENBS is the sum of the net benefits at stage 1 and 2 and reaches a 
maximum at nO=92. At this optimal sample size 46 entrants will be allocated to the 
test and 46 to the no test arm at stage 1, and 23 will be allocated to tl and 23 to to 
at stage 2. The maximum ENBSln" =£442,340, and this is the second hurdle that 
proposed research must overcome. If the fixed cost of the research is less than the 
expected net benefit then the proposed research is cost-effective when conducted 
at this technically efficient scale. 
Figure S.2.Sa 
The expected net benefits of sampling are greater at stage 2 than stage 1, indeed 
the ENBS(l)II\I) <0. This is because the marginal sampling cost at stage 1 is high, -
due to the additional costs of the diagnostic test, and because at 1/g=£4,000 the 
prior decision not to test is less uncertain than the prior decision to choose to at 
stage 2 (L(D0(2»)>L(DO(I») in figure S.2.3b). Although the ENBS(dn(I) <0 it is still 
worth taking a sample at stage 1 because it enables a sample to enter stage 2 
which will produce positive net benefits ofENBS(2)ln(2). The ENBSdn(2) is 
identical to the expected net benefits of the single stage treatment decision 
problem considered in chapter 4, but because of the negative net ben~fits at stage 
1 the optimal sample size of 46 at stage 2 is less than the optimal sample size for 
the single-stage decision problem. 
Value of Bealth Outcome 
The expected net benefit of sampling and optimal sample size is dependent on the 
value placed on health outcome. In this example when 1/g is higher at £ 1 0,000, 
the expected net benefit and the optimal sample size is also higher. This is 
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illustrated in figure S.2.Sb where the ENBS reaches a maximum at n·=260. The 
fixed allocation rule dictates that 130 entrants will be allocated to the testing and 
130 to the no test arm, so that n(2)o=130, and 70 entrants will be allocated to tl and 
70 to to at stage 2. Now the expected net benefits of sampling are greater at stage 
1 than at stage 2 because there is less weight attached to the higher cost of 
sampling at stage 1 and the prior decision not to test is less certain than the prior 
decision to select tl at stage 2 (L(DO(I»)>L(Do(2)) in figure S.2.3b). The ENBS(2)ln(2) 
reaches a maximum when n=376, but the ENBS(l)ln(l) reaches a maximum at 
n=20 1 due to the higher marginal sampling cost. 
Figure S.2.Sb 
The expected net benefits of sampling when the value of 1Ig is increased to 
£20,000 is illustrated in figure 5.2.5c. Optimal sample size is greater (n·=372) and 
the maximum ENBSln* is also higher. Again the expected net benefits at stage 1 
are substantially greater than net benefits at stage 2, because even less weight is 
placed on the higher marginal sampling costs at stage 1, and because the prior 
decision (which is now to test), is less certain than the prior decision to treat at 
stage 2 (L(Do(l))>L(D0(2)) in figure 5.2.3b). 
Figure 5.2.5c 
In this example of a sequential decision problem optimal sample size increases 
with the value placed on health outcome. The relationship between l/g and 
optimal sample size is illustrated in figure 5.2.6. Optimal sample size with a more 
sceptical (no=2) and a less sceptical prior (no=18) is also illustrated in figure 5.2.6. 
When the value of health outcome is low the optimal sample size is zero and 
decisions should be based only on prior information, which in this example would 
be not to test and not to treat. Sampling becomes optimal at lower values of l/g 
when the prior is more sceptical (ifno=2 then n*=O when l/g<£2,000) because the 
prior decision is more uncertain and less information is required to change the 
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prior decision than with a more confident prior (if Ilo=18 then n*=O when 
1/g<£5,000). 
Figure 5.2.6 
The discontinuities in the relationship between 1/g and n· when no=2, and no=6 is 
at the point where the clinician is indifferent between the testing and the expected 
net benefits of not testing from stage 2. This point changes with n* because the 
expected net benefit of not testing depends on the sample generated at stage 2. 
The discontinuity in the relationship between n· and 1/g when no=18 occurs when 
the net benefits of sampling at stage 2 are less than zero. 
Once optimal sample size is established for each value of l/g the relationship 
between the ENBSln· and the value of 1/g can be considered. Figure S.2.7a 
illustrates this relationship for each stage of the decision problem. The ENBSln· 
is the second hurdle that proposed research must overcome before it can be 
considered cost-effective, and figure S.2.7a demonstrates that the second hurdle is 
sensitive to the value of 1/g and budgetary restrictions on service provision. There 
are two discontinuities in the relationship between ENBSln* and 1/g. The 
ENBS(2)11\2)· reaches a peak when the clinician is indifferent between tl and to 
based only on prior information. The discontinuity in the ENBS(I)ln(I)· occurs when 
the clinician is indifferent between the test and no test alternatives which (from 
S.2.8a) is partly determined by sample size. 
Figure S.2.7a 
The ENBSln· for three different priors is illustrated in figure 5.2.7b. The ENBSln· 
increases with the value placed in health outcome, but the value of sample 
information is also sensitive to the confidence in prior information. When the prior 
is more sceptical (no=2) then the expected cost of uncertainty surrounding this 
decision problem is higher and the value placed on additional sample information 
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is also high. However when there is more confidence in prior information (no=18) 
the cost of uncertainty is lower and the value of additional sample information is 
also low. This confirms the interpretation placed on the EVSI that the benefit of 
sample information is the reduction in the costs of uncertainty surrounding a 
decision problem. 
Figure 5.2.7b 
5.2.3 Implications for Research Design 
This numerical example has demonstrated that the expected net benefits of sample 
information and the optimal sample size can be established and the second hurdle 
can· be constructed for a sequential decision problem. An analysis which did not 
recognise the sequential nature of the decision problem by only considering the 
single-stage treatment decision and excluding the diagnostic process would bias 
efficient research design and cause errors at the second hurdle. This illustrates the 
dangers of ruling out alternatives from consideration based on implicit decision 
rules and inconsistent judgements. For example if the value of l/g is £6,500 then 
the clinician would be indifferent between t\ and to at stage 2. The clinician is most 
uncertain about this treatment decision and prospective research may only be 
considered for this single-stage treatment decision. The diagnostic process may be 
excluded and regarded as not relevant because prior information suggests that 
testing will not be cost-effective (prior cost-effectiveness ratio = £11,SOO). 
However by arbitrarily excluding the diagnostic process from prospective research 
the expected net benefits of sample information and optimal sample size will be 
underestimated. This is illustrated in figure 5.2.Sa and figure 5.2.Sb where the 
ENBSln* and n* for this sequential problem are compared to the single stage 
treatment decision considered in chapter 4 . 
Figure 5.2.Sa 
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Figure 5.2.8b 
The ENBSjn· for this two-stage problem is greater than the single-stage problem, 
and excluding the diagnostic process from the design of a proposed trial will 
underestimate the expected net benefits of sample information and the optimal 
scale of the research. The second hurdle will be biased and there will be a danger 
that cost-effective research will be rejected at the second hurdle. The optimal 
- sample size will also be underestimated and research design will be technically 
inefficient. The bias in the estimates of the expected net benefits of sampling may 
also lead to inefficient allocation between clinical decision problems and the 
allocation of research and development resources to technically inefficient designs. 
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5.3 A Four-Stage Sequential Clinical Decision Problem 
The same approach to the value of information can be applied to more complex 
decision problems, and in this section the first and second hurdles can be 
constructed for a four-stage decision problem. This is the same problem which 
was used to generalise the Phelps and Mushlin strategy for the economic 
evaluation of diagnostic information in chapter 3. This decision problem is 
identical to the two-stage problem in section 5.2 except that an alternative 
treatment t2 is available. 
Figure 5.3.1 
The decision problem is illustrated in figure 5.3.1 and is structured to follow the 
correct chronology and includes Bayesian probability revision. Now that an 
alternative treatment (t2) is available the clinician must choose between two testing 
and three fallback strategies. At stage 4 the clinician must choose to treat with 
either tl or t2 following a positive test result, and those with negative test results 
are not treated (to)· If the clinician decides not to test at stage 1 they must decide 
whether to treat (tr) or not treat (to) at stage 2, and if they decide to treat they 
must then decide whether to treat with either t\ or t2 at stage 3. In this section the 
same numerical example as chapter 3 is used but with prior distributions for the 
health outcomes and path probabilities. These are reported in table 5.3. Again the 
assumptions of normality and independence allow normal loss fi!.nctions to be used 
and covariance terms to be zero when calculating the prior and population 
variance at each stage. 
Table 5.3 
The problem is to construct the first hurdle for this decision problem by 
establishing the expected value of perfect information at each stage. If proposed 
research passes this first hurdle the expected net benefits of sample information 
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must be established and the technically efficient scale of the research must be 
identified to construct the second hurdle. 
5.3.1 Hurdle I: The Expected Value of Perfect Information 
The clinician is faced with an uncertain choice between two alternatives at each 
stage of this decision problem. Without any additional information these choices 
must be made based on prior information and there will be a chance that 
opportunity losses will be incurred. The expected cost of uncertainty at each 
stage is the expected value of perfect information and the EVPI for this four-
stage decision problem will be the sum of the EVPI(s) at each stage (s=l, .. ,4). 
EVPI at Stage 4 
If the clinician decides to use the test a contingent treatment decision must be 
made at stage 4 in figure 5.2.1, because now if a patient has a positive test result 
the clinician must decide to treat with either tl or t2 (prior CER=£5,800). This 
contingent decision is based on the prior incremental net benefit oftl (00(4» and is 
the difference between the prior net benefit oftl given a positive test result 
(E(Ult/, t,)-g.E(Clt/, tl))' and the prior net benefit oft2 given a positive test result 
(E(Ult/, t2)-g·E(Clt/, t2»· 
EVPI at Stage 3 
The clinician also faces an uncertain contingent decision at stage 3 and must 
choose either tl or t2· This decision is based on the prior incremental net benefits 
oftl at stage 3 (00(3»' and is the difference between the prior net benefits oftl 
(E(Ult1)-g.E(Clt1» and the prior net benefits oft2 (E(Ult2)-g.E(Ult2» (prior 
111 
CER=£lO,OOO). 
5.3.2 
EVPI at Stage 2 
If the clinician decides not to test they also face a choice between treatment (tr), 
following the contingent treatment decision at stage 3, and no treatment (to) at 
stage 2. This contingent decision is also uncertain and opportunity losses may be 
incurred. The EVPI(2) at stage 2 is in addition to the EVPI(3) because to must be 
compared with either t1 or t2 depending on the contingent decision made at stage 
3. The decision at stage 2 is based on the prior incremental net benefits of 
treatment (00(2) which is the difference between the prior net benefits of treatment 
(E(Ultr)-g.E(Cjtr)), and the prior net benefits of no treatment (E(Ulto)-g.E(Ulto)). 
EVPI at Stage 1 
Finally the clinician faces an uncertain choice at the initial diagnostic decision. At 
stage 1 the clinician must choose whether to test and follow the contingent 
decision at stage 4, or choose not to use the test and follow the contingent 
treatment decisions at stage 2 and stage 3. The uncertainty surrounding this initial 
decision is in addition to the uncertainty surrounding each of the three contingent 
decision problems at stages 2,3, and 4. The decision is based on the prior 
incremental net benefit of testing (00(1) ) which is the difference between the prior 
net benefits of testing (E(Ulte)-g·E(Cjtc)) given the contingent decisions at stage 4 
and the prior net benefits of not using the test (E(Ulntc)-g.E(Clntc)) given the 
contingent decisions at stage 2 and stage 3. 
5.3.4 
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EVPI for the Four-Stage Problem 
The EVPI for this sequential decision problem is the sum of the EVPI(s) at each 
stage (each point where the clinician faces an uncertain decision) and this is 
illustrated for this numerical example in figure S.3.2a. The EVPI rises with the 
value of 1/g because the value placed on opportunity losses increases (~ =2/g). 
This is the first hurdle for this decision problem and if the EVPI exceeds the 
estimated cost of proposed research then it is potentially cost-effective and passes 
the first hurdle. Figure S.3.2a. demonstrates that this first hurdle is sensitive to the 
value of health outcome, and (just as in chapter 4 and section 5.2) the value of 
information is dependent on budgetary restrictions on service provision. If the 
budget constraint is relaxed then the value of l/g and the value of information will 
increase, similarly when the budget constraint is tightened the value of l/g will fall 
and the value of information will also fall. 
Figure S.3.2a 
This approach allows the value of perfect information to be identified at particular 
points in a sequential decision. This can be used to indicate where additional 
information about particular contingent decisions will be valuable. Figure S.3.2b 
illustrates the EVPI(s) at each stage in this decision problem and it demonstrates 
that the points in a sequential decision problem where information is most valuable 
will depend on the value of 1/g. In this numerical example when l/g is low 
(£3,000) the expected cost of uncertainty is highest at stage 2 where the clinician 
must choose between to and t2. But when the value of 1/g is higher (£14,000) the 
point where information may be most valuable will now be at stage 1 where the 
clinician faces a choice between using the test and treatment without testing. 
Figure S.3.2b 
The relationship between the EVPI(s) at each stage and the value of lIg contains a 
113 
number of discontinuities at the points where the prior contingent decisions 
change. The discontinuity in the EVPI(4) occurs at 1/g=£5,800 which is where the 
clinician will be indifferent between tl and t2 at stage 4. At this point D0(4) =0 in 
figure 5.3.3a and L(DO(4») reaches a maximum in figure 5.3.3b. The discontinuity 
in the EVPI(3) occurs at 1/g=£lO,OOO where the clinician is indifferent between tl 
and t2 at stage 3. At this point the D0(3) =0 in figure 5.3.3a and the L(D0(3») reaches 
a maximum in figure 5.3.3b. There are two discontinuities in the EVPI(2). The first 
occurs when l/g=£3,000 where the clinician is indifferent between to and t2. At 
this point D0(2) =0 in figure 5.3.3a and L(D0(2») reaches a maximum in figure 
5.3.3b. The second discontinuity occurs at l/g=£10,000 when the decision facing 
the clinician at stage 2 changes from a choice between to and t2 to a choice 
between to and t\. The discontinuities the EVPI(\) reflect the changes in the 
contingent decisions at stages 2, 3, and 4 outlined above, but in addition there is a 
discontinuity in the EVPI(l) where the clinician will be indifferent between testing 
and not testing at 1/g=£11,800. At this point the initial diagnostic decision is most 
uncertain and DO(I)=O in figure S.3.3a and the L(DO(I) reaches a maximum in figure 
S.3.3b. 
Figure 5.3.3a 
Figure S.3.3b 
The EVPI depends on the confidence in prior information. Figure 5.3.4 illustrates 
the EVPI for 3 different levels of confidence in prior information. When the prior 
is more sceptical (the quasi sample size is lower (f1o=2) then the uncertainty 
surrounding each decision will be greater and the EVPI is higher. Similarly when 
the prior is less sceptical (the prior sample size is higher (I1o=18)) then the 
uncertainty surrounding each decision will be lower and the EVPI is also lower. 
Figure 5.3.4 
The EVPI for this four-stage decision problem and for the two-stage decision 
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problem discussed in section 5.2 is illustrated in figure 5.3.5. These decision 
problems are identical except that treatment alternative t2 is not available in the 
two-stage problem. An analysis of this clinical problem which simplified what is a 
four-stage decision problem to a two-stage problem by excluding t2 as a relevant 
alternative would clearly underestimate the EVPI. The first hurdle would be 
biased and there would be a danger that potentially cost-effective research would 
be rejected. In this numerical example if the value of l/g is greater than £10,000 
then t2 will not be selected at any stage based on prior information. In these 
circumstances it may be tempting to conclude that t2 is not a relevant alternative 
and can be excluded from the analysis. However this process of simplification and 
arbitrarily excluding feasible alternatives as not relevant may introduce serious bias 
into the analysis. It is possible that a feasible alternative is not relevant if it will 
never be selected. This could be established by comparing the EVPI with and 
without the alternative and if the alternative is not relevant then both estimates of 
the EVPI should coincide. 
Figure 5.3.5 
5.3.2 Hurdle II: The Expected Net Benefit of Sample Information 
If the EVPI exceeds the estimated costs of proposed research then it is potentially 
cost-effective and the expected net benefits of sample information must be 
established to construct the second hurdle and identify the optimal sample size. 
The second hurdle can be constructed for this four-stage decision problem using 
the same methods which were used to construct the second hurdle for the two-
stage decision problem in sections 5.2. The same fixed allocation rule is used at 
each stage where equal numbers of trial entrants are assigned to each arm at each 
stage. Following the principles of backward induction the expected net benefits 
and the posterior variance at each contingent decision is uaed as the prior 
information at earlier stages. 
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The expected net benefits of sampling for this decision problem is the sum of the 
ENBS(s) at each stage, taking into account that sampling at an early stage implies a 
sample at later stages which will reduce the uncertainty surrounding the 
alternatives considered at these earlier stages. The optimal number of trial 
entrants at stage 1 is the sample size that maximises the ENBS and it is this 
maximum value which is used as the second hurdle. 
ENBS at Stage 4 
At stage 4 the clinician must decide whether to use treatment t1 or t2 following a 
positive test result. The fixed and equal allocation of trial entrants means that if a 
sample of n(l) enters stage 1 then the number of entrants entering stage 4 will be 
1\4)= (n(l/2).p(tc+)· The EVSI(4)in(4) given a'sample ofn(4) entering stage 4 can be 
calculated and the marginal cost of sampling at stage 4 is the additional cost 
(compared to to) of assigning half the entrants to t1 and half to t2 . 
5.3.5 
The costs of testing at this point are sunk, but will be taken into account when 
estimating the expected net benefits of allocating entrants to the testing arm at 
stage 1. 
ENBS at Stage 3. 
At stage 3 the clinician must choose between tl and t2. The fixed and equal 
allocation of trial entrants means that a sample ofn(l) at stage 1 generates a sample 
ofn(2)= (n(1/2) entering stage 2, with (n(2/3).2=n(3) assigned to the treatment arm 
and entering stage 3. This allocation rule ensures that equal numbers of entrants 
will be allocated to to, t}> and t2· The EVS1mlI\3) given a sample n(3) entering stage 
3 can be calculated and the marginal sampling cost is the additional treatment cost 
of assigning half the entrants at stage 3 to tl and half to t2• 
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5.3.6 
ENBS at Stage 2 
At stage 2 the clinician must decide whether to treat (tr) and follow the contingent 
treatment decision at stage 3 or not treat (to). If n(l) patients enter the trial at stage 
1 then n(2)=n(l/2 will enter stage 2 with (n(2/3)2 assigned to tr and n(z/3 will be 
allocated to to. The EVSIdn(2) must take into account that a sample of n(2) at 
stage 2 implies a sample ofn(3)=(n(2/3)2 at stage 3. This will change the expected 
net benefits oftr and will reduce the uncertainty surrounding the treatment arm at 
stage 2. The EVSImln(2) can be established using the same approach that was used 
at stage 1 in section 5.2. The prior incremental net benefit of selecting tr (50(2» is 
the difference between the prior net benefit of treatment (E(Ultr)-g·E(Cjtr» and the 
prior net benefit of to (E(Ulto)-g·E(Cto»· The expected net benefit of treatment 
and therefore 00(2) is dependent on sample size because for each sample considered 
at stage 2 there is a probability that the sample which enters stage 3 will generate a 
posterior mean which will lead to t1 being selected (p( 5.t (3?5"(3)·» with net benefits 
of (E(Ult1)-g·E(Cjt1»· There is also a probability that the same sample will lead to 
t2 being selected (1-p(Ox(3?Ox(3)"» at stage 3 with net benefits of (E(Ult2)-
g.E(Cjt2»· 
(E(Ultr)-g.E(Cjtr» = P(5X(3?5x(3)·).(E(Ult1)-g.E(Cjt1» 5.3.7 
+ ~-p(5X(3»5x(3)·).(E(Ult2)-g.E(Cjt2» 
P(OX(3?OX(3)") = p(Z>«00(3)-5x(3)')/(on(3»» 
The prior net benefits of the treatment arm at stage 2 (E(Ultr)-g.E(Cjtr» is the 
expected net benefits from stage 3 and depends on the sample size considered at 
stage 2. The prior variance ofE(Ultr)-g·E(Cjtr) at stage 2 is dependent on the 
sample assigned to the treatment arm which will enter stage 3, because it is a 
combination of the posterior variance ofE(Ult1)-g.E(Clt1) and E(Ult2)-g.E(Cjt2) at 
stage 3 given a sample n(3)=(n(2/3)2. The population variance ofE(Ultr)-g.E(Cjtr) 
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is also dependent on the sample entering stage 3 because this determines the value 
of P(OX(3(>OX(3)*)' 
The marginal sampling cost at stage 2 is zero because the additional treatment 
cost of assigning an entrant to to is zero and the additional costs of assigning an 
entrant to the treatment arm is also zero because the additional costs of treatment 
with tl or t2 have been taken into account at stage 3. 
ENBS at Stage 1 
At the initial diagnostic decision the clinician must decide whether to test (te) and 
follow the contingent treatment decision at stage 4, or not test (nte) and follow 
the contingent treatment decisions at stage 2 and 3. The EVSI(I)ln(1) is the 
additional benefit of sample information at stage 1 given that each sample 
considered will generate sample information at the contingent treatment decisions. 
A sample of n(l) implies a sample of n(2)=n(1/2 entering stage 2 which will change 
the expected net benefits of not testing and reduce the uncertainty surrounding the 
no test arm. It also implies a sample of 1\4)= (1\1/2).p(t/) entering stage 4 which 
will change the prior expected net benefits of the test arm and will reduce the 
uncertainty surrounding the testing arm at stage 1. The reduction in uncertainty 
surrounding this initial decision due to sampling at contingent decisions will 
reduce the additional benefits of sample information at this stage. This can be 
taken into account in the same way as section 5.2 by using the expected net 
benefit and posterior variance from stage 4 and stage 2 as the prior information at 
stage 1. 
The prior incremental net benefit of testing (00(1) is dependent on sample size 
because it is the difference between the prior net benefits of testing (E(Ulte)-
g.E(Cltc)' which is partly determined by sample entering stage 4, and the prior net 
benefit of not testing (E(Ulnte)-g.E(Clnte», which is also determined by sample 
entering stage 2. 
118 
Each sample considered at stage 1 generates a sample of n(2)=n(l/2 at stage 2 and 
there is a probability that this sample will generate a posterior mean at stage 2 
which will lead to tr being selected (P(5X(2?<\(2)"») with net benefits of (E(Ultr)-
g.E(Cltr)). There is also a probability that the same sample will generate a 
posterior mean which will lead to to being selected at stage 2 (I-p( 5:«2) >5X(2)·» 
with net benefits of (E(Ulto)-g·E(Clto»· 
E(Ulntc)-g.E(Clntc) = P(5X(2?5x(2)·).(E(Ultr)-g.E(Cltr» 5.3.8a 
+ I-p(5X(2»5x(2)·).(E(Ulto)-g.E(Clto)) 
P(5X(2) >5X(2)·) = p(Z>«50(2) >5x(2)·)/( On(2»» 
Each sample at stage 1 generates a sample ofn(4)=(n(l/2).p(t/) at stage 4 which 
will lead to tl being selected following a positive result (E(Ult/,tl)-g·E(Clt/,t l» 
with a probability ofp(5x(4?5x·(4»' and t2 will be selected following a positive 
result (E(Ult/,t2)-g·E(Ult/,t2» with a probability of I-p(5x(4?5x·(4»' No treatment 
follows a negative test result (p(tc-» with net benfits of (E(Ultc-,to)-g.E(Clte-,to». 
E(Ultc)-g·E(Cltc) = p(tc").(E(Ultc-,to)-g·E(Cltc-,to» 5.3.8b 
+p(tc +). (p( 5X(4?5x(4)"). (E(Ultc +, tl)-g· E( Cite +, tl» 
+ I-p(5x(4?5x(4)·).(E(Ultc+,t2)-g·E(Ultc +, t2»)) 
p( OX(4) >OX(4)") = p(Z>« 00(4) >0:«4)·)/( On(4»)) 
The marginal sampling cost at stage 1 only includes the cost of the diagnostic test 
(etc) because the additional costs of treatment are taken in to account in the ENBS 
at stage 3 and at stage 4, and the additional cost of to for those with negative test 
results is zero. 
5.3.8c 
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ENBS and Optimal Sample Size 
The expected net benefits of sample information for this decision problem is the 
sum of the ENBS at each stage. The approach taken at stage 1 and 2 of using the 
expected net benefits from contingent decisions as the prior information at these 
earlier stages ensures that the benefits of sampling at each stage will not be 
overestimated. The ENBS for this numerical example is illustrated in figure S.3.6a 
when the value of lIg=£4,000. The ENBS reaches a maximum (ENBSln*) at an 
optimal sample size of n *= 191 and is the second hurdle that the this proposed 
research must overcome before it can be considered cost-effective. At this value 
of lIg the ENBS at stage 2 is greater than at the other stages. In particular it is 
greater than at stage 1 where the ENBS(l)<O. This is because of the high marginal 
sampling cost at stage 1 but also because the prior decision not to test is less 
uncertain than the decision to treat with t2 at stage 2 (L(D0(2» > L(Do(1) in figure 
S.3.3b). Although the ENBS(1) <0 it is still worth taking at sample at stage 1 
because it means that the positive net benefits at the contingent decisions can be 
realised. 
Figure S.3.6a 
The ENBS and optimal sample size for this decision problem depends on the value 
of l/g, and figure S.3.6b illustrates the ENBS for this numerical example when the 
value of lIg is higher at £10,0000. In this case the optimal sample size is higher 
(n-=432 ) and the ENBSln* is also higher. Now the ENBS at stage 3 and stage 1 
is highe'r than at stage 2. This is because less weight is placed on the marginal 
sampling cost at stage 1, and because the prior decision to treat at stage 2 is less 
uncertain than the decision not to use the test at stage 1 (L(Do(2)<L(DO(I) in figure 
S.3.3b) and it is also less uncertain than the choice between tl and t2 at stage 3 
(L(D0(2» < L(D0(3» in figure S.3.3b). 
Figure S.3.6b 
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The ENBS when the value of Ilg is increased to £20,000 is illustrated in figure 
5.3.6c. The optimal sample size is greater (n·=666) and the maximum ENDS is 
also higher. The highest ENBS(s) is at stage 1 and the lowest is at stage 2, this is 
because the prior decision to treat at stage 2 is less uncertain than the prior 
decision at stage 1, which is now to use the test (L(D0(2) < L(DO(I» in figure 
5.3.3b). 
Figure 5.3.6c 
These examples demonstrate that it is possible to construct the second hurdle for 
more complex sequential decision problems and this hurdle operates in the same 
way as in the previous section and in chapter 4. If the ENBSln'" exceeds the fixed 
cost of proposed research then it is cost-effective when conducted at the 
technically efficient scale. Similarly the difference between the ENBS and the 
fixed cost of research can be used to set priorities across research proposal that 
pass the second hurdle. If those proposals where the difference between ENBSln'" 
and fixed cost are greatest are implemented first then the maximum benefits can be 
gained for a fixed research and development budget. So again this approach and 
construction of the second hurdle can be used to ensure the optimal allocation of 
research and development resources among technically efficient research designs. 
The relationship between the value of l/g and the optimal sample size for this 
numerical example is illustrated in figure 5.3.7. Optimal sample size is illustrated 
for a range of values of lIg and for three quasi prior samples (I1o=2, 6, 18). This 
illustrates that when the value of lIg is low there will be a point where the optimal 
sample size is zero and decisions should be based only on prior information which 
in this example would be not to treat. However sampling becomes optimal at 
lower values of lIg when the prior is more sceptical (no=2) just as in the analysis 
of the two stage decision problem. This is because if there is less confidence in 
prior information then the prior decision will be more uncertain and the benefits of 
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sample information will be greater. In this numerical example the optimal sample 
size increases with 1/g and is not particularly sensitive to the strength of the prior 
information. The discontinuities in this relationship occur where the clinician is 
indifferent between the alternatives at each stage. These points of indifference at 
stage 1 and stage 2 where information will be most valuable change with sample 
size. 
Figure 5.3.7 
Once the optimal sample size has been established the relationship between 
ENBS!n" and the value of 1/g can be illustrated in figure S.3.8a. The 
discontinuities in the relationship between the value of l/g and the ENDS are at 
those values of 1Ig where the clinician would be indifferent between the 
. alternatives. For example the discontinuity in the ENBS(3) occurs when 1Ig 
=£10,000 and the clinician is indifferent between treatment t1 and t2. Figure S.3.8a 
also illustrates that the stages where information will be most valuable will also 
depend on the value of 1Ig. When the value of l/g is high (greater than £ 11,000) 
the ENBS is highest at stage 1 and lowest at stage 2, however if the value of 1/g is 
lower (less than £6,000) then the ENBS is highest at stage 2 and lowest at stage 1. 
This approach can identify those points in sequential decision problems where 
information will be most valuable and this can be used to set priorities in acquiring 
additional information, however the point at which information is most valuable 
will depend on the value of 1/g. 
Figure 5.3.8a 
Figure 5.3. 8b 
The ENBS!n" for this decision problem using three quasi prior samples (no=2, 6, 
18) is illustrated in figure 5.3.8b, and demonstrates that the second hurdle is also 
sensitive to the quality or strength of prior information. When the prior is more 
sceptical (00=2) then the ENBS is higher at each value of l/g because the prior 
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decisions are more uncertain and additional information will be more valuable. 
Similarly when the prior is less sceptical the ENBS is lower for each value of lIg, 
because the prior decisions are less uncertain and the value of additional 
information will be lower. 
5.3.3 Implications for Research Design 
This numerical example demonstrates that this approach can be applied to more 
complex sequential decision problems. This four-stage decision problem is 
identical to the two stage decision problem in considered in section 5.2 of this 
chapter except that an alternative treatment t2 is available. An analysis which 
either did not recognise that t2 is a feasible alternative or ruled it out as not 
relevant would bias the second hurdle and lead to errors in efficient research 
design by excluding arms of the trial, and biasing the optimal sample size. 
These dangers can be illustrated by comparing the ENBSln" for the four-stage 
problem considered in this section and the ENBSln" for the two-stage problem 
considered in section 5.2. This comparison is illustrated in figure 5.3.9a. The 
ENBS for the two-stage problem represents the results of an analysis which has 
ruled out t2 as an irrelevant alternative. Treatment t2 may have been regarded as 
not relevant because it may not be part of current practice. If the value of 1/g is 
greater than £10,000 it will not be selected at any stage based on prior 
information, and if purely clinical decision rules are used to select existing patient 
management strategies it will never be selected at any prior probability of disease. 
This was discussed in more detail in chapter 2. However iftz is excluded for what 
ever reason figure 5.3.9a demonstrates that the ENBS will be underestimated, the 
second hurdle will be biased. There will be a danger that a cost-effective research 
proposal will be rejected at this second hurdle. 
Figure 5.3.9a 
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Figure 5.3.9b 
The design of the proposed trial will be inefficient and will exclude the random 
allocation of trial entrants at stage 4 and stage 3. The optimal sample size will also 
be biased and this is illustrated in figure 5.3.9b where the optimal sample size for 
the four stage problem is greater than for the two stage problem which excludes 
t
2
• Once again this illustrates that arbitrarily excluding feasible alternatives and 
using implicit rules and inconsistent judgements to identify which alternatives are 
regarded as relevant will bias research design. In this example the value of 
information and the technically efficient scale of proposed research will be 
underestimated. There is a danger that cost-effective proposals will be rejected 
and those that are accepted will be conducted at less than the technically efficient 
scale. 
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5.4 Conclusions 
The examples considered in this chapter have demonstrated that the decision 
analytic approach to valuing the information generated by clinical research can be 
applied to sequential clinical decision problems. The first and second hurdles can 
be constructed and they can be used to achieve technically efficient research 
design and allocative efficiency across proposed clinical research. 
In a sequential clinical decision problem the clinician faces an uncertain choice at 
each stage ( decision node) and with no sample information these decisions must 
be made based only on prior information. There is a chance that these decisions 
will be wrong and opportunity losses will be incurred at each stage. The EVPI, or 
the expected opportunity loss, for the full decision problem will be the sum of the 
EVPI at each stage (at each point where the clinician faces an uncertain decision). 
The EVPI can be used as the first hurdle for proposed research which will be 
potentially cost-effective if the EVPI exceeds its fixed cost. Just as in chapter 4 
the EVPI is sensitive to the value of health outcome and demonstrates once again 
that the value of information and research priorities cannot be separated from the 
budgetary restrictions on service provision. This approach to sequential decision 
problems allows the EVPI to be established at each stage and can be used to 
identify those points in a sequence of decisions where the cost of uncertainty is 
greatest and where additional information may be most valuable. This may 
provide very different results to a simple sensitivity analysis which is potentjally 
misleading if it is used to identify points where additional information will be 
valuable. 
If proposed research passes the first hurdle then it is potentially cost-effective. The 
next step is to establish the expected net benefit of sample information at the 
optimal sample size. In a sequential decision problem trial entrants are allocated 
to each arm of the trial at each stage. The problem is that the benefits of sampling 
at an initial decision cannot be separated from the sample which will be generated 
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at later stages. Therefore the ENBS is not simply the sum of the ENBS calculated 
separately at each stage. A sample at the initial stage implies acquiring sample 
information about contingent decisions which will change the prior incremental net 
benefit and reduce the uncertainty surrounding the initial decision. This problem is 
solved by making contingent sampling decisions and calculating the posterior net 
benefits and posterior variance at later stages which is used as the prior 
information at earlier decisions. This approach is consistent with the principles of 
-backward induction where contingent sampling decisions must be made and 
posterior values calculated before the ENBS can be established at the initial stage. 
These methods ensure that the ENBS for the full decision problem can be 
established by taking the sum of the ENBS at each stage without the danger that 
the benefit of sampling will be overestimated by double counting at each stage, or 
underestimated by simplifying a sequential problem to a single-stage decision. 
The ENBS at the optimal sample size is the second hurdled that proposed research 
must overcome. If the ENBS exceeds the fixed cost of the research then it can be 
regarded as cost-effective and should be implemented. The optimal sample size or 
the technical efficient scale of research is where the ENBS reaches a maximum 
and this is the value of the second hurdle. These numerical examples demonstrate 
that the value of the second hurdle is dependent on the value of health outcome, 
and reaffirms the conclusion that the value of information and research priorities 
can not be separated from the budgetary restrictions on service provision. 
The comparison of the results of the two-stage problem in section 5.2 and the 
single-stage problem in chapter 4 demonstrated that an analysis which did not 
recognise the sequential nature of this problem by excluding the diagnostic test 
would seriously bias efficient research design and underestimate the value of the 
research. Similarly, an analysis which simplified the four-stage decision problem 
in section 5.3 to the two-stage problem in section 5.2 by excluding t2 would also 
lead to serious errors at the second hurdle and a technically inefficient design. 
These examples demonstrate the dangers of using implicit and inconsistent 
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decision rules to identify relevant alternatives and exclude others. This is an issue 
which was also discussed in chapter 3. The examples used in this chapter are the 
same examples which were used in chapter 2 and 3 to show that valid inferences 
may not necessarily be made by observing current clinical practice. At the end of 
chapter 3 this conclusion posed a number of problems: 
"If valid inferences cannot be based on observing current clinical 
practice, but the prospective evaluation of all possible alternatives 
in a sequential clinical decision problem is not possible, efficient, or 
ethical, then: (a) how should information of different quality from 
different sources be combined consistently and explicitly; (b) which 
clinical decision problems will be worth evaluating in a clinical trial; 
(b) if a clinical decision problem is worth evaluating which of the 
competing alternatives should be compared in a clinical trial; and 
(c) what is the optimal scale of this prospective research?" 
The approach taken in this chapter and the last has solved, at least in principle, all 
but one of these problems. The Bayesian view of probability and the prior 
distributions assigned to the key variables can consistently and explicitly 
incorporate prior information from different sources and of different quality (with 
the quasi sample size representing a more or less sceptical prior). The first and 
second hurdles can identify which clinical decision problems should be considered 
for prospective clinical research, and the construction of the second hurdle 
identifies the efficient scale of this research. 
However there remains the problem of which of a number of competing 
alternatives should be compared within a clinical trial. This has not been 
addressed, because the analysis in this chapter and in chapter 4 assumed an fixed 
and equal allocation of trial entrants at each stage. This means that a sample is 
allocated to each arm of the trial irrespective of the cost and benefit. This 
arbitrary rule forces part of the sample to be allocated to each alternative and does 
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not provide a method to identify which of the alternative are irrelevant. In the 
next chapter this arbitrary fixed and equal allocation rule is relaxed and a simple 
dynamic programming approach is used to establish optimal patient allocation and 
provide an explicit and consistent method to identify relevant alternatives which 
should be compared in the trial. 
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Figure 5.2.1 Decision Tree for the Two Stage Decision Problem 
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Table 5.2 
Numerical Example for the Two-Stage Decision Problem 
Prior Prior Population 
Mean SD SD 
Ull 6 0.5164 1.2649 
UOI 8 0.5164 1.2649 
UIO 2 0.2582 0.8942 
Uoo 10 0.2582 0.8942 
C ll £12,000 
COl £8,000 
C IO 0 
Coo ° 
Cte £8,000 
p(D) 0.6 0.1 0.4899 
p(t/ID) 0.9 0.0866 0.3 
p(t;IND) 0.8 0.1155 0.4 
p(t/ID) = probability of a true positive rl!sult (sensitivity) 
p(t;IND) = probability of a true negative result (specificity) 
Quasi prior 
sample size (110) 
12 
12 
6 
6 
24 
12 
12 
In this example 1000 patients enter the decision problem in one year. 
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Figure 5.3.1 Decision Tree for the Four Stage Decision Problem 
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Table 5.3 
Numerical Example for thl~ Four-Stage Decision Problem 
Prior Prior Population Quasi prior 
Mean SD SD sample size (no) 
VII 6 0.5164 1.2649 12 
VOl 8 0.5164 1.2649 12 
V IO 2 0.2582 0.8942 6 
Uoo 10 0.2582 0.8942 6 
V12 4 0.5164 1.2649 12 
U02 4 0.5164 1.2649 12 
CII £12,000 
COl £8,000 
Cia 0 
Coo 0 
-
C12 £2,400 
CO2 £2,400 
Cit £8,000 
peD) 0.6 0.1 0.4899 24 
p(t;ID) 0.9 0.0866 0.3 12 
p(t;IND) 0.8 0.1155 0.4 12 
p(t:'ID) = probability of a true positive rt!sult (sensitivity) 
p(t;IND) = probability of a true negative result (specificity) 
In this example 1000 patients enter the decision problem in one year. 
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Figure S.3.6b ENBS for the Four Stage Decision Problem (1/g=£10,000) 
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6.1 Introduction 
The analysis in chapters 4 and 5 made a number of assumptions and simplifications 
when establishing the value of sample information. In particular a fixed and equal 
allocation of trial entrants to the alternative arms of the trial at each stage has been 
assumed. In this chapter this assumption is relaxed and a dynamic programming 
approach to optimal patient allocation is proposed. This is applied to the same 
numerical examples which were considered in previous chapters and demonstrates 
that optimal patient allocation increases the value of sample information and can 
be used to identify and rule-out irrelevant alternatives which should not be 
included in an efficient trial design. Indeed if arbitrary fixed allocation rules are 
used then the research design will be technically inefficient, the expected net 
benefits of sampling will be underestimated and there will be a danger that cost-
effective research proposals may be rejected at the second hurdle. 
The equal allocation of patients between experimental and control arms of a trial is 
often used and is implicitly justified by assuming that the variance of the outcome 
of interest for the control arm of the trial is the same as the experimental arm, so 
that the benefits (reduction in sample variance) of assigning an additional trial 
entrant to either arm of the trial will be the same 84,123. However there is little 
justification for this rule of precedent when the costs and benefits of allocating a 
trial entrant to the alternative arms of the trial are explicitly considered. In 
principle, whether an additional trial entrant should be allocated to a particular 
arm of a trial should be determined by the marginal benefits of assigning the 
patient to that arm (which will be determined by the variance of the net benefits of 
that arm) and the marginal costs of assigning the patient to that arm (which is 
determined by the additional treatment costs). The only circumstances in which an 
equal allocation could be justified would be when the variance and the marginal 
sampling costs of both arms of the trial are the same. In these circumstances the 
marginal net benefits of assigning the patient to the experimental arm will equal 
the marginal net benefits of assigning the patient to the control arm. 
132 
In the examples considered in the previous chapters the variance of the net 
benefits of the alternatives at each stage are not assumed to be the same but they 
are calculated based on the variance of the health outcomes, path probabilities, 
the values of costs and 1Ig. Also the marginal cost of assigning a trial entrant to 
either of the alternatives at each stage will not be the same. In the single-stage 
decision problem which was considered in chapter 4 the marginal cost of assigning 
a patient to the treatment arm will be the additional treatment cost, but the 
marginal cost of assigning a patient to no treatment will be zero. In these examples 
the marginal reporting costs are assumed to be negligible but even if reporting 
costs are substantial it would not alter the key argument that the marginal 
sampling cost of assigning entrants to different arms of the trial will not be the 
same and should be taken into account when establishing optimal patient 
allocation at each stage. 
There is a body of literature which considers the optimal allocation of trial entrants 
in sequential clinical trials were the results of the trial accumulate over time and 
can be used to assign entrants to the different arms 7. An example of this type of 
approach is Bather's "play the winner rule" where patients are assigned to the arm 
of the trial which appears to be most effective given the accumulated trial results 8, 
9. This approach and others addressing the same problem 73, 7S, lSI do not consider 
the marginal cost of sampling and tend to focus on minimising the potential health 
cost to individuals enrolled in the trial by establishing allocation rules so that the 
minimum number of individuals need to be enrolled in the less effective arm of the 
trial to achieve the specified power and statistical significance. They are primarily 
concerned with individual medical ethics rather than the collective ethical 
concerns for the costs of acquiring sample information and the future patients who 
will benefit from the information generated by the research 133. These approaches 
are also primarily concerned with sequential clinical trials were the accumulated 
results from earlier participants in the trial are available and are used to allocate 
those entering the trial. This chapter addresses a more fundamental problem of 
optimal allocation in a fixed sample design where sample information is only 
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available at the end of the trial. The value of sample information, optimal sample 
size and the allocation of patients at each stage must be established before any 
sample information is available. 
The analysis in chapter 4 and 5 assumed that the population of future patients who 
will benefit from the information generated by the proposed research is 
independent of the numbers enrolled in the trial. This assumption means that 
those entering the trial are regarded as separate and not part of the population 
which will ultimately benefit from the results of the research. Clearly this is not the 
case and those enrolled in a clinical trial are drawn from the same population of 
patients who will benefit from the sample information. This assumption is relaxed 
in this chapter and the incidence of patients entering the decision problem is 
endogenous and depends on the sample size. This means that the population of 
patients who could benefit from the results of the research are "used up" as the 
size of the sample considered is increased. This will reduce the benefits of sample 
information because an additional entrant will provide sample information but -
there will be one less patient available to benefit from it at the end of the trial. This 
can be regarded as an additional opportunity cost of sampling because an 
additional trial entrant will impose an opportunity cost equal to the EVSI for that 
individual. The results of optimal allocation in section 6.2, 6.3, and 6.4 are 
compared to the fixed allocation rule using the same example but with the 
population also dependent on sample size in the same way. 
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6.2 A Single-Stage Clinical Decision Problem 
The analysis of the single-stage treatment decision problem in chapter 4 (the 
selection of the fallback strategy in chapter 2) assumed a fixed and equal 
allocation of trial entrants between the two alternative arms of the trial when the 
expected net benefits of sample information were estimated. The fixed and equal 
allocation rule used in chapter 4 implicitly assumes that the marginal benefits and 
marginal costs of assigning a trial entrant to either alternative are equal. Inthe 
traditional approach the marginal costs of sampling are not considered and it is 
often assumed that the variance of the control and experimental arms of the trial 
will be the same. In these circumstances the marginal benefits of assigning a trial 
entrant to either alternative would be equal and the fixed and equal allocation rule 
may be justified if the marginal cost of sampling is ignored. 
However, when the marginal costs of sampling are explicitly considered and the 
variance of expected net benefits of tl and to are derived from the-variance of each 
of its components, the fixed and equal allocation rule will not be optimal because 
the marginal benefits and the marginal costs of assigning an entrant to the 
alternative arms of the trial will not be equal. The fixed allocation rule which was 
used in chapter 4 can be relaxed and an optimal patient allocation can be 
established by making contingent allocation decisions for a given sample size 
before the optimal sample size is selected. The expected net benefits of sampling 
using optimal patient allocation will be higher than t~e fixed allocation rules of 
chapter 4 and in this example the optimal sample size will be higher and the total 
cost of sampling will be lower. Proposed research which uses an arbitrary fixed 
allocation rule will be technically inefficient, the value of the proposed research 
will be underestimated and cost-effective research my be rejected at the second 
hurdle. 
The same numerical example that was used in chapter 4 is used to illustrate the 
approach to optimal patient allocation. The decision problem is illustrated in 
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figure 6.2.1 and this is identical to figure 4.2.1 except that the expected net 
benefits of sampling and the optimal sample size is estimated in a two-stage 
process. At stage 2 an optimal contingent allocation between t} and to is made 
based on the expected net benefits of every feasible allocation of each sample 
entering stage 2. The optimal sample size which maximises the expected net 
benefits of sampling is selected at stage 1 given that it will be allocated optimally 
at the second stage. This approach is consistent with the principles of backward 
induction where the contingent allocation decisions are solved at stage 2 before 
the expected net benefits of sampling are established and optimal sample size is 
selected at stage 1. 
Figure 6.2.1 
The first hurdle for this decision problem is identical to the analysis in chapter 4, 
because the EVPI depends only on prior information and is unaffected by how the 
sample is allocated between the alternatives. If the proposed research passes the 
first hurdle described in chapter 4 then the expected net benefits of sample 
information must be estimated to construct the second hurdle. In chapter 4, where 
a fixed allocation rule was used, only one estimate of the expected net benefit of 
sampling was required for each sample size considered and the maximum ENBS at 
the optimal sample size provided the value of the second hurdle. Once the fixed 
allocation rule is relaxed there will be a number of alternative estimates of the 
ENBS for each sample size. 
This problem can be solved in two stages. Following the principles of backward 
induction the second and final stage is solved first where contingent optimal 
allocation decisions for a given sample size are established. The allocation of a 
given sample between t} and to will determine both the benefits and the costs of 
sampling so the EVSI, the cost of sampling, and the ENBS, must be established 
for every feasible allocation between to and t} of each sample size entering stage 2. 
There are a number of estimates of the ENBS for each sample entering stage 2 
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because it can be allocated between to and tl in a number of different ways. For 
example two patients entering stage 2 can be allocated in three ways: with two 
allocated to tl and zero to to; or one allocated to tl and one to to; or zero to tl and 
two allocated to to. In general there will be n+ 1 ways to allocate each sample of n 
entering stage 2. 
In this numerical example the sample sizes considered range from zero to 500. 
This generates 125,500 possible alternative combinations of sample size and 
allocation between t\ and to which must be considered and 125,500 estimates of 
the EVSI, the cost of sampling, and the ENBS, will be required. This is 
considerably more than the 501 estimates of the ENBS which were required for 
the same range of sample size when using the fixed allocation rule in chapter 4. 
6.2.1 Optimal Allocation at Stage 2 
The expected benefits of sampling will depend on both the size of the sample 
entering stage 2 and the way it is allocated between tl and to. The benefit of 
additional sample information is the reduction in the sample variance of the 
incremental net benefits oftl (0n(2/)' The variance of the expected net benefits of 
tl and to are not assumed to be the same and if the variance of the net benefit of tl 
(01/) is greater than to (01(/) then the marginal benefit (reduction in On(2/) of 
assigning a trial entrant to tl will also be greater than to. In these circumstances 
assigning a trial entrant to tl would lead to a greater reduction in the uncertainty 
surrounding the treatment decision (greater reduction in On(2)2). 
EVSI at Stage 2 
To establish the expected benefits of sampling an estimate of the EVSI for every 
feasible allocation of each sample entering stage 2 is required The EVSI In. n 
. . G)-~2»"1 
is a measure of the expected benefits of sample information given a sample of n(2) 
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entering stage 2 where t;1 is allocated to tl and (n(2)-t;I) is allocated to to· 
6.2.1a 
00(2) = prior incremental net benefit oftl 
2 • • f So 00(2) = pnor vanance 0 u0(2) 
0r¥..2)2 = (Ot/1t;1) + (Ot02/(n(2)-t;I)) 
The EVSIm\I\2)' ntt takes account of the alternative ways to allocate a given 
sample entering stage 2 because the sample variance of 00(2) (On(2)2) is the sum of 
the sample variance of the net benefits of tl (Ot/lt;l) and the sample variance of 
the net benefits of to (Ot02/(n(2)-t;I»' Sample variance and therefore the EVSI not 
only depends on the size of the sample entering stage 2 (n(2») but also how it is 
allocated between tl (t;I) and to (I\2)-t;1)· The marginal benefits of allocating an 
additional entrant to tl or to will only be equal if ou2= 0102 and allocating an equal 
number of trial entrants to tl and to would minimise On(2)2. In this numerical 
example 0t12 is greater than ou2 (when lIg=£4,OOO) and the marginal benefits of 
assigning a trial entrant to tl Viill be greater than to· 
However 0/ and 0102 are dependent on the value of Ilg because g is regarded as a 
constant in the calculation of the variance of expected costs, and as g falls the 
variance of the expected costs also falls. In this numerical example the variance of 
the expected costs is a large component of Otl2 and as the value of Ilg increases 
the difference between Ot/ and 0102 falls (when I/g=£20,OOO ou2 < 0102). Ifno 
sample is allocated to one of the alternatives (either t;1=O or n(2)=nU) then no 
comparison can be made between the alternatives using sample information and 
the EVSI will be zero. This may be the optimal allocation in some circumstances 
and indicates that one alternative can be ruled-out as not relevant because 
comparing the alternatives using sample infonnation is not efficient. 
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Cost of Sampling at Stage 2 
The optimal patient allocation will also depend on the cost of sampling 
(Csmln(2)'~I) when trial entrants are allocated to the treatment alternatives. The 
marginal cost of assigning a trial entrant to to will not be the same as assigning the 
entrant to t\ at stage 2, because the marginal cost of sampling includes the 
additional treatment costs compared to current practice, which in this example is 
assumed to be to (it is possible that the marginal sampling cost could be negative if 
the experimental treatment is less costly than current practice). The marginal cost 
of assigning an entrant to tl will include the additional cost of tl compared to to 
(E(Clt1) -E(Clto)) but the additional treatment cost of assigning an entrant to to will 
be zero. It is assumed that the marginal reporting costs are negligible, but this 
assumption does not weaken the argument that the marginal sampling cost will 
differ between the alternative anns of the trial as long as the additional treatment 
cost is one component. 
6.2.1b 
Payoff at Stage 2 
In this example the cost of assigning trial entrants to tl at stage 2 is higher than to 
but the marginal benefits of assigning entrants tl are higher than to. The optimal 
allocation between tl and to will involve a trade-off between the additional benefits 
of assigning entrants to tl and the lower costs of assigning entrants to to. The 
ENBS(2)11\2)'~1 is the difference between the expected benefits and the cost of a 
sample of 1\2) entering stage 2 with ~l allocated to tl and 1\2)-1\1 allocated to to. 
The payoff at stage 2 from a sample of n(2) entering stage 2 (ITmin(2),ntl) is the 
expected net benefits of sample information and can be estimated for every 
feasible allocation between tl and to. 
6.2.1c 
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The optimal allocation of any sample entering stage 2 (n.l·) will be where the 
payoff (ENBS) reaches a maximum. The ITm!l\2),n.l· for each sample entering 
stage 2 can now be established and optimal contingent allocation decisions can be 
made. This approach of solving contingent a1locative decisions at stage 2 
illustrated in table 6.2.1a where the possible sample sizes entering stage 2 are 
represented by each row, the feasible allocations to t, are represented by the 
columns, and the payoffs are illustrated in the body of the table. The optimal 
allocation of each sample is the row maximum, and the optimal contingent 
allocations and associated payoffs are illustrated in the right hand columns. 
Table 6.2.1a 
Optimal Allocation at Stage 2 
The optimal contingent allocation of a sample (n(2») entering stage 2 to tl (nu) for 
three values of 1/g is illustrated in figure 6.2.2. The fixed and equal allocation of 
the sample entering stage 2 is represented by the rising diagonal where half the 
sample is assigned to tl and half to to· A greater proportion of trial entrants are 
allocated to to than with the fixed allocation rule because the marginal cost of 
assigning patients to tl is higher than to where the cost of sampling is zero. This 
difference in marginal sampling cost offsets the higher marginal benefits of 
assigning entrants to t} (01/>0102 when 1/g <£20,000). So in this numerical 
example the optimal allocation of trial entrants will reduce the expected benefits 
of sample information, but this will be more than offset by the reduction in 
sampling cost. As the sample size entering stage 2 increases, the marginal benefits 
of additional sample information fall and the differences in the marginal benefits of 
assigning trial entrants to t1 and to will become less significant but the difference in 
the marginal cost of sampling remains constant. This means that the optimal 
allocation will change with sample size and in this example because the costs of 
assigning a patient to tl is higher than to the proportion of the sample allocated to 
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tl falls as the sample size increases. 
Figure 6.2.2 
The optimal allocation is also dependent on the value placed on health outcome 
for two reasons: firstly because this determines the weight placed on the 
differences in the benefits and costs of assigning a trial entrant to each alternative, 
so that less weight is placed on the additional cost oftl; and secondly the value of 
g partly determines the variance of the expected costs of each alternative and 
therefore the marginal benefits of assignment to tl and to. In this example when 
the value of IIg is increased the difference between GIl2 and Gt02 falls (because the 
variance of the expected cost is a larger component of GIl2), consequently the 
effect on the marginal benefits and on the weight attached to differences in 
marginal costs both work in the same direction, and a greater proportion of the 
sample is assigned to t l· 
6.2.2 Optimal Sample Size at Stage 1 
The first stage is simply to select the optimal sample size given that each sample 
will be allocated optimally at stage 2. The payoff given a sample of n(l) at stage 1 
(II(l)I~I» is the payoff from stage 2 given an optimal allocation between tl and to 
(II(2)I~2),I\1 *). The optimal sample size at stage 1 (n(l;) can now be identified In 
table 6.2.1 b, where II(l)l~l) (or ENBS(I)I~I» reaches a maximum. 
II(l)ln(l) = II(2)I~2),ntl· 
ENBS(l)I~I) = ENBSdn(2)' ntl• 
~I) = ~2) 
6.2.2 
Once the optimal sample size has been selected at stage 1 the allocation of this 
sample at stage 2 is given by the contingent allocative decisions that have been 
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made at stage 2, and which were illustrated in table 6.2.1a and figure 6.2.2. It is 
the payoff (or the ENBS) at the optimal sample size which is the second hurdle 
that the proposed research must overcome. This will be greater than the ENBS 
when the fixed and equal allocation rule is used. 
Table 6.2.1b 
The two-stage approach to this single-stage decision problem is in fact the full 
enumeration of all possible allocative decisions for a range of sample size and it 
does provide an optimal solution to this problem. It is convenient to separate the 
contingent allocative decision at stage 2 from the selection of optimal sample size 
at stage 1, because it helps the explanation of the dynamic programming approach 
which is used to solve the two and four-stage decision problems in section 6.3 and 
6.4. In these more complex problems there is a recursive relationship between the 
payoffs at each stage and the full enumeration of these more complex sequential 
problems quickly become intractable. 
In general the solution to this single-stage problem using a fixed allocation rule 
will require n+ 1 estimates of the ENBS where n is the maximum sample size 
considered, but the solution to the same problem using an optimal allocation of 
the sample will require «n+l)2+n+l)/2 estimates of the ENBS. Solving this 
problem using optimal allocation rule requires considerable additional 
computation. The solution using a fixed allocation rule requires just over one 
minute of computing time (6 estimates of the ENBS per second) but the solution 
to the optimal allocation problem requires almost 6 hours of computing time when 
considering a maximum sample size of500 (125,751 estimates of the ENBS). 
The computational requirements become even more extreme in the two and four 
stage decision problems considered in section 6.3 and 6.4. 
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6.2.3 Expected Net Benefits of Sample Information 
The expected net benefit of sampling at stage 1 given an optimal allocation at 
stage 2 is illustrated in figure 6.2.3a when the value of 1Ig is £4,000. The 
expected net benefit when a fixed and equal allocation rule is used is illustrated in 
figure 6.2.3b. The expected net benefit reaches a maximum of £724,970 at a 
sample size of 116 (ntl=29) when an optimal allocation is used. This is higher than 
when the fixed allocation rule is used, where the maximum ENBS is £626,920 
with an optimal sample size of76 (nu=38). The optimal allocation of trial 
entrants increases the ENBS and the value of the second hurdle. If arbitrary 
allocation rules are used then the ENBS will be underestimated, the value of the 
second hurdle will be biased, and there is a danger that proposed research which 
would be cost-effective will be rejected. 
Figure 6.2.3a 
Figure 6.2.3b 
The expected value of sample information and the costs of sampling are also 
illustrated in figure 6.2.3a and 6.2.3b. The EVSI increases at a decreasing rate and 
actually declines in figure 6.2.3a as sample size is increased above 121 (and 185 in 
figure 6.2.3b). This is because the population of patients who will benefit from 
sample information is no longer independent of sample size and as the sample size 
increases this population is "used up" in the trial. This was not the case in chapter 
4 where the estimates of the EVSI assumed that the popUlation who would benefit 
from the information generated by the trial was independent of sample size .. Now 
an additional trial entrant will increase the sample information and increase the 
EVSI for each individual but will reduce the number of patients who will benefit 
from this additional information. This can be regarded as an additional opportunity 
cost of sampling because an additional trial entrant will impose an opportunity 
cost eqwrl to the EVSI for that individual. 
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Figure 6.2.3a also shows that the total variable cost of sampling will not increase 
at a constant rate as in figure 6.2.3b but will increase at a decreasing rate as the 
optimal allocation of trial entrants changes as sample size increases. In this case 
the marginal cost of sampling declines because the proportion of the sample 
allocated to tl declines with sample size in figure 6.2.2. 
The ENBS in figure 6.2.3b is negative when the sample size is low (n(l)<6), 
because the benefit of small amounts of sample information is less than the costs. 
However when an optimal allocation is used the ENBS will not be negative at low 
sample sizes because all the sample can be allocated to to at zero cost. If all the 
sample is allocated to to no comparison between to and tl using sample information 
is possible and the EVSI, the cost of sampling, and the EN)3S is zero (when I\1)<5 
in figure 6.2.3a). 
Value of Health Outcome 
The value of sample information depends on the value of IIg and the budgetary 
restrictions on service provision. The ENBS when 1/g is increased to £10,000 is 
illustrated in figure 6.2.4a when optimal allocation at stage 2 is used, and this can 
be compared to the ENBS in figure 6.2.4b when a fixed and equal allocation rule 
is used. The optimal allocation of trial entrants generates a maximum ENBS of 
£4,308,900 at an optimal sample size ofI\I)·=123 (~/=46). This is higher than 
when the fixed allocation rule is used where the maximum ENBS =£4 234 305 , , 
and n(l)·=110 (n.l=55). The value of information increases with the value of IIg 
and in this example the optimal sample size also increases. Figure 6.2.4a and 
6.2.4h also shows that the EVSI not only increases at a decreasing rate but will 
ultimately decline because the population benefits are no longer independent of 
sample size. Figure 6.2.4a also illustrates that the marginal cost of sampling at 
stage 1 is no longer constant but declines because as sample size increases the 
proportion of trial entrants allocated to t1 at stage 2 declines. 
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Figure 6.2.4a 
Figure 6.2.4b 
The expected net benefit of sampling when the value of I1g is increased to 
£20,000 is illustrated in figure 6.2.5a when an optimal allocation is used and in 
figure 6.2.5b when a fixed and equal allocation rule is used. With optimal 
allocation the ENBS reaches a maximum of £4,390,086 at an optimal sample size 
of 153 (ntl·=57). This is greater than when a fixed allocation rule is used where 
the maximum ENBS is £4,297,885 at an optimal sample size of 140 (nt l=70). The 
EVSI will decline when the n(l? 172 in figure 6.2.5a and when n(l? 191 in figure 
6.2.5b. The marginal costs of sampling in figure 6.2.5a also declines because a 
smaller proportion of the sample is allocated to tl at stage 2 as the sample size is 
increased. 
Optimal Patient Allocation 
Figure 6.2.5a 
Figure 6.2.5b 
The optimal patient allocation increases the value of information and it will also 
change the optimal scale of research. The optimal sample size when optimal 
patient allocation is used can be compared to optimal sample size with the fixed 
allocation rule in figure 6.2.6. In this numerical example the optimal sample size is 
higher when optimal allocation is used. Indeed figure 6.2.6 shows the 
circumstances in which optimal allocation will result in a positive sample size but 
the fixed rule indicates that no sample should be taken (when I1g=£3,200). So it 
is possible that by using optimal patient allocation sampling may become efficient 
whereas with a fixed rule a trial would not be cost-effective and the optimal 
sample size would be zero. 
Figure 6.2.6 
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The allocation of the sample is also illustrated in figure 6.2.6 and this 
demonstrates that optimal patient allocation assigns fewer entrants to t1, because 
the marginal cost of assigning trial entrants to tl is higher. Consequently the total 
variable cost of the research is lower when optimal patient allocation is used 
despite the fact that the total sample size is higher. The optimal sample size using 
fixed allocation rules is not the same as in chapter 4 because the population 
benefits are not independent of sample size and in this example the discontinuity in 
the relationship between sample size and IIg occurs at IIg=£6,500 where the 
clinician would be indifferent between t1 and to. At this point the opportunity cost 
of enrolling an additional trial entrant (EVSI) reaches a peak. 
Figure 6.2.7 
The difference between the E~13S, the EVSI, and the cost of sampling when 
optimal and fixed allocation rules are used is illustrated in figure 6.2.7. This 
demonstrates that the optimal patient allocation will increase the maximum 
expected net benefits of sampling and the value of the second hurdle. If an 
arbitrary allocation rule is used to design a clinical trial then the potential benefits 
of this research may be underestimated, the costs may be overestimated, and there 
will be a danger that proposed research which is cost-effective may be rejected at 
the second hurdle. The design and scale of proposed research will also be biased 
and by using arbitrary rules those proposals which pass the second hurdle will be 
conducted at less than the technically efficient scale with possibly higher cost and 
lower net benefits. In this numerical example the optimal allocation of trial 
entrants means that fewer entrants are allocated to t1 and this reduces the benefits 
of sample information (when I/g>£4,OOO), but this is more than offset by the 
reduction in the costs of sampling. 
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Implications for Research Design 
This approach to optimal allocation of trial entrants explicitly considers the 
marginal benefit and marginal cost of assigning trial entrants to the alternative 
arms of the trial. The marginal costs and benefits of allocating trial entrants to 
alternative arms may differ and in these circumstances an optimal allocation should 
be applied when designing efficient clinical research. This numerical example 
demonstrates that the optimal allocation of trial entrants is not simply an issue for 
sequential clinical trials but is a more fundamental issue which is also relevant to 
the fixed sample design considered here, where all the results are available at the 
same time at the end of the trial. There appears to be little justification for using 
arbitrary fixed rules of precedent and these arbitrary rules will lead to inefficient 
research design and errors at the second hurdle. The approach taken to this single-
stage decision problem involves the full enumeration of all feasible allocations of 
each sample size considered and therefore provides the optimal solution to this 
problem. This requires a considerable increase in computation compared to the 
fixed allocation rule used in chapter 4, however the additional computation 
becomes extreme when more complex decision problems are considered. Full 
enumeration of more complex decision problems is simply not feasible and a 
dynamic programming solution to the two and four-stage decision problems is 
presented in section 6.3 and 6.4. 
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6.3 A Two-Stage Sequential Clinical Decision Problem 
The approach to optimal patient allocation can also be applied to sequential 
clinical decision problems. In this section it is applied to the two-stage decision 
problem which was considered in chapter 5.2. This is the same problem which was 
also considered in chapter 2, where the clinician must decide whether to use a 
diagnostic test and treat according to the test results, or use the fallback treatment 
strategy. This decision problem is illustrated in figure 6.3.1 and it is identical to 
the problem illustrated in figure 5.2.1 except that it is solved in three stages when 
optimal patient allocation is required. 
Figure 6.3.1 
At stage 3 an optimal contingent allocation between t\ and to for each sample 
entering stage 3 is made based on the expected net benefit of every feasible 
allocation of each sample. At stage 2 an optimal contingent allocation between 
the test and no test arm of the trial is made for each sample entering stage 2. This 
is based on the expected net benefit of sampling at stage 2 and the payoff from' the 
optimal allocation of the sample assigned to the no test arm which enters stage 3. 
Finally the optimal sample size which will maximise expected net benefits can be 
selected at stage 1. Solving contingent allocation decisions before the optimal 
sample size is selected at stage 1 is consistent with the principle of backward 
induction and can be characterised as a simple three-stage dynamic programme, 
where the payoff for each sample size considered at stage 1 is the expected net 
benefit given that an optimal patient allocation policy will be followed from stage 
1 to the end. This approach of making contingent allocative decisions avoids the 
full enumeration of all possible allocations of each sample and dramatically 
reduces the computation required. Indeed the full enumeration of all the possible 
alternatives in a sequential decision problem for the range of possible sample sizes 
considered here is not feasible. The approach taken in this chapter provides a 
practical solution to the problem. 
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The same numerical example that was used in chapter 5.2 is used to illustrate this 
approach to optimal patient allocation. The expected net benefits using optimal 
patient allocation are compared to the fixed and equal allocation that was used in 
chapter 5.2 but in this section (as in section 6.2) the population of patients who 
will benefit from the information generated by the research is no longer assumed 
to be independent of the sample size selected. Consequently the results with 
optimal patient allocation are compared to the fixed allocation rule when both 
have endogenous population benefits. 
The estimates of the EVPI and the value of the first hurdle is identical to the 
estimates in chapter 5.2 because the EVPI is based only on prior information and 
is not affected by the allocation rules. If the proposed research passes the first 
hurdle the second hurdle must be constructed to demonstrate that it will be cost-
effective and to establish the technically efficient scale of the research. Just as in 
section 6.2 the second hurdle is dependent on the allocation rules used to assign 
trial entrants to the alternative arms of the trial at each stage because this will 
determine both the expected benefits and the costs of a given sample. 
6.3.1 Optimal Allocation at Stage 3 
At stage 3 the optimal contingent allocation between t1 and to for each sample 
entering stage 3 must be made based on estimates of the expected net benefits of 
sampling for every feasible allocation of each sample entering stage 3. The optimal 
contingent allocation will be where the expected net benefit reaches a maximum 
for a given sample size. This is the same problem that was considered in the 
previous section of this chapter except that it is now a contingent treatment 
decision which follows the initial diagnostic decision. 
Once the fixed allocation rule is relaxed the expected benefits of sampling depend 
not only on the sample size entering stage 3 but also on the way this is allocated to 
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tl and to. An estimate of the expected benefits of sampling for every feasible 
allocation of each sample entering stage 3 is required. The EVSI(3)ln(3)'~1 is a 
measure of the expected benefit of sample information given a sample of 1\3) 
entering stage 3 with I\lallocated tl and (n(3)-I\,) allocated to to and from 6.2.1 a: 
00(3) = (E(ultl)-g·E(Clt l )) - (E(Ulto)-g·E(Cjto)) 
JVn(3),ntl = 00(3/1(00(3/+00(3/) 
On(3)2 = (Ot/lnu)+(0[Q2/(n(2fnu)) 
6.3.1a 
In this numerical example 0t! 2 is greater than O[Q 2 and the marginal benefits of 
assigning a trial entrant to tl will be greater than to. However ou2 and 0[Q2 are 
partly determined by the value of I1g, and the difference between 0u2 and 0[Q2 
declines as l/g is increased. 
The total variable cost of sampling (Cs(3)11\3),nU) is also determined by how the 
sample is allocated between tl and to because the additional treatment cost of 
assigning a patient to to will be zero but the marginal cost of assigning a trial 
entrant to t, will be the additional treatment cost ?f t1. 
6.3.1b 
The payoff at stage 3 given a sample of n(3) entering stage 3 (II(3)ln(3),nll ) is the 
expected net benefits of sampling given a sample ofn(3) entering stage 3, with 0.1 
allocated to tl and 1\3f~1 allocated to to. 
The payoff can now be established for every feasible allocation of each sample 
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entering stage 3. The optimal contingent allocation is the allocation where the 
ENBS reaches a maximum for each sample size. This is illustrated in table 6.3.1a. 
The payoffs in the body of the table and the optimal contingent decision are the 
same as at stage 2 from table 6.2.1a in the previous section of this chapter. 
Table 6.3.1a 
The optimal contingent allocation of a sample entering stage 3 for this numerical 
example is illustrated in figure 6.3.2a. These contingent allocations for three 
values of l/g are the same as the contingent optimal allocation at stage 2 in section 
6.2. The marginal cost of allocating entrants to t1 results in a smaller proportion 
of the sample allocated to t1 than when using the fixed and equal allocation rule in 
chapter 5. 
Figure 6.3.2a 
6.3.2 Optimal Allocation at Stage 2 
At stage 2 the optimal contingent allocation between the test (te) and the no test 
(nte) arm of the trial for each sample entering stage 2 must be made based on the 
expected net benefit of sampling at stage 2 and the payoff given the optimal 
allocation of the sample which will enter stage 3. 
Payoff at Stage 2 
A sample entering stage 2 (1\2» which is allocated between test (o.e) and no test 
alternatives (1\2fI\c) will generate benefits and costs of sampling at stage 2, but 
when part of the sample entering stage 2 is allocated to the no test arm of the trial 
it will enter stage 3 (n(3)=n(2)-ntc) and will be allocated optimally, generating 
payoffs of II(3)11\3),o.l· which where illustrated in table 6.3.la. This is a recursive 
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relationship 10, 11 where the payoff at stage 2 is partly determined by the payoffs 
associated with the optimal contingent allocation at stage 3. So the payoffs 
(IIdI\2),I\e) and the optimal contingent allocation at stage 2 will be determined by 
the ENBS at stage 2 and the payoff from allocating part of the sample to the no 
test arm given that an optimal allocation policy will be followed at stage 3. 
6.3.2a 
The payoffs for every feasible allocation of each sample entering stage 2 are 
illustrated in table 6.3.lb (when 1/g=£4,000). The possible samples entering stage 
2 are represented by each row. The feasible allocations to the testing arm of the 
trial (nlc) are represented by the columns, and the sample allocated to the no test 
arm I\2)-~C will enter stage 3 and will be allocated optimally in table 6.3.1b. The 
optimal contingent allocation at stage 2 and the associated payoffs are the row 
maximums and are illustrated on the right hand columns of the table. 
Table 6.3.lb 
EVSI at Stage 2 
The payoffs in the main body of table 6.3.1b require estimates of the 
ENBS(2)II\2)'~C and both the expected benefit and cost of sampling will be 
determined by the sample size and how it is allocated. The expected benefit of 
sampling (reduction in sample variance (On(2)2» depends on n(2) and how it is 
allocated between the alternatives. The marginal benefits of assigning a trial 
entrant to either the test or no test arms will be determined by the variance of the 
net benefit of testing (Ot/) and the variance of the net benefit of not testing (ontc2). 
In this numerical example Otc2 is greater than Ont/ and the marginal benefits of 
assigning an entrant to the test arm will be greater than the no test arm of the trial. 
However the difference between Ot/ and Onte2 declines as 1/g increases. The 
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EVSldn(2),nte is a measure of the expected benefit of an sample ofn(2) entering 
stage 2 with nte allocated to the test arm and ~2rnte allocated to the no test arm of 
the trial. 
/Vn(2),nte = 00(2/1(00(2)2 + on(Z/) 
On(2/ = (Ot/lnte) + (ontc2/(~z)-I\.)) 
6.3.2b 
The prior incremental net benefit (00(2)' the prior variance of 00(2) (00(2)2), and the 
variance of the net benefits of not testing (onl/) depend on the sample assigned to 
nt. which will enter stage 3 (n(3)=Dc2)-n1e). This is the same problem of establishing 
the net benefits of sampling at stage 1 in chapter 5.2 when a fixed allocation rule is 
used. But now the prior mean and the variance of the net benefits of not testing 
depend not only on the sample allocated to the no test arm, but also on the way 
this sample will be allocated between t1 and to at stage 3. 
The prior net benefits of not testing (E(Ulntc)-g·E(CJntc» and therefore 00(2) is 
dependent on the sample allocated to the no test alternative at stage 2 which will 
enter stage 3, and from 5.2.8a and 5.2.8b: 
E(Ulnt.)-g.E(CJnt.) = p(0x(3»oX(3)*).(E(Ult1)-g·E(CJt1» 6.3.2c 
+ I-p(Ox(3) >0x(3)*)·(E(Ulto)-g.E(CJto» 
P(0x(3) >OX(3)*) = p(Z>«00(3»oX(3)*)/on(3») 
On(3/ = (ou2/nu*) + (oro2/(Dc3)-nu*» 
The value of p( OX(3) >0x(3) *) is determined by the sample assigned to the no test 
arm (Dc2)-n1c=Dc3» which will enter stage 3 and the way it is allocated between t1 
and to. The value ofE(Ulntc)-g·E(CJnt.) is calculated assuming an optimal 
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allocation policy is followed at stage 3, and this is the prior information used to 
establish the EVSI at stage 2. 
The prior variance of (E(Ulntc)-g.E(Cjntc» and therefore 0 0(2/ are also dependent 
on the sample allocated to nte which enters stage 3. This is because it determines 
the value of p( OX(3) >OX(3) *) and because the prior variance of (E(Ulntc)-g·E(Cjnte)) 
at stage 2 is based on the posterior variance of (E(Ultl)-g.E(Cjtl» and (E(Ulto)-
g.E(Cjto» from stage 3. The posterior variance of (E(Ult1)-g.E(CJtJ) and 
(E(Ulto)-g.E(Cjto)) is a combination of the prior and sample variance of each and is 
calculated for each sample assigned to the no test arm assuming that an optimal 
allocation policy is followed at stage 3. The population variance of the net benefit 
of not testing (Onle2) is also partly determined by the sample entering and allocated 
at stage 3, because this determines the value ofp(OX(3»O~(3)*)' The expected 
benefit of every feasible allocation of each sample entering stage 2 can now be 
established given that a sample allocated to the no test arm will be allocated 
optimally at stage 3. 
Cost of Sampling at Stage 2 
The cost of sampling at stage 2 (CSml~2)'~e) is the additional treatment cost. The 
marginal cost of assigning an entrant to the no test arm of the trial at stage 2 will 
be zero because the additional cost of assigning a trial entrant to tl has already 
been taken into account in the estimates of the ENE S at stage 3. However the 
additional treatment cost of assigning an entrant to the testing arm of the trial will 
be the additional expected cost of the testing strategy. 
6.3.2d 
The ENBSd~2),~e can now be established and is the difference between the 
expected benefit and the expected cost of a sample entering stage 2 with nle 
allocated to the test arm of the trial and n(2)-nle allocated to the no test arm. 
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6.3.2e 
Optimal Allocation at Stage 2 
The optimal allocation will be where the marginal payoff of assigning a trial 
entrant to test arm is equal to the marginal payoff of assigning the entrant to the 
no test arm, or where the II(2)in(2),Il,c reaches a maximum for each sample entering 
stage 2 (row maximum in table 6.3.1b). The optimal contingent allocation of the 
sample entering stage 2 for this numerical example is illustrated in figure 6.3.2b 
for three values of l/g. The optimal allocation to the testing arm of the trial can 
be compared to the fixed allocation rule used in section 5.2 where half the sample 
is allocated to the test and half to the no test arm. 
Figure 6.3.2b 
Figure 6.3.2b illustrates that the optimal allocation depends on both the sample 
size entering stage 2 and the value of l/g because this will determine the weight 
placed on the differences in the marginal cost and benefit of assigning entrants to 
either tc or to ntc. In this example the variance of the test arm is greater than the 
no test arm so the marginal benefits of allocating an entrant to tc will be greater 
than ntc. However the marginal costs of assigning an entrant to te is greater than 
ntc. When the value of 1Ig=£4,000 n(C=O and the optimal allocation is to assign all 
the sample to the no test arm. In these circumstances it is not efficient to compare 
the test and no test strategies using sample information and the testing arm of the 
trial can be ruled out as an irrelevant alternative. However if the value of l/g is 
increased to £10,000 then less weight is placed on the additional costs of assigning 
entrants to the testing arm of the trial and more weight is placed on the additional 
benefits. Now it is efficient to assign entrants to tc and the test arm becomes a 
relevant alternative. 
155 
6.3.3 Optimal Sample Size at Stage 1 
The first stage is simply to select the optimal sample size given that a sample 
considered at stage 1 will enter stage 2 and will be allocated optimally between 
test and no test arms, and the sample entering stage 3 will be allocated optimally 
between tl and to. The payoff from a sample ofl\l) at stage 1 (IIdn(I» is simply 
the payoff given that an optimal patient allocation policy is followed at each 
subsequent stage. 
II(l)ll\l) = IId~2)'~c· 6.3.3 
ENBS(l)ll\l) = ENBS(2)ln(2)'~C· + ENBS(3)ln(3),ntl • 
~l) = 1\2) 
The optimal sample size at stage 1 (~l)·) can now be selected in table 6.3.1c and 
will be where II(l)l~l) (ENBS(l)II\l) reaches a maximum. This is the value of the 
second hurdle for this two-stage decision problem and will be higher than when a 
fixed and equal allocation rule is used. Once the optimal sample size has been 
selected at stage 1 the allocation of this sample between each alternative at each 
stage is given by the contingent allocative decisions that have already been made 
at stage 2 and 3 and which were illustrated in tables 6.3.1 band 6.3.1 a, and figures 
in 6.3.2b and 6.3.2a. 
Table 6.3.lc 
The Dynamic Programming Approach 
This approach to optimal patient allocation dramatically reduces the computation 
required to establish the optimal sample size and the value of the second hurdle. 
The optimal contingent allocation which has been made at stage 3 reduces the 
number of alternatives which must be considered at stage 2 because only the 
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payoffs from stage 3 given optimal contingent allocation need to be considered. 
Only one estimate of II(3)11\3),f\1· is required for each sample allocated to the no 
test arm, rather than estimates for all the feasible allocations of each sample. This 
is a considerable reduction in the computation required because using this 
approach the optimal allocation of a sample at stage 2 requires (( n+ 1 )2+( n+ 1»)/2 
estimates of II(3)11\3),f\1 at stage 3 and (( n+ 1 )2+( n+ 1 ))/2 estimates of II(2)ln(2),f\c at 
stage 2, where n is the maximum sample size considered. 
In this numerical example the maximum sample considered is 500 and a total of 
251,502 estimates of payoff are required to solve the optimal contingent allocation 
at stage 2 and stage 3 (12 hours computer time at 6 estimates per second). 
However the full enumeration of all feasible allocations of the sample at stage 2 
and stage 3 would require 125,7512 estimates which would take almost 84 years 
of computing time. Even if a 100-fold increase in computing speed was possible 
the solution would still require more than 10 months of computing time. Clearly 
the full enumeration of all possible alternatives is not feasible and this surprising 
result is a consequence of the problem of dimensionality 10,11. When A is the 
number of alternative combinations of sample size and allocation at each stage, 
and S is the number of stages in the decision problem then total number of 
alternatives will be AS. The simple dynamic programming approach 99, 124 to the 
problem taken in this chapter provides a feasible and practical solution by reducing 
the number ·of alternatives which must be considered to A * S for an S stage 
decision problem 10. 
6.3.4 Expected Net Benefit of Sample Information 
The expected net benefits of sampling at each stage with optimal patient allocation 
at stage 3 and stage 2 is illustrated in figure 6.3.3a and this can be compared to the 
expected net benefits when a fixed and equal allocation rule is used in figure 
6.3.3b, when 1/g=£4,000. The ENBS(l) when a optimal allocation rule is used 
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reaches a maximum of £724,970 at an optimal sample size of 116 (n1c·=0, and 
nl1·=29) with all the sample allocated to the no test arm and the treatment decision 
at stage 2, consequently ENBS(2)=O and ENBS(I)=ENBS(3). This is greater than 
when the fixed allocation rule is used where the maximum ENBS(I) is £362,366 at 
an optimal sample size ofn(1;=80. This is because the negative ENBS(2) from 
allocating half the sample to test alternative at stage 2 in figure 6.3.3b can be 
avoided when the optimal allocation rule is used. In this example the optimal 
allocation reduces the benefits from sampling (because no sample is allocated to te 
which has a higher variance of net benefits), but this is more than off-set by the 
reduction in the cost of sampling. 
Figure 6.3.3a 
Figure 6.3.3b 
The optimal allocation of the sample at each stage allows irrelevant or inefficient 
alternatives to be identified and ruled-out explicitly and consistently because it is 
possible to allocate none of the sample to that arm of the trial. This is not the case 
when a fixed allocation rule is used in chapter 5 because half the sample is always 
allocated to each alternative at each stage irrespective of the costs and benefits. In 
this example the optimal allocation enables no sample to be assigned to the test 
arm of the trial, and the test arm can be ruled-out as an irrelevant alternative 
because the comparison of the test and no test alternative using sample 
information is not cost-effective. Once the test alternative has been ruled-out as 
irrelevant the optimal trial design is identical to single-stage problem in section 6.2 
with the same optimal sample size and the same expected net benefits. 
Value of Health Outcome 
The ENBS, the optimal sample size, and optimal allocation is dependent on the 
value of l/g and the budgetary restrictions on service provision. The ENBS when 
the value of I1g is increased to £10,000 is illustrated in figure 6.3.4a when the 
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sample is allocated optimally and in figure 6.3.4b when the fixed allocation rule is 
used. In figure 6.3.4a the ENBS reaches a maximum of £12, 155,102 at an 
optimal sample size of 136 (n.e·=68 and n.1·=31). The testing arm at stage 2 is now 
a relevant alternative because less weight is placed on the marginal costs of 
assigning entrants to the test arm and the additional benefits are valued more 
highly. Half the sample is allocated to the testing arm and this demonstrates that 
what can be regarded as a relevant alternative is dependent on the value placed on 
health outcome. Once again the maximum ENBS and optimal sample size with 
fixed allocation is lower (ENB S=£l 2,098, 145 and n(I)·=133). In this case the 
expected benefits of sampling are higher and the costs of sampling are lower with 
optimal allocation despite the fact that the optimal sample size is higher. 
Figure 6.3.4a 
Figure 6.3.4b 
The ENBS when the value of lIg is increased to £20,000 is illustrated in figure 
6.2.5a when optimal patient allocation is used and in figure 6.2.5b when a fixed 
allocation rule is used. In figure 6.3.5a the ENBS reaches a maximum of 
£18,499,910 at an optimal sample size of 147 (n.e*=86, and nil *=28), and now 
more than half of the sample is assigned to the testing arm of the trial at stage 2. 
This is because more weight is placed on additional benefits of assigning the 
sample to the testing arm and less weight is placed on the additional costs (this 
was also illustrated in figure 6.3 .2b). Clearly the testing arm is a relevant 
alternative and in figure 6.3.5a the greatest share of the ENBS(I) is accounted for 
by the net benefits of sampling at stage 2. 
Figure 6.3.5a 
Figure 6.3.5b 
The ENBS when the fixed allocation rule is used in figure 6.3.5b is lower 
(£18,313,023) but the optimal sample size is higher (153). So in this case the 
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optimal patient allocation leads to a smaller optimal sample size, but this smaller 
sample generates a higher expected benefit which off-sets the higher sampling 
cost. This is because more entrants are assigned to the testing arm of the trial 
where the benefits and costs are highest. This example demonstrates that the 
optimal patient allocation at each stage of the decision problem may increase or 
reduce optimal sample size and may also increase or reduce the costs of sampling 
depending on the particular example and the value of IIg. However what is clear 
is that optimal allocation will increase the expected net benefits of sampling and 
the value of the second hurdle. 
Optimal Patient Allocation 
The optimal sample size and allocation to the testing arm of the trial for both fixed 
and optimal allocation rules can be compared in figure 6.3.6 for a range of values 
of l/g. As already noted the optimal allocation of the sample can lead to greater 
or smaller optimal sample size and more or less assigned to the testing arm of the 
trial depending on the value of IIg. However figure 6.3.6 also illustrates 
circumstances where optimal allocation leads to a positive sample size when no 
sample would be taken if a fixed rule is used. When l/g<£4,000 no sample is 
taken when a fixed allocation rule is used because it forces trial entrants to be 
assigned to the costly testing arm of the trial. However when 1/g~£3,000 the 
optimal allocation of trial entrants leads to positive sample size, demonstrating 
that optimal patient allocation can lead to proposed research being cost-effective 
when an arbitrary fixed rule would make it inefficient. 
Figure 6.3.6 
The difference in the ENBS(l)' EVSI(l) and the cost of sampling at the optimal 
sample size between the optimal and fixed allocation is illustrated in figure 6.3.7 
for a range of values of lIg. This demonstrates that the optimal allocation of trial . 
entrants will increase the expected net benefits of sampling. This may be achieved 
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by a reduction in the cost of sampling (possibly with a reduction in the expected 
benefits of sampling) or alternatively it may be achieved by an increase in the 
expected benefits of sampling (possibly with an increase in the cost of sampling). 
These differences are detennined by the value of lIg because this determines the 
relative weight placed on the additional benefits and costs of assigning entrants to 
each arm of the trial. 
Figure 6.3.7 
The way that the optimal allocation of trial entrants can be used to identifY 
relevant alternatives explicitly and consistently can be illustrated in figure 6.3.8a 
and 6.3.8b where the maximum ENBS(l) and the optimal sample size for the 
single-stage decision problem considered in 6.2 can be compared with the two-
stage decision problem considered here. When the value of lIg~£4,OOO the 
ENBS(l) for the two-stage decision problem is the same as the ENBS(J) for the 
single-stage decision problem and the optimal sample size is also the same for this 
range of value of lIg. The test alternative at stage 2 is not a relevant alternative 
and should not be included in the design of prospective research. This approach to 
optimal patient allocation allows no sample to be allocated to an alterative at each 
stage and if it is optimal not to allocate a sample to an alternative then it can be 
regarded as irrelevant and can be excluded from prospective research. 
Figure 6.3.8a 
Figure 6.3.8b 
In this example when lIg~£4,OOO the two-stage decision problem is identical to 
the single-stage decision problem because the testing arm is an irrelevant 
alternative and no sample is assigned to testing at stage 2. However when the 
value of lIg>£4,OOO less weight is placed on the higher marginal cost of assigning 
entrants to the testing arm of the trial and testing is a relevant alternative. An 
analysis which simplified this two-stage decision problem to a single-stage 
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treatment decision would underestimated the value of the research and seriously 
bias the trial design. This demonstrates that what are relevant alternatives depends 
on the value of lIg and alternatives cannot be ruled-out as irrelevant before the 
shadow price of the budget constraint (the value of health outcome) has been 
established. 
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6.4 A Four-Stage Sequential Clinical Decision Problem 
The dynamic programming approach to optimal patient allocation can also be 
applied to more complex sequential clinical decision problems. In this section the 
approach is applied to the four-stage decision problem that was considered in 
chapter 5.3. This is the problem that was used to generalise the Phelps Mushlin 
strategy in chapter 3 and is identical to the two-stage problem considered in the 
previous section except that an alternative treatment t2 is available. This is 
illustrated in figure 6.4.1 and is identical to figure 5.3.1 except that this four-stage 
decision problem is solved in five stages when optimal patient allocation is 
required. 
Figure 6.4. 1 
At stages 5 and 4 the optimal contingent allocation between t1 and t2 is made 
based on the expected net benefits of sampling for every feasible allocation of each 
sample entering the stage. At stage 3 contingent allocation decisions must be made 
between treatment (with either t1 or t2) and no treatment. The optimal allocation 
is based on the expected net benefits of sampling at stage 3 and the payoff from 
stage 4 given an optimal allocation of the sample allocated to the treatment arm of 
the trial. At stage 2 an optimal allocation between the test and no test arms of the 
trial is made for each sample entering stage 2. This contingent allocation is based 
on the expected net benefits of sampling at stage 2, the payoff from the optimal 
allocation of the sample which will enter stage 3, and the payoff from the optimal 
allocation of the sample which will enter stage 5. Finally the optimal sample size 
can be selected at stage 1 given that an optimal allocation policy will be followed 
at each subsequent stage. 
The value of the first hurdle and the EVPI for this decision problem is identical to 
chapter 5.3 and if the proposed research passes this first hurdle the second hurdle 
must be constructed to demonstrate that the research will be cost-effective at the 
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optimal scale. The value of the second hurdle is dependent on the allocation rules 
used at each stage because this will determine the expected benefit and cost of a 
given sample. Once again this example demonstrates that arbitrary rules will 
underestimate the value of proposed research and will lead to technically 
inefficient research design. The same numerical example that was used in chapter 
5.3 is used to illustrate this approach to optimal patient allocation. The results are 
compared to the fixed an equal allocation rule used in chapter 5.3 but assuming 
that the population benefits of the proposed research are endogenous. 
6.4.1 Optimal Allocation at Stage 5 
At stage 5 the optimal contingent allocation between t1 and t2 for each sample 
entering stage 5 must be made. The expected benefit of sampling not only 
depends on the sample entering stage 5 but also on the way it is allocated to tl and 
t2• The EVS~s)l~s),1\1 is a measure of the expected benefit of sample information 
at stage 5 given a sample of ~s) entering stage 5 with 1\1 allocated to tl> and n(S)-nt! 
allocated to t2• 
JVn(5),nt1 = oO(s/l( 00(S)2+on(s/) 
Orl.,S)2 = (0,ct!2/nu)+( 0lcl2 2/(n(s)-~I)) 
6.4.1a 
The benefit of a sample entering stage 5 is the reduction in the sample variance 
(on(s)2) of the incremental net benefits of t1. The benefit of sampling is determined 
by both the size of the sample entering stage 5 and the way it is allocated between 
the alternatives. In this example (when 1/g=£4,OOO) the variance of the net 
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benefits of t\ given a positive test result (Otetl 2) is greater than the variance of the 
net benefits of t2 given a positive test result (a tet2 2) so the marginal benefits of 
assigning an entrant to t\ will be higher than t2. However the variance is partly 
determined by the value of g and when lIg is higher (lIg=£20,OO) atet/ is greater 
than 0tetl2 and the marginal benefits of allocating a trial entrant to t2 will be greater 
than t1. 
The cost of sampling at stage 5 (Cs(s)ln(s),ntl ) is also determined by the way the 
sample is allocated because the marginal cost of assigning a patient to t\ will be 
greater than the additional cost of assigning a patient to t2· 
6.4.1b 
The payoff at stage 5 (II(s)ln(5),n,\ ) is simply the expected net benefits of sampling 
given a sample of flcs) entering stage 5 with nil allocated to t1 and n(5)-nl1 allocated 
to t2. 
The payoff can be established for every feasible allocation of each sample entering 
stage 5. This is illustrated in table 6.4.1a where the rows represent the sample 
entering stage 5, the feasible allocations are represented by the columns, and the 
optimal contingent allocation to t\ are the row maximums (II(s)lflcs),nu·) on the 
right of the table. 
Table 6.4.1a 
The optimal contingent allocation of a sample entering stage 5 to t1 is illustrated in 
figure 6.4.2a for three values of lIg. These optimal allocations can be compared 
with the fixed allocation rule used in chapter 5.3 where half the sample was 
allocated to t\ and half to t2• In this example more trial entrants are allocated to t2 
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because the marginal cost of assigning a trial entrant to tl is greater than t2. The 
proportion of the sample allocated to tl falls as the sample size entering stage 5 
increases because differences in the marginal benefit of assigning trial entrants to t1 
and tz become less significant as the sample size increases, but the difference in the 
marginal cost of sampling remains constant. When the value of 1/g increases a 
greater proportion of the sample is allocated to t\ because less weight is placed on 
the additional cost of assigning the entrant to t1. 
Figure 6.4.2a 
6.4.2 Optimal Allocation at Stage 4 
At stage 4 the optimal contingent allocation between tl and t2 must be made based 
on the expected net benefits of sampling for every feasible allocation of each 
sample entering stage 4. The EVSI(4)II\4),I\\ is a measure of the expected benefits 
of a sample of I\~) entering stage 4 with 1\\ allocated to t1 and n(4)-ntl allocated to 
t2· 
00(4) = (E(Ult1)-g·E(Clt\» - (E(ultz)-g·E(Clt2» 
JVn(4)'~1 = 00(4)2/( 00(4)2+0n(4)2) 
On(4/ = (0tl2/ntl)+(0t22/(I\4rntl» 
6.4.2a 
The benefit of sample information at stage 4 is the reduction in the sample 
variance (0n(4/) of the incremental net benefit oft1 and the marginal benefit of 
assigning a trial entrant to tl or t2 is determined by the variance of the net benefit 
of tl (0,/) and the variance of the net benefit of t2 (0t2 2). In this example 01/ is 
greater than 0112 and the difference between 0 1/ and Otl2 increases with the value 
of 1/g, so the marginal benefits of assigning an entrant to t2 will be greater than t1. 
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The cost of sampling at stage 4 (Cs(4)1I\4)'~I) is also determined by the additional 
treatment cost of assigning an entrant to tl which is greater than the additional 
treatment cost of t2· 
6.4.2b 
The payoff at stage 4 (II(4)1I\4)'~I) is simply the expected net benefit of sampling 
given a sample of n(4) entering stage 4 with ~I allocated to tl and n(4)-~1 allocated 
to t2. 
6.4.2c 
The optimal contingent allocation can now be established by calculating the payoff 
for every feasible allocation of each sample entering stage 4. This is illustrated in 
table 6.4.1 b where the possible samples entering stage 4 are represented by each 
row, and the feasibie allocations are represented by each column. The optimal 
allocation for a given sample size entering stage 4 is the row maximum 
(II(4)1~4)'~1 *) on the right of the table. 
Table 6.4.1 b 
The optimal contingent allocation of each sample size entering stage 4 for three 
values of 1/g is illustrated in figure 6.4.2b. A smaller proportion of each sample is 
allocated to t2 than with the fixed and equal allocation rule because the marginal 
cost of assigning entrants to tl is higher than t2. This optimal allocation is not the 
same as at stage 5 because although the marginal cost of sampling is the same, the 
marginal benefits of assigning entrants to either t2 or tl differ. In general a greater 
proportion of the sample is allocated to t2 because the marginal benefits of 
allocating an entrant to t2 is higher than at stage 5. The proportion of the sample 
allocated to tl falls as the sample size is increased because the difference in 
marginal benefit of assignment to t2 or tl declines with sample size. The proportion 
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of each sample allocated to tl increases with 1/g because less weight is placed on 
the additional cost of assigning an entrant to t}> and this does not offset the 
additional benefits of allocating entrants to t2. 
Figure 6.4.2b 
6.4.3 Optimal Allocation at Stage 3 
At stage 3 the optimal contingent allocation between treatment (tr ) (with either t\ 
or t2 at stage 4) and no treatment (to) must be made based on estimates of the 
expected net benefits of sampling at stage 3 and the payoff from stage 4 given that 
the sample allocated to the treatment arm will be allocated optimally between t\ 
and t2 at stage 4. 
Payoff at Stage 3 
A sample entering stage 3 (n(3») which is allocated between the treatment and no 
treatment arms will generate an expected net benefit of sampling at stage 3, but 
the sample allocated to the treatment arm will enter stage 4 and will be allocated 
optimally between t\ and t2 generating a payoff of II(4)iI\4),ntl •. So there is a 
recursive relationship between the payoff at stage 3 and stage 4, where the payoff 
and the optimal allocation at stage 3 is determined by the ENBS at stage 3 and the 
payoff given an optimal allocation policy at stage 4. 
TI(3)11\3),I\r =ENBS(3)11\3)'flu. + II(4)in(4),ntl • 
. 1\4) = flu. 
6.4.3a 
The payoffs given optimal contingent allocation at stage 4 have already been 
determined at stage 4 and were illustrated in table 6.4.1b and figure 6.4.2b. But to 
establish the optimal contingent allocation at stage 3 estimates of the 
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ENBS(3)ln(3),n,c are required for every feasible allocation of each sample entering 
stage 3. 
EVSI at Stage 3 
The EVSImI1\3),ntr is a measure of the expected benefits of a sample of n(3) entering 
stage 3 with ~ allocated to the treatment arm and n(3f~ allocated to to· 
00(3) = (E(ultr)-g·E(Cltr» - (E(Ulto)-g·E(Clto» 
/Vn(3)'"u = 00(3/1(00(3)2+on(3)2) 
On(3)2 = (otr2/~)+( ot02/(n(3J-~» 
6.4.3b 
Following the analysis of stage 2 in chapter 5.3 the prior incremental net benefits 
of treatment (00(3»' the prior variance of 00(3) (00(3)2), and the variance of the net 
benefit of treatment (Otr2) all depend on the sample allocated to the treatment arm. 
The prior net benefits of treatment (E(Ultr)-g·E(Cltr» and therefore 00(3) are 
dependent on the sample allocated to the treatment arm, because this sample will 
be allocated optimally between t1 and t2 at stage 4, and from 5.3.7: 
(E(Ultr)-g.E(Cltr» = P(3X(4?3x(4»)(E(Ult1)-g.E(Clt1» 
+ I-p(Ox(4?OX(4)·).(E(ult2)-g·E(Clt2» 
P(OX(4?OX(4)·) = p(Z>«00(4)-OX(4)·)/on(4/» 
On(4/ = (Ot/1ntl·)+(Ot/I(1\4f",1·» 
6.4.3c 
The value ofp(ox(4) >OX(4)·) is determined by the both the size of the sample 
allocated to the treatment arm of the trial (~) and the allocation of this sample at 
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stage 4. The value of (E(ultr)-g·E(CJtr» is calculated for each sample assigned to 
the treatment arm given an optimal allocation between tl and t2 at stage 4, and 
these values are the prior information used to establish the EVSI stage 3. 
The prior variance ofE(ultr)-g.E(CJtr) at stage 3 is a combination of the posterior 
variance ofE(Ultl)-g.E(Clt1) and E(Ult2)-g.E(Clt2) from stage 4. The sample 
allocated to tr (Ilv=f\4» determines the value of P(OX(4,>OX(4») and the sample 
variance ofE(Ultl)-g.E(CJtl) and E(Ult2)-g·E(qt2) (OUz/ntl-' and ot//(n(4r~I-) 
respectively). Since posterior variance is a combination of sample and prior 
variance, the prior variance of (E(Ultr)-g.E(Qtr» at stage 3 is calculated for every 
sample assigned to tr given an optimal allocation policy at stage 4. The 
population variance of the net benefits of treatment (0/) is also partly determined 
by the sample allocated to tp because this determines the value ofp(ox(4,>ox(4)")' 
so 0./ is also calculated for every sample assigned to 1r given an optimal allocation 
at stage 4. 
Cost of Sampling at Stage 3 
The marginal cost of sampling at stage 3 will be zero because the additional 
treatment cost of assigning an entrant to to will be zero and the cost of assigning 
an entrant to the treatment arm will also be zero because the additional treatment 
cost oftl and t2 has been included in the estimates of the ENBS at stage 4. The 
expected net benefit of sampling for every feasible allocation of each sample 
entering stage 3 can now be established: 
6.4.3d 
The payoffs at stage 3 for every feasible allocation of each sample entering stage 3 
can now be calculated in 6.4.3a and the optimal contingent allocation can be 
established. This is illustrated in table 6.4.1 c where the payoffs at stage 3 in the 
main body of the table include the ENBS at stage 3 and the payoff given an 
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optimal allocation of the sample assigned to tr which enters stage 4. The sample 
entering stage 3 is represented by each row of the table and the feasible allocations 
to the treatment arm are represented by each column. The optimal allocations at 
stage 3 are the row maximums and the optimal allocation (nlr*) and associated 
payoff (II(4)ln(.J),I\I*) for each sample entering stage 3 are illustrated on the right of 
the table. This approach of using the contingent allocation established at stage 4 
reduces the computation required at stage 3 because only one estimate of 
II(4)1"<4),I\I* is required for each sample allocated to the test arm, rather than 
estimates for every feasible allocation. 
Table 6.4.lc 
Optimal Alloc'ation at Stage 3 
The optimal allocation at stage 3 is illustrated in figure 6.4.2c for three values of 
1/g. The optimal allocation depends on the sample entering stage 3 and as n(3) 
increases the marginal benefits of sampling decline and a greater proportion of the 
sample is allocated to to where the marginal cost of sampling is zero. The optimal 
allocation also depends on the value of 1/g, and as 1/g is increased a greater 
proportion of the sample will be allocated to the treatment arm because the payoff 
at stage 4 (the net benefits of assigning an entrant to tr) will be greater as less 
weight is placed in the costs of allocating entrants to tl and t2. Indeed in this 
example when 1/g=£20,OOO and when "<3)<33 all the sample is allocated to the 
treatment arm of the trial because the payoff at stage 4 is greater than the 
expected net benefits of allocating the entrant to to. Over this range of sample 
sizes to is not a relevant alternative. 
Figure 6.4.2c 
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6.4.4 Optimal Allocation at Stage 2 
At stage 2 the optimal contingent allocation between the test and no test arms of 
the trial must be established for every feasible allocation of each sample entering 
stage 2. The payoff at stage 2 is based on the ENBS at stage 2, the payoff from 
the optimal allocation of the sample assigned to the no test arm which enters stage 
3 and the payoff from the optimal allocation of the sample assigned to the test arm 
which enters stage 5. 
Payoff at Stage 2 
A sample entering stage 2 (n(2J which is allocated to the test (nle) and no test 
alternatives (f\2fnle) will generate an expected benefit and cost of sampling at 
stage 2. Also f\2)-~e=f\3) will be allocated optimally at stage 3 generating a payoff 
ofII(3)If\3)'f1u.", and p(t/).~e=f\5) will be allocated optimally at stage 5 generating a 
payoff ofII(5)if\s),I\lo. This is a recursive relationship where the payoff and the 
optimal contingent allocation at stage 2 is determined by the expected net benefits 
of sampling at stage 2 but also by the payoffs given an optimal allocation policy at 
subsequent stages. 
6.4.4a 
f\3) = n(2)-n1e 
f\S) = p(t/)·I\e 
The payoffs from the sample assigned to the no test arm, which will be allocated 
optimally at stage 3, have already been established (II(3)in(3)'f1u.°) and were 
illustrated in table 6.4.1c. The payoff from the sample assigned to the test arm, 
which is allocated optimally at stage 5, have also been established (II{s)if\s),I\lO) 
and were illustrated in table 6.4.1a. To determine the optimal allocation at stage 2 
the ENBSm1f\2),~e must be estimated for every feasible allocation of each sample 
entering stage 2. 
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EVSI at Stage 2 
The EVSldn(2),nIC is a measure of the expected benefit of a sample of n(2) entering 
stage 2 with n.e allocated to the test alternative and n(2)-n1c allocated to the no test 
alternative. 
6.4.4b 
Following the analysis of stage 1 in chapter 5.3 the prior incremental net benefit of 
testing (00(2»)' the prior variance of 00(2) (00(2/)' and the population variance of the 
net benefit of test and no test alternatives (01/, and 001/) are all partly determined 
by the sample allocated to the test and the no test arms of the trial. From 5.3.8a 
the net benefit of not testing will be the expected net benefit from stage 3 given 
the optimal allocation ofa sample ofn(2)-nIC="<3) at stage 3. 
E(Ulntc)-g.E(Clntc) = P(0x(3,>OX(3)*).(E(Ultr)-g.E(Cltr)) 
+ I-p(ox(2) >oX(2)*).(E(Ulto)-g·E(Clto)) 
P(0x(3»OX(3)·) = p(Z>«00(3rOX(3)·)/oO(3/)) 
0
0
(3)2 = (ob?lntr°)+(ot02/("<3)-ntO°)) 
"<3) = "<2)-n.c 
6.4.4c 
The value ofp(0x(3?0x(3)") and therefore E(Ulntc)-g·E(Clntc) are determined by the 
sample allocated to the no test arm. The value ofE(Ulntc)-g.E(Clnte) is calculated 
for each sample allocated to the no test arm given that this sample will be 
allocated optimally at stage 3 (and subsequently at stage 4), and these values are 
used as the prior information used to establish the EVSI at stage 2. The prior 
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variance of E(Ulnt.)-g.E(C/nt.) at stage 2 is a combination of the prior variance of 
(E(Ulto)-g.E(Clto» and the posterior variance of(E(UI~)-g.E(C/tr» at stage 3. The 
prior variance of E(Ulnt.)-g.E(Clntc) at stage 2 is calculated for each sample 
allocated to the no test arm given that it will be allocated optimally at stage 3. The 
population variance ofE(ulntc)-g·E(C/nte) is partly determined by P(OX(3?OX(3)·) 
and is also calculated for each sample assigned to the no test arm given an optimal 
allocation policy at stage 3 (and subsequently at stage 4). 
The prior net benefit of treatment following a positive test result and therefore the 
net benefit of testing at stage 2 (E(ulte)-g·E(C/tc) are determined by the sample 
allocated to the test arm, and from 5.3.8b: 
6.4.4d 
+ p(t/).(p(OX(S) >ox*(S»).(E(ultc\ t1)-g.E(C/t/, t l )) 
+ I-p(ox(S) >ox*(S».(E(Ult/, t2)-g·E(Ult/, t2») 
P(OX(5?OX(S)·) = p(Z>«oO(S)-ox(5)·)/on(S)2)) 
0nl..s/ = (oICtl2/I\1·)+(Olct/I(Ilcs)-nu·») 
Ilcs) = p(t/)·I\c 
The value ofp(ox(s?OX(S)·) is detennined by the sample allocated to the test arm of 
the trial which enters stage 5 and E(ultc)-g·E(C/tc) is calculated for each sample 
allocated to the test ann at stage 2 given that the sample entering stage 5 will be 
allocated optimally. These values are the prior infonnation used to establish the 
EVSI at stage 2. 
The prior variance ofE(Ultc)-g·E(C/tc) at stage 2 is a combination of the prior 
variance of(E(Ultc·, to)-g·E(qt;, to), and the posterior variance of (E(Ujtc+' t l )-
g.E(C/t/, t l», and (E(Ult/, t~-g.E(ult/, t2») given the optimal allocation at stage 
5 of each sample allocated to the test alternative at stage 2. The population 
variance ofE(Ult.)-g.E(C/t.) can also be calculated for each sample allocated to 
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the test arm which enters stage 5 because this determines the value of 
p(OX(s?ox(S)*)' The expected benefit for every feasible allocation of each sample 
entering stage 2 can now be established given that the sample allocated to the no 
test arm will be allocated optimally at stage 3 (and subsequently stage 4) and given 
that the sample allocated to the test arm of the trial will be allocated optimally at 
stage 5. 
Cost of Sampling at Stage 2 
The cost of sampling for each sample entering stage 2 (Csdnc2),nlc) is the 
additional treatment cost of the test and no test alternatives. The marginal cost of 
assigning an entrant to the no test alternative will be zero because the additional 
treatment costs at stage 3 and stage 4 are included in the payoff from stage 3. The 
additional cost of assigning a trial entrant to the test arm will simply be the cost of 
the diagnostic test (CIC) because the additional cost of to given a negative test 
result will be zero and the additional treatment cost given a positive test result is 
included in the payoff at stage 5. 
6.4.4e 
The expected net benefit of sampling at stage 2 (ENBSdn(2),ntc) can now be 
established for each sample of n(2) entering stage 2, with n.e allocated to the test 
arm, and nc2fntc allocated to no test arm of the trial. 
6.4.4f 
The optimal contingent allocation of each sample entering stage 2 can be 
determined based on the payoff at stage 2 (II(2)1I\2),I\c) for every feasible allocation 
of each sample entering stage 2. This is illustrated in table 6.4.1 d where the 
sample entering stage 2 is represented by the rows of the table and the feasible 
allocations by the columns. The optimal allocation of each sample is the row 
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maximum (IIdI\2)'n.c") and the optimal allocation (n.c*) and the associated payoffs 
are illustrated in the right hand columns of the table. 
Table 6.4.1d 
Optimal Allocation at Stage 2 
The optimal contingent allocation of a sample entering stage 2 to the test arm of 
the trial for three values of 1/g is illustrated in figure 6.4.2d. The optimal 
allocation depends on both the size of the sample entering stage 2 and the value of 
1Ig. In general a greater proportion of the sample is allocated to the more costly 
test arm of the trial as the value of 1Ig is increased and less weight is placed on the' 
cost of sampling. It is worth noting that when 1Ig is low (£4,000) and n(2{ 50 
then no sample is allocated to the test arm of the trial and testing is not a relevant 
alternative, however when 1/g=£20,000 and n(2) <50 then almost all the sample is 
allocated to the test arm of the trial. The proportion of the sample allocated to the 
test arm of the trial also tends to decline as the sample size entering stage 2 
increases because any difference in the marginal benefit of allocation to the test 
and no test alternatives becomes less significant. The relationship between the 
optimal allocation, the value of 1/g, and I\2) is more complex at stage 2 because 
the optimal allocation is not simply determined by the ENBS at stage 2 but also by 
the payoffs and the optimal allocation at subsequent stages. 
Figure 6.4.2d 
6.4.5 Optimal Sample Size at Stage 1 
The first stage is simply to select the optimal sample size given that an optimal 
allocation policy will be followed at each subsequent stage. The payoff given a 
sample of n(l) selected at stage 1 (II(I)II\l) is simply the payoff from stage 2 given 
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an optimal allocation of n(2) between the test arm (I\e") and the no test arm n(2)-I\e·' 
II(l)ln(l) = IIdn(2),ntc• 
ENBS(I)II\I) = ENBSdn(2),nte·+ENBS(3)11\3),I\r· 
+ ENBS(4)ln(4),I\1· + ENBS(s)ln(s),nu• 
1\2) = 1\1) 
• 
1\4) = ntr 
I\S) = p(te+)·nte• 
6.4.5 
The optimal sample size at stage 1 (n(I)·) can be selected in table 6.4.1e and is 
where II(l)ln(l) or the ENBS(l)ll\l) reaches a maximum. The ENBS(l)ln(I)· provides 
the value of the second hurdle for this 4 stage decision problem. Once the optimal 
sample size at stage 1 has been selected the allocation of this sample at each 
subsequent stage is given by the contingent allocative decisions which have 
already been made and which were illustrated in tables 6.4.1 a, 6.4.1 b, 6.4.1 c, 
6.4.1d, and figures 6.4.2a, 6.4.2b, 6.4.2c, 6.4.2d. 
Table 6.4.1e 
The Dynamic Programming Approach 
The approach taken to this four-stage decision problem is a simple five-stage 
dynamic programme where contingent allocative decisions at each stage are 
solved before the optimal sample at stage 1 can be selected. The payoff for each 
sample considered at stage 1 is established given that an optimal allocation policy 
will be followed at each subsequent stage. This approach reduces the 
computation required to solve this problem even more dramatically than in the 
two-stage decision problem considered in section 6.3. Only one estimate of 
ENBS(3)II1t3),ntr• and ENBS(.J)ln(.J),ntl • is required for each sample allocated to the no 
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test arm at stage 2 and only one estimate ofENBS(s)ln(s),ntl • is required for each 
sample allocated to the test arm, rather than estimates of the ENBS for every 
feasible allocation of each sample allocated to the test and no test arms. This 
reduces the number of estimates of the ENBS from 125,751 4 if full enumeration of 
this four stage decision problem is required to 125,751 *4 where a maximum 
sample of 500 is considered at each stage. The solution for this numerical 
example using this approach requires 503,004 estimates of the ENBS which takes 
approximately 24 hours of computing time (6 estimates per second). This 
compares very favourably to the full enumeration of all possible alternatives which 
(even with a 100 fold increase in computing speed) would require over 13 billion 
years of computing time, a task so enormous it can safely be regarded as 
impossible. 
6.4.6 Expected Net Benefits of Sample Information 
The expected net benefit of sampling given optimal patient allocation at each stage 
is illustrated in figure 6.4.3a when 1Ig=£4,000. This can be compared to the 
expected net benefit when the fixed and equal allocation rule is used at each stage 
in figure 6.4.3b. The ENBS(I) with optimal patient allocation reaches a maximum 
of £3,865,420 at an optimal sample size of 165, with an allocation of~e·=67 at 
stage 2, flrr·=27 at stage 3, ~1·=12 at stage 4, and ~1·=19 at stage 5. This is 
greater than with fixed allocation where the ENBS(I) reaches a maximum of 
£3,529,502 at an optimal sample size of 148. In this example the optimal patient 
allocation increases the expected benefits and reduces the costs of sampling. An 
arbitrary allocation rule will lead an underestimate of the value and optimal scale 
of the proposed research. 
Figure 6.4.3a 
Figure 6.4.3b 
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Value of Health Outcome 
The expected net benefit of sampling when the value of lIg is increased to 
£ I 0,000 is illustrated in figure 6.4.4a when an optimal allocation policy is followed 
at each stage. The expected net benefit of sampling reaches a maximum of 
£20,207,332 at an optimal sample size of 199. This sample is allocated optimally 
at each stage with n,c·=96 at stage 2, flu.·=53 at stage 3, nu·=24 at stage 4, and 
1\1·=27 at stage 5. A greater proportion of the sample is allocated to the more 
costly alternatives at each stage because less weight is placed on the additional 
sampling cost when the value of lIg is increased. The expected net benefit when 
the fixed allocation rule is used is lower and reaches a maximum of £ 19,988, 081 
at an optimal sample size of 192 in figure 6.4.4b. 
Figure 6.4.4a 
Figure 6.4.4b 
The expected net benefit of sampling when the value of lIg is increased to 
£20,000 illustrated in figure 6.4.5a when the optimal allocation is used and in 
figure 6.4.5b when the fixed allocation is used. The ENBS reaches a maximum of 
£28,865,947 at an optimal sample size of257 when an optimal allocation policy is 
followed. This sample is allocated optimally with nlc• = 116 at stage 2, flu.. =75 at 
stage 3,1\1·=34 at stage 4, and 1\/=33 at stage 5. The ENBS with optimal 
allocation is greater than with the fixed allocation rule where the ENBS reaches a 
maximum of £28,543,130 at an optimal sample size of244 in figure 6.4.4b. 
Figure 6.4.5a 
Figure 6.4.5b 
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Optimal Patient Allocation 
These examples demonstrate that the optimal patient allocation increases the 
ENBS and the value of the second hurdle, and in this numerical example optimal 
patient allocation also increases the optimal sample size. It also demonstrates that 
the difference in the ENBS, optimal sample size and the allocation at subsequent 
stages is determined by the value placed on health outcome. This is illustrated in 
figure 6.4.6 where the optimal sample size and the allocation to the test arm of the 
trial for optimal and fixed allocation rules can be compared. In this example 
optimal sample size with optimal patient allocation is greater than with fixed 
allocation and a smaller proportion of the sample is allocated to the test arm which 
has high sampling cost. Indeed when 1/g=£3,000 no sample is assigned to the test 
arm of the trial and the testing alternative can be excluded as an irrelevant 
alternative. The difference in the ENBS, the EVSI and the cost of sampling 
between optimal and fixed allocation is illustrated in figure 6.4.7. This 
demonstrates that using arbitrary allocation rules will underestimate the ENBS. In 
this example optimal patient allocation increases the expected benefit of sampling 
and it also reduces the cost of sampling despite larger sample size. 
Figure 6.4.6 
Figure 6.4.7 
The optimal allocation of trial entrants in this example assigns a sall!ple to every 
arm of the trial when 1/g~£4,000. This means that it is efficient to compare each 
alternative at each stage using sample information and all the alternatives can be 
regarded as relevant. However when 1/g=£3,000 ~c·=O at stage 2 and nl1=O at 
stage 4, and the sample is allocated to to and t2 which in this case are the only 
relevant alternatives. The new treatment t2 is a relevant alternative and this is also 
confirmed by comparing the ENBS and optimal sample size for the two stage and 
the four stage decision problem in figure 6.4.Sa and 6.4.Sb. The difference 
between the two and five-stage problem is that treatment t2 was not available in 
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the two-stage problem. Since the ENBS and the optimal sample size is greater 
when t2 is included in the decision problem it is clear that t2 is a relevant 
alternative. An analysis which simplified what is a four-stage problem to a two-
stage problem by excluding t2 would underestimate the ENBS and the optimal 
scale of the research at the second hurdle. 
Figure 6.4.8a 
Figure 6.4.8b 
The analysis of the two-stage problem in the previous section of this chapter 
found that testing was not a relevant alternative when l/g=£4,000 and ntc·=O. 
However when t2 is included testing is a relevant alternative with ~c·=67 when 
l/g=£4,000. So excluding t2 would also exclude the testing arm of the trial. This 
demonstrates a theme which has been discussed in previous chapters: that the 
selection of relevant alternatives and the exclusion of some alternatives based on 
judgements and implicit decision rules can seriously bias the analysis, lead to 
errors at the second hurdle, and inefficient research design. If this inconsistency 
arose (due to a higher implicit value of health outcome) the ENBS would be 
seriously underestimated (£3,865,420 compared to £724,970) and there would be 
a very real danger that this research could be rejected at the second hurdle when it 
would be cost-effective ift2 was included. The design of the research would also 
be inefficient because testing would be excluded as an irrelevant alternative and 
rather than a trial that assigned patients to each alternative at each stage, it would 
simply compare t1 and t2 at a single-stage. If the value of l/g is lower (£3,000) 
then the ENBS and the sample size is zero when t2 is wrongly excluded and no 
research will be undertaken. 
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6.5 Conclusions 
In this chapter the fixed and equal allocation rule which was used in chapter 4 and 
5 is relaxed. The numerical examples in this chapter demonstrate that the optimal 
allocation of trial entrants is not simply an issue for sequential clinical trials but is a 
more fundamental problem which is also relevant to the fixed sample designs 
considered here. 
The approach to optimal patient allocation taken in this chapter explicitly 
considers the marginal cost and the marginal benefit of assigning trial entrants to 
the alternatives arms of the trial at each stage. In section 6.2 the single stage 
decision problem was solved in two stages and required the full enumeration of all 
feasible allocations of each sample considered. However the full enumeration of 
all feasible allocations in more complex sequential decision problems is not 
tractable and in section 6.3 and 6.4 the two and four-stage decision problems were 
solved using three and five-stage dynamic programmes. This simple dynamic 
programming approach utilises the recursive relationship between the payoffs at 
each stage of the decision problem and provides a practical solution to the 
problem. This may not be the optimal solution (because although there is a 
recursive relationship between the payoffs at each stage the prior variance and 
incremental net benefit at earlier stages are partly determined by the contingent 
allocation at later stages), but the dynamic programming approach is the only 
feasible solution and clearly p~ovides a better solution than the arbitrary fixed 
allocation rule used in chapter 5. 
The optimal allocation of trial entrants will increase the expected net benefit of 
sampling and the value of the second hurdle. This may be achieved by a reduction 
in the cost of sampling (possibly with a reduction in the expected benefits of 
sampling) or alternatively it may be achieved by an increase in the expected 
benefits of sampling (possibly with an increase in the cost of sampling). The 
optimal allocation at each stage, optimal sample size, and the expected net benefits 
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of sampling are determined by the value of health outcome because this 
determines the relative weight placed on the additional benefits and costs of 
assigning entrants to each arm of the trial. These numerical examples demonstrate 
that arbitrary and fixed allocation rules are inefficient and will lead to an 
underestimate of the value of proposed research and there is a danger that 
research which should be accepted at the second hurdle will be rejected. Research 
which is accepted at the second hurdle despite an arbitrary allocation will be 
designed inefficiently, may include the comparison of irrelevant alternatives, and 
the value of the research will be underestimated. 
The simple dynamic programming approach to optimal patient allocation provides 
and explicit and consistent method to identify relevant alternatives which should 
be compared in the trial. This is one of the problems which was posed by the 
analysis of the Phelps Mushlin strategy in chapter 3 and could not be adressed by 
using the fixed allocation rule in chapter 5. Optimal allocation provides a method 
to rule out irrelevant alternatives consistently based on an assessment of the 
expected benefit and cost of comparing alternatives, because it allows no sample 
to be allocated to an alterative at each stage. If it is optimal not to allocate a 
sample to an alternative then it can be regarded as irrelevant and can be excluded 
from prospective research. 
These numerical examples demonstrate that what are relevant alternatives depends 
on the value of 1Ig and alternatives cannot be ruled out as irrelevant before the 
shadow price of the budget constraint (the value of health outcome) has been 
established. They also illustrate the danger of ruling-out alternatives based on 
implicit and inconsistent decision rules. An analysis which simplified the two-stage 
decision problem in section 6.3 to the single-stage treatment decision in section 
6.2 would underestimated the value of the research and seriously bias the trial 
design. Similarly an analysis which simplified the four-stage problem in section 
6.3 to the two-stage problem in section 6.3 by excluding t2 would underestimate 
the ENBS and the optimal scale of the research at the second hurdle. This 
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demonstrates an argument which was also made in previous chapters: that the 
selection of relevant alternatives and the exclusion of some alternatives based on 
judgements and implicit decision rules can seriously bias the analysis, lead to 
errors at the second hurdle, and lead to inefficient research design. 
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Figure 6.2.1 Decision Tree for the Single-Stage Decision Problem 
Vtilities Costs 
Vij Cij 
Disease D) VII CII 
Treatment (tl) 
No Disease 1- VOl COl 
Stage 1 Stage 2 
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Table 6.2.1a Optimal Allocation of the Sample Entering Stage 2 (l/g=£4,OOO) 
Payoff at stage 2 II(2)ln(2),1\1 = ENUS(2)ln(2),1\1 Maximum payoff 
nil and optimal 
Allocation to t. (1\.) (with 1\. allocated to t •• and n(2)-I\. allocated to to) allocation (nil') 
0 1 2 3 4 5 6 7 8 9 10 II 12 II(2)1~2),1\1 , , n(2) .. 1\1 
Sample 0 0 . 0 0 
Entering 1 0 .£10.400 . . · 0 0 
Stage 2 
-1 n(2)= nO) 2 0 ·L9.952 ·L20,8oo . · 0 0 
3 0 ·L8,395 .L18,405 -01,200 0 0 
4 0 ·L7,031 ~£&.72g ·£26,905 .L4 I ,(iO() . 0 0 
5 0 ·LG.OIS L712 ,£S,IG6 ·L35,BI2 ·L52,OOO £712 2 
6 0 ·L5,257 L8,216 LII,289 ·L9,355 ·L45,065 ·LG2,400 · £ll,289 3 
7 0 ·L4,671 L14,053 £27.397 L19,266 ·U2,344 ·L54,572 ·L72,8OO . · - £27,397 3 
8 0 -L4,224 L1S,645 L4O;J01 L43,646 04,092 ·U6,786 ·LG4,259 ·£83,200 - - £43,646 4 
9 0 ·0,860 L22,314 LSO,664 L63,540 LS5,766 L26,223 .L22,3OO ·74,084 ·L93,6OO - - £63,540 4 
10 0 -0,562 £25,304 £59,072 £79,752 L8I,979 L64,I82 L26,199 .L28.7JJ ·L84,OIO -LI04,ooo - - . £81,979 5 
11 0 -0.314 .. £27,795 .. L66,028. £93,093.. £103,658.. £96,005 .. L69,5SK .. £24,479 .. -35,753£ .£94,013 .. -£114,400 .. . £103,658 5 
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Table 6.2.1 b Optimal Sample Size at Stage 1 (1 /g=£4,OOO) 
Payoff at stage 1 II(I)ln(l) = II(2)ln(2).I\. . Maximum payotT I 
and optimal 
Sample Selected at Stage 1 (n(I») (1\1) = n(2) sample entering stage 2) sample size (n,:) 
n(1) 0 1 2 3 4 5 6 7 8 9 10 11 12 II(I)ln(l) . " n(l) 
0 0 0 0 0 £712 .U1.289 £27.397 £43.646 £63,540 Vl I ,979 £\03.658 L122,536 .. 0 0 
-_._--- L 
Figure 6.2.3a Optimal Allocation: ENBS, EVSI, and Cs (]/g=£4,OOO) 
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Figure 6.2 .3b Fixed Allocation: ENBS, EVSI, and Cs (1/g=£4,000) 
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Figure 6.2.4a Optimal Allocation: ENBS, EVSI, and Cs (l/g=£lO,OOO) 
£5 ,500,000 
£5 ,000,000 -.-
£4,500,000 -
EVS[ 
£4,000,000 - J ENBS 
U £3 ,500,000 -.-
"-'~ 
C/] > £3 ,000,000 
~ 
~ £2,500,000 
~ £2,000,000 
£1 ,500,000 
£1 ,000,000 
£500,000 
£-
1/ Ie, 
0 20 40 60 80 100 120 140 160 180 200 
Sample Size Selected at Stage 1 (n(l ») 
Figure 6.2.4b Fixed Allocation: ENBS, EVSI, and Cs (l/g=£lO,OOO) 
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Figure 6.2.Sa Optimal Allocation: ENBS, EVSI, and Cs (lIg=£20,OOO) 
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Figure 6.2 .6 Optimal Sample Size with Fixed and Optimal Allocation 
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Figure 6.2.7 Difference Between Optimal and Fixed Allocations 
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Figure 6.3.1 Decision Tree for the Two Stage Decision Problem 
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Table 6.3.1a Optimal Allocation of the Sample Entering Stage 3 (lIg=£4,OOO) 
Payoff at stage 3 II(l)I,\,),1\1 = ENBSp)I'\l),nt l Maximum payoff I nil and optimal 
Allocation to tl (1\1) (with nil allocated to t l , and n(l)"nll allocated to to) allocation (nil·) 
0 1 2 3 4 S 6 7 8 9 10 11 12 II(l)ln(l),1\1 
. . 
n(3) .. 1\1 
Sample 0 0 - - - - 0 0 
Entering 1 0 -£10,400 -
Stage 3 
- - - 0 0 
n(l) =n(2) - nle 2 0 -19,952 ·120,800 - - - 0 0 
3 0 ·£8,395 -£18,405 ·01,200 - - 0 0 
4 0 ·£7,03\ -fB,728 -126,905 .£.41,600 - . 0 0 
5 0 ·£6.015 1712 ·fB,l66 ·£35,812 ·£52.000 £112 2 
6 0 ·15,257 £8,216 £11,289 ·19,355 -£.15,065 ·£62,400 - - £11,289 3 
7 0 ·£4,677 £14,053 127,397 £19,266 ·£12,144 ·£54,572 ·172,800 - - £27,397 3 
8 0 ·£.1,224 £18,645 L40,301 £.13,646 124,092 ·£16,786 -164,259 ·£83,200 . . £43,646 4 
9 0 -0,860 122,314 L50.664 £63.540 155,766 £26,223 ·122,300 .74,084 ·193,600 - - - £63,540 4 
10 0 ·0,562 125,304 £59,072 179,752 £81,979 164,182 £26,199 ·L28,711 ·£84,010 ·1104,000 - £81,979 5 , 
11 0 • 0,314 .. 127,795 .. £66,028 .. £93,093 .. £103,658 .. 196,005 .. £69,558 .. £24,479 .. ·35.7531 ·194,013 .. .£1 14.400 .. - £103,658 S 
12 0 ·0,108 129,906 171,840 £104,237 £121,602 1122,536 £106,255 £72,503 £21,399 ·£.11,304 ·£104,078 ·£124,800 £122,536 6 
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Figure 6.3.2a Optimal Allocation at Stage 3 
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Table 6.3.1b Optimal Allocation of the Sample Entering Stage 2 (lIg=£4,OOO) 
Payoff at stage 2 II(2)\n(2).I\. = ENBS(2)\n(2),1\1 + 11(3)\1\3),1\1 
. 
Maximum payoff 
nle and optimal 
Allocation to te (1\.) (with nl' allocated to te, and n(2fl\.allocated to nte) allocation (nte*) 
0 1 2 3 4, 5 6 7 8 9 10 11 12 11(2)\n(2)'u,. 
. . 
n(2) , .. u,. 
Sample 0 0 - - - 0 0 
Entering 1 0 ·£15,120 - - - - - 0 0 
Stage 2 
I\")=n(l) 2 0 ·£15,120 ·130.240 0 0 
3 0 ·£lS,120 ·£30,236 ·£45.360 . . · · 0 0 
4 0 ·£15.120 ·£30,218 ·145.307 ·£60.480 
· - 0 0 
5 1'712 ·£15,120 ·£30,212 ·144,990 ·L60,214 ·L15,t>OO . - · L712 0 
6 £11,289 ·£14.408 ·130.212 ·£44,853 ·158,851 ·£75,126 ·190,720 - · · L11,289 0 
7 127,397 ·13.831 ·129,495 ·£44,830 ·£58.146 ·L71,493 ·£89.886 ·1105,840 · · £27,397 0 
8 143.646 L12,2n ·£18,917 ·£44,054 .£57,969 ·£69,524 ·£82,953 ·£I().1,585 ·£120,960 . · £43,646 0 i 
9 £63.540 £28.526 ·£2.811 133.450 £57,024 £68.932 178,941 ·193,440 ·£119,249 ·£136.080 · · · · £63,540 0 
10 £81,919 £48,420 £13,438 ·£17,366 ·£46,322 .£67,709 .£n.m ·£86,637 ·£103,204 ·1133,898 ·1151,200 · £81,979 0 
11 £103,658 £66.859 133,329 ·£1,103 ·£30,261 ·£56,799 .£76,017 ·£84.169 ·£92,958 ·1112,465 ·£148,545 ·£166,320 · · £\03,658 0 
12 £122,538 £88,538 £51,769 £18,753 ·£13,948 ·£40,703 ·£64,719 ·£82.211 ·£89,034 ·198.250 ·£121,409 ·£163,201 ·1181,440 · £122,536 0 
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Figure 6.3 .2b Optimal Allocation of Sample at Stage 2 to Ie (nle) 
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Table 6.3.1c Optimal Sample Size at Stage 1 (l/g=£4,OOO) 
Payoff at stage I II(I)ln(l) = II(2)lu(2).Ilt. Maximum payoff 
I and optimal 
Sample Selcctcd at Stage I (n{l») (n(l) = u(2) sample entering stage 2) sample size (1\:) 
n(l> 0 1 2 3 4 S 6 7 8 9 10 11 12 II(I)ll\l) . .. n(l) 
0 0 0 0 0 £712 £11.289 £27,397 £43,646 £63,540 £81,979 £103,658 £122,536 .. .. 
- - ----
Figure 6.3.3a ENBS with Optimal Allocation (l/g=£4,OOO) 
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Figure 6.3.3b ENBS with Fixed Allocation (1/g=i4,OOO) 
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Figure 6.3.4a ENBS with Optimal Allocation (l/g=£lO,OOO) 
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Figure 6.3.4b ENBS with Fixed Allocation (\/g=£10,OOO) 
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Figure 6.3.5a ENBS with Optimal Allocation (lIg=£20,OOO) 
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Figure 6.3.Sb ENBS with Fixed Allocation (1/g=£20,000) 
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Figure 6.3 .6 Optimal Sample Size with Fixed and Optimal Allocation 
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Figure 6.3.7 Difference Between Optimal and Fixed Allocation 
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Figure 6.3.8a ENBS for the Single and Two Stage Decision Problems 
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Figure 6 .3 .8b Optimal Sample Size for the Single and T:-vo-Stage Decision Problems 
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Figure 6.4.1 Decision Tree for the Four Stage Decision Problem 
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Table 6.4.1 a Optimal Allocation of the Sample Entering Stage 5 (l/g=£4,OOO) 
Payoff at stage 5 II(I)ln(I),1\1 = ENI3S(I)ln(I),ntl Maximum payoff 
nn and optimal 
Allocation to t1 (ntl ) (with 1\1 allocated to t l , and n(I)-1\1 allocated to t2) allocation (1\1°) 
n(5) 0 1 2 3 4 5 6 7 8 9 10 11 12 ll(I)I'\I),1\1 . . .. 1\1 
Sample 0 0 . . · · · · · 0 0 
Entering 1 ·£2.400 ·LlI.484 
· 
. 
· · · ·£2,400 0 
Stage 5 
n(I)= p(t"').1\e 2 ·£4,800 11.458 ·£22.968 . . · · · £1,458 1 
3 ·£7,200 LlI.631 £\0.833 ·£34,412 . · · £15,631 1 
4 ·£9.000 £22.714 £15.929 £12.467 ·£45.935 · · · · · L55,929 2 
5 -£12.000 ' £26.200 LS\.219 £81,378 £9.533 -£57,'119 L8.:1,219 2 
6 '£14.400 £27.780 £102,306 £128'53S £95.897 £3,990 -£68.903 . · · · · L128,535 3 
7 ·£16,800 £28.204 1114.376 £160.815 £158.261 £103.413 ·£3.172 -£80,387 · · · £160,815 3 
8 -£19.200 £27.935 £122.651 £183,667 1202.633 11n,887 £106,301 ·£11,394 ·£91.811 . · · - · L202,633 4 
9 -£21.600 127.158 £128.419 £200,367 1235.156 £232.414 £190.583 £106.036 -£20,315 ·Ll03,355 · · · £235,156 4 
10 -£24.000 £26.1l46 £132.436 £212.860 £259.627 £273,256 £253.568 Ll98,320 £103.488 ·£29.766 ·£114.839 · · · £273,256 5 
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Table 6.4.1b Optimal Allocation of the Sample Entering Stage 4 (l/g=£4,OOO) 
Payoff at stage 4 ~4)1"<4),n,1 = ENBS(4)1"<4).I\1 Maximum payoff 
1\1 and optimal 
Allocation to tl (I\I) (with I\I allocated to t l • and n(4j"I\1 allocated to lz) allocation (I\I O ) 
0 1 2 3 4 5 6 7 8 9 10 11 12 ~4)1"<4).I\1 ° ° 1\4) .. I\I 
Sample 0 0 0 0 
Entering 1 ·12,400 -£10,400 - - -£2,400 0 
Stage 4 I 
"<4)=n.r 2 -£,4,800 ·£I2,7Sl -£20,800 -£4,800 0 
3 ·(7)00 -LI4,806 -122,837 -01)00 -
-£7,200 0 
4 -£9,600 -LI6,782 -122,179 -02,869 -£41,600 
-
- -£9,600 0 
5 -112,000 -UK,HU -(20,411 -L2H,~)2 -(41,Y51 -(52,000 
-£12,000 0 
6 -L I 4,400 -L20,916 -111,970 -L21,s10 -OS,so1 -il3,106 -162,400 -£14,400 0 
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8 ·£19,200 -US;zao ·U7,78S £9,0(1) 110,905 U,.!198 -LSO,Il82 -L73,s4' -00,200 - -£9,069 3 
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Table 6.4.1c Optimal Allocation of the Sample Entering Stage 3 (lIg=£4,OOO) 
Payoff at stage 3 TI(3)\1\3),l\r = ENBS(3)\n(3),l\r + TI(4)\n(4),1\1 
0 
Maximum payotf 
n lr and optimal 
Allocation to tr (l\r) (with l\r allocated to tr, and n(3)-l\r allocated to to) allocation (nlr°) 
0 1 2 3 4 S 6 7 8 9 10 11 12 TI(3)\n(3),l\r° 
0 
n(3) .. n tl 
Sample 0 0 - - 0 0 
Entering I 0 -£2.400 -
Stage 3 
- - - 0 0 
n(3) =n(2) -1\. 2 0 £359.898 ·£4,800 - £359,898 I 
3 0 £464,708 £538.405 -£7,200 - - - - £538,760 2 
4 0 £511,470 £802,531 £582.041 -£9,600 - - - - £802,531 2 
5 0 L~37.71o L9~l,!Ib) L917.413 L~o,3N -l.l2,OOO - - - - £951,965 2 
6 0 £554,465 £1,048,880 £1,128,581 £951,155 £578,408 ·£14,400 - - - - £1,128,581 3 
7 0 £566,007 £1,116,999 £1,276,244 £1,192,266 L954,985 £565,915 -£14,704 - - - £1,276,244 3 
8 0 £574,336 £1,167,607 £1,385,955 £1,367,582 £1,210,928 £946,474 £616,005 ·£9,069 - - - - £1,385,955 3 
9 0 !580,575 £1,206,393 £1,470,400 £1,501,327 £1,400.610 £1,209,477 £1,003,363 £614,545 -£269 - - - £1,501,327 4 
, 
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Table 6.4.1d Optimal Allocation of the Sample Entering Stage 2 (1/g=£4,OOO) 
Payoff at stage 2 ~2)\n(2).1\. = EN13S(2)\1\2).1\. + II(l)\n(l).l\l" + II(5)\n(5),1\1" Maximum payoff I n le and optimal 
Al1ocation to te (I\.) (with nte al10cated to teo and n(2)-nt• al10cated to nte) allocation (nt.") 
0 1 2 3 4 5 6 7 8 9 10 11 12 IIm \I\J),l\. " " n(2) .. n tl 
Sample 0 0 - - 0 0 
Entering 1 0 -£10.400 - - - 0 0 
Stage 2 
n(2)= n(1) 2 0 ·£10.400 ·L18.4OO 0 0 
3 £359,898 £349,498 -L18,399 ,£12,542 - - . - - £359,898 0 
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7.1 Introduction 
The thesis has considered two aspects of the value of clinical information. The 
value of information provided by diagnostic technology was considered in 
chapters two and three. The value of information generated by clinical research 
was examined in chapters four, five and six. 
Background 
This thesis was developed in response to the methodological problems which were 
encountered when faced with the economic evaluation of complex sequential 
clinical decision problems which include a number of treatment and diagnostic 
strategies 25. The issues posed by this type of decision problem are: (a) can 
diagnostic information be valued without the prospective evaluation of all feasible 
strategies of patient management; (b) ifnot then is it worth collecting additional 
information about this decision problem through prospective research; (c) if it is 
then what is the optimal scale of this research; and (d) which of the many 
competing strategies of patient management should be included (regarded as 
relevant alternatives) in the evaluation. The methodological developments in the 
thesis are an attempt to address these practical problems which are the issues of 
allocative and technical efficiency in research and development. 
Summary 
The thesis aims to provide methods which can address these problems, and these 
are iIIustrated throughout the thesis using the same simple numerical examples 
which are introduced in chapters two and three. In chapter two a strategy for the 
evaluation of diagnostic information which could in principle avoid prospective 
evaluation is examined. In chapter three it is generalised to a more complex 
decision problem. It is argued that this strategy will only provide consistent 
valuations if critical assumptions which are unlikely to be met in most clinical 
188 
settings hold. The consequences of violating these assumptions are demonstrated 
using the same numerical example. It was found that the value of diagnostic 
information will be biased: a cost-effective technology many be rejected; and a 
technology which is not cost-effective may be accepted. It was also found that 
current clinical practice may not include those treatment strategies which will 
become optimal once the new technology is adopted. Therefore observing current 
practice may not be able to provide the information which would be required to 
evaluate the new technology. This posed a number of problems: 
"If valid inferences can not be based on observing current clinical practice, 
but the prospective evaluation of all possible alternatives in a sequential 
clinical decision problem is not possible, efficient, or ethical, then: (a) how 
should information of different quality from different sources be combined 
consistently and explicitly; (b) which clinical decision problems will be 
worth evaluating in a clinical trial; (c) if a clinical decision problem is 
worth evaluating which of the competing alternatives should be compared 
in a clinical trial; and (d) what is the optimal scale of this prospective 
research?" 
These are the questions of how to establish both technical efficiency in research 
design, and how to achieve allocative efficiency in research and development 
across clinical decision problems and between research and service provision. It is 
these questions which were addressed in chapters four, five and six. 
The analysis in chapter four used a decision analytic approach to the valuation of 
clinical information which combined a Bayesian view of probability with a 
framework for decision making. This approach was used to establish the cost of 
uncertainty surrounding the decision problem (the expected value of perfect 
information). The marginal benefit and the cost of acquiring sample information 
was then explicitly considered. This enabled the technically efficient scale of the 
research to be identified and the expected net benefit of proposed research to be 
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established. These methods were generalised from the single-stage decision 
problem considered in chapter four to the two- and four-stage sequential clinical 
decisions in chapter five. However, although the decision analytic approach taken 
in these chapters addressed the issues of which clinical decision problems are 
worth evaluating and what the technically efficient scale of the research should be, 
it does not allow the relevant alternatives to be identified. 
In chapter six the fixed and equal allocation rule which assigned equal numbers of 
trial entrants to each of the alternative arms of the trial was relaxed. A dynamic 
programming approach was used to identify the optimal allocation of trial entrants 
at each stage of the decision problem. By explicitly considering the marginal 
benefit and marginal cost of assigning trial entrants to the alternative arms of the 
trial, the expected net benefit of the proposed research is higher than with fixed 
allocation rules. It enabled relevant alternatives to be identified because it is 
possible that no sample will be assigned to an arm of the trial and in this case it 
can be ruled out as an irrelevant alternative. At the end of chapter six the 
methodological problems which originally motivated the thesis have been 
addressed and methods proposed which can in principle provide a practical 
solution. 
l\tlethodological and Policy Issues 
In the process of addressing these problems some interesting methodological 
issues have been highlighted. One of the implications from chapter three is that 
there are problems when using the traditional approach to priority-setting using 
league tables of cost-effectiveness ratios. Chapter four demonstrates that the 
traditional approach to clinical trial design is inconsistent with concepts of 
efficiency even when economic evaluations is conducted alongside a clinical trial. 
The decision analytic approach to the value of information shows that there are 
circumstances when it will not be efficient to conduct a clinical trial and clinical 
practice should be based only on prior information. Establishing the expected net 
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benefit of research also means ethical judgements about proposed research can be 
based on a consistent estimate of the opportunity cost of particular ethical 
concerns. 
The thesis has also provided tools which can address some interesting policy 
questions, in particular methods for research priority-setting. Two hurdles are 
proposed for clinical research. The first ensures that only potentially cost-effective 
research is considered. The second ensures that this research will be cost-effective 
when conducted at the technically efficient scale. The expected net benefits of 
research can be used to establish allocative efficiency in research and development 
across clinical decision problems or broader areas of clinical research. Perhaps 
most importantly, it can be used to establish the optimal allocation of resources 
between research and development and service provision. Indeed what is clear 
from the analysis is that the value of information and research priorities cannot be 
separated from the budgetary constraints on service provision. These 
methodological issues and the policy implications of this work are discussed in 
more detail later in this chapter. 
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7.2 Consistency in the Evaluation of Diagnostic Information 
The strategy for the economic evaluation of diagnostic information proposed by 
Phelps and Mushlin 107 was an attempt to combine information from a number of 
sources (although not explicitly taking account of the variable quality of this 
information) and to focus clinical research more sharply by: (a) eliminating new 
technologies which will not be cost-effective by constructing two hurdles that 
proposed technology must overcome; (b) by avoiding randomised experimental 
design where possible; and ( c) by focusing on a clinically relevant range of test and 
patient characteristics. 
The Phelps Mushlin strategy was applied to a simple numerical example of a two-
stage test/treatment decision problem and two hurdles for the new technology 
were constructed. The first hurdle compared the expected value of the test 
assuming that it provided perfect information with an estimate of the cost of the 
new technology. Once the accuracy of the test is established existing information 
about current patient management is used to estimate the expected value of this 
imperfect clinical information. The relationship between the value of diagnostic 
information and the critical cost-effectiveness ratio (the shadow price of the 
budget constraint on service provision) was explored. This demonstrated that 
both hurdles are sensitive to this decision rule and that the explicit monetary 
valuation of health outcome is unavoidable in the valuation of clinical information. 
The approach to the economic evaluation of diagnostic information has a number 
of advantages and attractions: it is consistent with economic decision rules and it 
enables research to be focused on new diagnostic technologies which are 
potentially cost-effective. However the presentation of the approach by Phelps 
and Mushlin, where treatment following diagnosis is determined only by the test 
results, implies that no other treatment alternatives are possible. The approach 
simply added a diagnostic device to existing patient management strategies and 
clinical practice is changed only to the extent that the test changes the probability 
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of assigning a patient to a particular diagnosis. 
However in most clinical decision problems there is a range of treatment 
alternatives (and other diagnostic processes) which are at least possible following 
the results of the test, even if these alternatives are currently not used as part of 
existing patient management. In these circumstances diagnostic information may 
change patient management by changing the probability of assigning a patient to a 
particular diagnosis and by changing the optimal treatment choice. 
To establish the circumstances in which this strategy will be appropriate to these 
less restrictive decision problems the Phelps Mushlin strategy was generalised in 
chapter three to accommodate more than one treatment for a given diagnosis, and 
applied to a simple numerical example of a four-stage decision problem. It was 
argued in chapter three that the Phelps and Mushlin strategy depends critically on 
two assumptions: Firstly it is assumed that the decision problem facing the 
clinician prior to the introduction of the test must be identical to the decision 
problem when the test is introduced and the test results are known. Secondly it 
accepts current practice as an appropriate baseline (or relevant alternative) to 
eval~ate a new diagnostic device and implicitly assumes that the existing strategies 
of patient management are correct. In the context of an economic evaluation this 
means that existing strategies of patient management are efficient (the most cost-
effective) at the critical cost-effectiveness ratio. Current practice will only be the 
relevant alternative if there is consistency between the value of health outcome 
which is implicit in the selection of current practice (1Ig) and the value of the 
critical cost-effectiveness ratio CCeER), which is the shadow price of the budget 
constraint 
This assumption is unlikely to hold because the appropriate critical ratio is 
uncertain and depends on which budget is regarded as relevant. It was argued 
that the value of health outcome implicit in existing patient management may be 
greater than the CCER because clinicians may only consider clinical effectiveness 
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or may not have full information about the budget constraint they face and the 
costs of competing programmes within the budget. 
The consequences of violating this assumption were demonstrated in chapter three 
and two types of error were identified at each of the hurdles. The first type of 
error occurs when the value of diagnostic information is overestimated and a 
diagnostic technology which is not cost-effective may be accepted. Ifboth the 
fallback and the test/treatment strategy are selected using an inconsistent implicit 
value of health outcome then the value of clinical information is underestimated 
and a potentially cost-effective diagnostic technology may be rejected. Also a 
less effective but less costly alternative treatment may exist which would be 
optimal at the CCER but may not be part of current practice. In these 
circumstances it can no longer be assumed that treatment alternatives which are 
optimal following the new test will be part of existing patient management. It will 
not be possible to estimate the EVPI or the EVCI based on existing information 
and the investigator may be forced to consider an experimental design which 
includes both the test and the subsequent treatment strategies. 
The analysis of the Phelps Mushlin strategy in chapter three suggests it is likely to 
fail when applied to more complex decision problems because: (a) the key 
assumption of consistency between the value of health outcome implicit in current 
practice and the CCER is unlikely to hold; (b) when this assumption is violated the 
values of both the first and second hurdles will be biased; and (c) it is not 
necessarily the case that information about current practice before the test is 
introduced will be sufficient to construct the first hurdle. The Phelps Mushlin 
strategy fails, but if the prospective evaluation of all possible alternatives in a 
sequential clinical decision problem is not possible, efficient or ethical, then this 
poses the questions of how to establish both technical efficiency in research 
design, and achieve allocative efficiency in research across clinical decision 
problems and between research and service provision. The analysis in chapter 
three also poses some methodological problems for constructing league tables of 
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cost-effectiveness ratios to set priorities in service provision. 
Setting Priorities in Service Provision 
The decision problem considered in chapter three includes six possible strategies 
of patient management and can generate four cost-effectiveness ratios, none of 
which can be ruled out as extendedly dominated 78, 140. This poses a problem for 
the traditional approach to priority-setting and decision making using cost-
effectiveness or cost utility analysis. The traditional approach would be to place 
the cost-effectiveness ratio for this new diagnostic test in a league table along with 
the cost-effectiveness ratios of other non-mutually exclusive alternatives 
competing for the same budget. The social decision-maker should implement each 
in turn until the budget is exhausted 47, 141. The value of health outcome is set 
implicity, and will be the cost-effectiveness ratio of the marginal project. In this 
traditional approach health outcome does not need to be valued explicitly prior to 
an economic evaluation, and league tables of cost-effectiveness ratios which allow 
decision-makers to determine the valuation of health outcome implicitly according 
to their budget assume that the cost-effectiveness ratios are independent of the 
value of health outcome. 
However the example in this chapter shows that when considering sequential 
decisions problems there is no unique cost-effectiveness ratio and there are a 
number of ratios which could be placed in a league table IS, 16. The relevant ratio 
depends on the valuation of health outcome, so a league table for a particular 
value of 1/g could be constructed with a unique ratio for each intervention. 
Howwever, in this case the league table as an aid to decision-making is redundant 
because 1/g would already have been selected and the projects which should be 
accepted have already been determined. 
One approach to this issue is essentially to ignore the problem, and this is 
embodied in much of the work on league tables and published cost-effectiveness 
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ratios 47. This approach accepts cost-effectiveness ratios which compare 
alternatives dictated by current clinical practice using some implicit rule, but as we 
have already seen this will lead to inconsistencies and inefficient allocations. Each 
of the cost-effectiveness ratios which have been included in published league 
tables must be based on some implicit decision rule used to identify which 
alternatives are relevant. There is no reason to believe that these implicit rules are 
consistent with the shadow price of the budget constraint. 
An alternative approach is to evaluate every possible strategy. Sequential clinical 
decision problems are a comparison of a number of mutually exclusive 
alternatives. By evaluating each they can be ranked by effectiveness and those 
alternatives which are dominated and extendedly dominated can be ruled out 78, 140. 
Those that remain can be used to generate cost-effectiveness ratios implied by 
moving to more effective but more costly strategies. These ratios can be placed 
in a section of a league table and as the budget increases a more effective strategy 
will be accepted and the less effective strategy will be rejected. Although this 
approach does provide a theoretical solution if the assumptions of constant 
returns, non repeatability, and perfect divisibility are accepted it does require that 
all possible alternatives should be evaluated. In this simple decision problem this 
would involve the evaluation of six rather than two possible strategies but in more 
complex decision problems it could involve a very large number of alternatives. 
Adopting this approach would involve the prospective evaluation of each, a 
proposal which may well be inefficient, _or infeasible (in terms of recruitment into 
such a trial) and would probably be regarded as unethical. 
Health outcome must be valued explicitly prior to an economic evaluation so that 
relevant alternatives can be selected in a way which is consistent with the decision 
rules which will be used when the cost-effectiveness analysis is complete. 
However this also implies that the decision rule must capture all the relevant 
decision criteria. In this example the value of health outcome is the only criteria, 
but if social decision-makers 129 wish to include other criteria such as equity and 
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access these must be included prior to evaluation so they can be used to select the 
relevant alternatives which are compared. If different criteria are used to decide 
whether the project should be implemented then there may be other alternatives 
previously rejected which would meet these new criteria more effectively, and in 
these circumstances it becomes difficult to separate issues of equity and efficiency 
33,34,35, 117 
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7.3 A Decision-Analytic Approach to Trial Design and Research 
Priority Setting 
The analysis in chapter three demonstrated that a clinical trial may be unavoidable 
even in the evaluation of a non-invasive diagnostic technology. This posed the 
problems of allocative efficiency across clinical research and technical efficiency in 
research design. In chapter four it was argued that the traditional approach to 
clinical trial design is inconsistent with concepts of efficiency, leads to either 
infinite or arbitrary sample sizes, and cannot address the issues of allocative or 
technical efficiency in clinical research. The methods developed in chapter four 
and five address these problems by using a decision-analytic approach which 
combines a Bayesian view of probability with a framework for decision-making. 
The Traditional Approach to Trial Design 
The problems encountered when running an economic evaluation alongside a 
clinical trial have been well documented. However, the traditional approach to the 
design of pragmatic clinical trials is inconsistent with concepts of efficiency, 
because an infinite value is implicitly placed on the benefits of sample information. 
Furthermore, the traditional approach does not directly address the decision 
problem faced by clinicians and cannot incorporate prior information explicitly and 
consistently. 
In the traditional approach (assuming a fixed sample design, where all the results 
are available at the same time at the end of the trial) the key design issue is the 
number of patients to recruit. Sample size is very sensitive to the reference 
improvement and if the reference improvement is not well defined or is chosen in 
an arbitrary way, then sample size will also be arbitrary. The clinical reference 
improvement has been defined as the smallest worthwhile difference in 
effectiveness. Very small improvements in effectiveness should be worthwhile, but 
as reference improvement approaches zero, sample size tends to infinity. The 
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allocative and technical efficiency in research design. 
A Decision-Analytic Approach to Trial Design 
The decision-analytic approach developed in chapter four and five combines a 
Bayesian view of probability with a framework for decision-making. The 
approach abandons traditional significance testing, confidence intervals and their 
Bayesian counterparts in favour of minimising the expected costs of making the 
wrong decision. 
The methods developed in these chapters address the problem of allocative and 
technical efficiency in research design by constructing two hurdles that proposed 
research must overcome before it can be considered cost-effective. The first 
hurdle asks if the cost of proposed research exceeds the maximum possible 
benefits (the expected cost of uncertainty). If the cost does not exceed the 
maximum benefit then it is potentially cost-effective. Whether the proposed 
research is cost-effective can be established by constructing the second hurdle 
which explicitly considers the marginal cost and marginal benefits of sample 
information. The second hurdle ensures that the research is conducted at the 
technically efficient scale and provides a measure of the expected net benefit of the 
proposed research. This approach was illustrated by application to the simple 
single-stage fallback treatment decision in chapter four before it was generalised 
to the more complex two and four-stage test/treatment decisions in chapter five. 
7.3.1 Hurdle I: The Expected Value of Perfect Information 
The expected value of perfect information (EVPI) was established and this forms 
the first hurdle for proposed research. It is the maximum benefit that could be 
provided by additional information and the maximum return to research effort. 
This gives a method for focusing research priorities because it can be used to 
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identify those clinical decision problems (or areas of clinical research) where the 
costs of uncertainty are highest and where the information from research will be 
most valuable. If the fixed costs of research are known, the EVPI can be used to 
eliminate proposals (where the costs exceed the EVPI) which will not be cost-
effective. The EVPI can also be used in the same way to identify priority areas 
for scientific reviews and Meta-analysis: clinical decision problems where the 
costs of uncertainty are greatest derive the most benefit from a review of existing 
research. The EVPI is a powerful tool for identifying research priorities in 
support of a move towards evidence-based medicine. Indeed this approach can 
set the limits to evidence-based medicine and provide a framework within which it 
can be applied consistently. 
The expected value of perfect information can be established based only on prior 
information, including evidence from previous intervention and observational 
studies, but it can also include expert judgements. The decision-analytic 
framework focuses attention on those variables where evidence or judgement is 
required and by making prior information and judgements explicit they are open to 
empirical falsification. This is not necessarily the case in input/output models for 
assessing payback in clinical research or in Delphic studies of research foresight 
which elicit preferences which are not open to criticism or empirical testing. The 
quality of the prior information is reflected in the prior variance and prior 
information can be regarded as a quasi-sample where a smaller sample size 
indicates a more sceptical prior. Th}s framework makes the prior information 
which is required explicit and allows evidence from a variety of sources to be 
combined and handled consistently using Bayes Theorem. 
The relationship between the EVPI and the value of l/g was examined for the 
single, two and four-stage decision problems and this demonstrated that the value 
of information is crucially dependent on the value of health outcome used to set 
priorities in service provision. This is because the value of l/g is determined by 
the budget constraint faced by clinical practitioners. If the budget constraint is 
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relaxed then more costly but effective health services can be provided, the cost-
effectiveness ratio of the marginal service will increase, and the EVPI will rise. If 
the budget is tightened the cost-effectiveness ratio of the marginal project will fall, 
service providers will be unable to take advantage of the information provided by 
clinical research, and the value placed on this information will diminish. The value 
of information, research priorities and the optimal level of research and 
development expenditure are all dependent on the budgetary constraint on the 
provision of health services. 
The relationship between the EVPI and the quality of (or confidence in) the prior 
information was also explored and this showed that when there is less confidence 
in the prior information the EVPI is higher because there is more uncertainty 
-
surrounding a decision based only on prior information. Similarly when the prior 
is less sceptical the decision will be less uncertain and the EVPI is lower. The 
point at which the clinician would be indifferent between the alternative strategies 
based on prior information is where she is most uncertain and at this point the 
EVPI reaches a maximum. 
Sequential Decision Problems 
The analysis of the sequential decision problems in chapter 5 also demonstrated 
that the cost of uncertainty for a clinical decision problem will be underestimated if 
some alternatives are ruled out as not relevant and a sequential decision problem is 
simplified to a single-stage problem. This is because the EVPI for the whole 
decision problem is the sum ofEVPI at each of the contingent decisions and at the 
initial decision. An analysis which simplified a sequential clinical problem to a 
single-stage problem would underestimate the EVPI because the process of 
simplification excludes some alternatives which are feasible and relevant and in 
certain circumstances could become the preferred strategy. 
Chapter five demonstrated that by calculating the EVPI at each stage of a 
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sequential decision problem, those points in the sequence of decisions where the 
cost of uncertainty is highest can be identified. This is not necessarily the case with 
conventional sensitivity analysis because the prior distributions for the key 
variables and the value placed on opportunity losses at sensitive decisions are not 
necessarily taken into account. It was shown that simple measures of sensitivity 
may be misleading particularly if they are used to identify those points where 
information may be most valuable 
7.3.2 Hurdle ll: The Expected Net Benefit of Research 
Proposed research which passes the first hurdle can be regarded as potentially 
cost-effective. To demonstrate that it will be cost-effective the optimal scale of 
the research (in this case sample size) was established. The expected benefit of 
sample information was measured by the reduction in expected opportunity loss. 
This can be calculated for a particular sample size based on prior information and 
an estimate of the sample variance of the incremental net benefits. The marginal 
cost of sampling includes the additional cost of treatment when patients entering 
the trial are allocated to the experimental treatment. In chapters four and five 
patients are allocated equally between the control and experimental arms of the 
trial. The expected net benefit of sampling (ENBS) was defined as the difference 
between the total benefit and the total variable cost for a particular sample size. 
Sample size is optimal when ENBS is positive and at a maximum. The ENBS is 
the expected net present value of research and can be used to prioritise research 
. proposals. If this is positive then the research passes the second hurdle and is 
cost-effective when conducted at the technically efficient scale. 
The ENBS also represents the opportunity cost of failing to implement cost-
effective proposals. If a proposal with positive ENBS was rejected on the 
grounds of medical ethics then the implicit opportunity cost of this ethical position 
can be established either in monetary terms or in terms of health benefits forgone. 
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Consideration of medical ethics is an essential element in trial design, but this 
approach makes it possible to estimate the opportunity cost of particular concerns 
for the individuals involved in a trial. In this way the trade-off between individual 
and collective ethics can be made explicit. If these trade-offs are explicit they can 
be made consistently and be open to criticism and debate. 
The analysis in chapters four and five explored the relationship between the value 
of health outcome and the ENBS and showed that the value of sample information 
and the technically efficient scale of clinical research is dependent on the 
budgetary constraints on service provision. The issues of allocative and technical 
efficiency cannot be addressed before health outcome has been valued in monetary 
terms. The relationship between the optimal sample size, the expected net benefits 
of research and the quality of prior information was also examined. This showed 
that when the value of health outcome is low and the prior is less sceptical the 
optimal sample size is zero and the decision should be based only on prior 
information. In these circumstances the prior decision will be to reject the 
experimental treatment. 
This analysis also showed that when the prior is less sceptical and the value of 
health outcome is high then the optimal sample size will also be zero. But the 
prior decision is now to treat using the experimental treatment, suggesting that 
there may be circumstances in which a new treatment should be adopted without 
gathering sample information through a clinical trial. This demonstrates that a. 
decision-analytic approach can be used to set rational limits to evidence-based 
medicine and to provide a framework where new treatments of potentially great 
benefit can be adopted without incurring the cost (including the opportunity cost 
of the delay before the results are available) of a clinical trial. 
Sequential Decision Problems 
The analysis in chapter five demonstrated that the expected net benefits of sample 
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information and the optimal sample size can be established and the second hurdle 
can be constructed for sequential decision problems. This also showed that an 
analysis which did not recognise the sequential nature of a decision problem by 
simplifying it to single-stage decision and excluding the diagnostic process would 
bias efficient research design and cause errors at the second hurdle. Similarly an 
analysis which simplified the four-stage decision problem to the two-stage 
problem by excluding one of the treatment alternatives will underestimate the 
ENBS and bias the optimal sample size. Once again this illustrates that arbitrarily 
excluding feasible alternatives and using implicit rules and inconsistent judgements 
to identify which alternatives are regarded as relevant will bias research design. In 
this example the value of information and the technically efficient scale of 
proposed research will be underestimated. There is a danger that cost-effective 
proposals will be rejected and those that are accepted will be conducted at less 
than the technically efficient scale. 
7.3.3 Setting Priorities in Research and Development 
The decision-analytic approach which was developed in chapters four and five can 
provide practical policy tools for research priority-setting. The information 
generated by clinical research is valued in a way which is consistent with concepts 
of efficiency and with the methods used to set priorities in service provision. The 
prior information, which is implicit in the traditional approach, is identified and 
handled consistently so that it is open to criticism, alternative formulation and 
empirical testing. 
The simple numerical example examples of a fixed sample pragmatic trial shows 
that these techniques can be used to identify areas of clinical practice where the 
cost of uncertainty is high and where the potential benefits of clinical research will 
also be high. Estimates of the EVPI and the ENBS can be used to construct two 
hurdles which proposed research must overcome before it can be considered cost-
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effective. The first hurdle is based only on prior information and asks if the EVPI 
(the cost of uncertainty or the maximum value of sample information) is greater 
than the costs of the proposed research. This hurdle can eliminate proposed 
research which will not be cost-effective before issues of research design must be 
addressed. Those proposals which pass the first hurdle can be regarded as 
potentially cost-effective and can be considered at the second hurdle. The second 
hurdle ensures that the design of potentially cost-effective research is technically 
efficient and that it will be cost-effective when conducted at the optimal scale. 
The ENBS represents the value of the proposed research to the providers and 
consumers of health services. It also represents the opportunity cost of rejecting 
cost-effective research proposals. This approach provides a means to decide 
which clinical decision problems are worth evaluating in a clinical trial and what is 
the technically efficient scale of this research. 
Estimates of the expected net benefit of research can be used to rank competing 
research proposals, and by implementing proposals with higher net benefit first, 
the maximum health benefits can be gained for limited research and development 
resources. If all proposals with positive net benefits could be implemented then 
the returns to research and development expenditure would be at a maximum. 
The net benefit provided by the marginal research proposal will be zero, and the 
level of expenditure would be optimal. At this point research and development 
should only be expanded if there is a corresponding expansion in health service 
provISion. 
These tools can be used to address the optimal allocation of resource between 
research and development and service provision. The optimal level of research 
and development expenditure is determined by the budgetary constraints on 
service provision, because it is the cost-effectiveness ratio of the marginal service 
which determines the value placed on the benefits of clinical research. The level 
of research funding would be less than optimal if the net benefit of the marginal 
research proposal was positive. Expenditure on research and development 
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should be increased, and in these circumstances health benefits to patients would 
improve if resources were transferred from service provision to research and 
development. This would reduce 11g as resources were transferred from service 
provision and reduce the value of proposed research. The optimal level of 
research and development expenditure would fall and converge on the efficient 
allocation between service provision and research and development. 
The estimates of the expected net benefit of proposed research can be used to 
allocate research resources between broad areas of clinical research. If there are 
areas of clinical research where the marginal expected net benefit is low then 
resources should be transferred to other areas of research where the marginal net 
benefits are higher. This transfer of resources would increase the health gains for 
patients within a fixed research and development budget and should continue until 
the marginal net benefit across all areas is the same and the share of research 
resources is optimal. This approach could also inform policy where there is joint 
commissioning of research in a clinical area. If there is evidence that the current 
level of research funding is less than optimal this will provide a framework for 
negotiation between coinmissioning agencies. If there is evidence that the 
expected net benefit of marginal research commissioned by one agency is higher 
than other agencies this suggest that the former should increase their share of 
research effort in this clinical area. These techniques provide a framework within 
which these broad policy issues can be discussed, although further work would be 
required implement this approach because it has implications for those who 
commission, design and use clinical research. 
207 
7.4 A Dynamic Programming Approach to Optimal Patient 
Allocation 
The approach taken in chapters four and five solved, at least in principle, all but 
one of the problems which motivated this thesis: the Bayesian view of probability 
can explicitly incorporate prior information from different sources and of different 
quality; the first and second hurdles can identify which clinical decision problems 
should be considered for prospective clinical research; and the construction of the 
second hurdle identifies the efficient scale of this research. 
However there remains the problem of which of a number of competing 
alternatives should be compared within a clinical trial. This was not addressed in 
chapter four or five because that analysis assumed an fixed and equal allocation of 
trial entrants at each stage. This means that a sample is allocated to each arm of a 
trial irrespective of the cost and benefit. This arbitrary rule forces part of the 
sample to be allocated to each alternative and does not provide a method to 
identify which of the alternatives are irrelevant. In chapter six this arbitrary 
allocation rule was relaxed and a simple dynamic programming approach was used 
to establish optimal patient allocation and provide an explicit and consistent 
method to identify relevant alternatives which should be compared in the trial. 
The Traditional Approach 
The equal allocation of patients between experimental and control arms of a trial is 
often used and is implicitly justified by assuming that the variance of the outcome 
of interest for the control and experimental arm is the same, so that the benefits 
(reduction in sample variance) of assigning an additional trial entrant to either arm 
of the trial will be the same. However there is little justification for this rule of 
precedent when the costs and benefits of allocating a trial entrant to the alternative 
arms of the trial are explicitly considered. Whether an additional trial entrant 
should be allocated to a particular arm of a trial should be determined by the 
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marginal benefit of assigning the patient to that arm (which will be determined by 
the variance of the net benefits of that arm) and the marginal costs of assigning the 
patient to that arm (which is determined by the additional treatment costs). The 
only circumstances in which an equal allocation could be justified would be when 
the variance and the marginal sampling costs of both arms of the trial are the 
same. In the examples considered the variance of the net benefits of the 
alternatives at each stage are not assumed to be the same and the marginal cost of 
assigning a trial entrant to either of the alternatives at each stage will differ. 
There are established allocation methods which are only concerned with clinical 
outcomes in sequential clinical trials, were the accumulated results from earlier 
participants in the trial are available and are used to allocate those entering the 
trial. Chapter six addressed a more fundamental problem of optimal allocation in a 
fixed sample design where sample information is only available at the end of the 
trial. The benefit and cost of sample information, optimal sample size and the 
allocation of patients at each stage must be established before any sample 
information is available. 
A Dynamic Programming Approach 
The numerical examples in chapter six demonstrate that the optimal allocation of 
trial entrants is not simply an issue for sequential clinical trials but is a more 
fundamental problem which is also relevant to the fixed sample designs considered 
here. The approach to optimal patient allocation taken in this chapter explicitly 
considered the marginal cost and the marginal benefit of assigning trial entrants to 
the alternatives arms of the trial at each stage. The single-stage decision problem 
was solved in two stages and required the full enumeration of all feasible 
allocations of each sample considered. However the full enumeration of all 
feasible allocations in more complex sequential decision problems is not tractable 
and the two and four-stage decision problems were solved using three and five-
stage dynamic programmes. This simple dynamic programming approach uses the 
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recursive relationship between the payoffs at each stage of the decision problem 
and provides a practical solution to the problem. This may not be the optimal 
solution (because although there is a recursive relationship between the payoffs at 
each stage the prior variance and incremental net benefit at earlier stages are partly 
determined by the contingent allocation at later stages), but the dynamic 
programming approach is the only feasible solution and clearly provides a better 
solution than the arbitrary fixed allocation rule used in chapter five. 
The optimal allocation of trial entrants will increase the expected net benefit of 
sampling and the value of the second hurdle. This was achieved by a reduction in 
the cost of sampling (possibly with a reduction in the expected benefits of 
sampling) or alternatively by an increase in the expected benefits of sampling 
-
(possibly with an increase in the cost of sampling). The analysis in chapter six 
showed that the optimal allocation at each stage, optimal sample size, and the 
expected net benefits of sampling are determined by the value of health outcome 
because this determines the relative weight placed on the additional benefits and 
costs of assigning entrants to each arm of the trial. The numerical examples 
considered in this chapter demonstrate that arbitrary and fixed allocation rules are 
inefficient and will lead to an underestimate of the value of proposed research and 
there is a danger that research which should be accepted at the second hurdle will 
be rejected. Research which is accepted at the second hurdle despite an arbitrary 
allocation will be designed inefficiently and may include the comparison of 
irrelevant alternatives. The value of the research will be underestimated. 
The simple dynamic programming approach to optimal patient allocation provides 
an explicit and consistent method to identity relevant alternatives which should be 
compared in the trial. Optimal allocation provides a method to rule out irrelevant 
alternatives consistently based on an assessment of the expected benefit and cost 
of comparing the alternatives, because it allows no sample to be allocated to an 
alterative at each stage. If it is optimal not to allocate a sample to an alternative 
then it can be regarded as irrelevant and can be excluded from prospective 
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research. 
These numerical examples demonstrate that what are relevant alternatives depends 
on the value of l/g and alternatives cannot be ruled out as irrelevant before the 
shadow price of the budget constraint (the monetary value of health outcome) has 
been established. They also illustrate the danger of ruling out alternatives based 
on implicit and inconsistent decision rules. An analysis which simplified the two-
stage decision problem to the single-stage treatment decision would 
underestimated the value of the research and seriously bias the trial design. 
Similarly an analysis which simplified the four-stage problem to the two-stage 
problem, by excluding one of the treatment strategies, would underestimate the 
ENBS and the optimal scale of the research at the second hurdle. This supports 
an argument which has been made in previous chapters: that the selection of 
relevant alternatives and the exclusion of some alternatives based on judgements 
and implicit decision rules can seriously bias the analysis and can lead to errors at 
the second hurdle and inefficient research design. 
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7.5 Further Developments 
The methods which have been developed and illustrated in each chapter have 
solved, at least in principle, the problems which originally motivated this thesis: 
the Bayesian view of probability can explicitly incorporate prior information from 
different sources and of different quality; the first and second hurdles can identify 
which clinical decision problems should be considered for prospective clinical 
research; the construction of the second hurdle identifies the efficient scale of this 
research; and the dynamic programming approach to optimal patient allocation 
can identify which alternatives should be regarded as relevant and included in a 
clinical trial. However there are further methodological developments which 
could be pursued and the application of these methods to research priority setting 
suggests a programme of empirical work and poses the problem of how to 
implement this approach to research design and priority setting. 
One way in which these methods could be extended would be to include the 
expected health benefit or cost to those enrolled in the trial. The analysis in the 
thesis has focused exclusively on collective ethical concerns by considering the 
expected benefit and cost of proposed research to future patients and society as a 
whole. This provides a measure of the opportunity costs of rejecting cost-
effective research on the grounds of individual ethical concerns. The valuations of 
the potential health benefit and cost to those enrolled in the trial is excluded from 
this analysis and it is left to ethical decision-makers to make this trade-off, albeit 
with more information about the expected benefits of the research. However it 
would be possible to include the expected health benefit and cost to those enrolled 
in the trial, although this would involve making a value judgement about the 
relative weight attached to the costs and benefits to entrants as compared to the 
benefits which will accrue to future patients. 
This thesis has been concerned with the value of information generated by 
pragmatic clinical research at the final stage (phase III or IV) of the development 
212 
of new technology. However it seems that in principle the same approach can be 
used to set priorities in the development of new technologies and pharmaceuticals 
at a much earlier stage of development. Indeed it may be possible to use the same 
approach to set priorities in fundamental and biomedical research. This could 
provide a useful method to identify new chemical entities which are most likely to 
be cost-effective and which will change clinical practice when fully developed. 
This could reduce the research and development cost of bringing successful 
technologies to the market and could also inform a regulatory framework to 
provide incentives for the development of technologies with these desirable 
characteristics. These techniques have provided a framework within which broad 
policy issues can be discussed, and in principle prospective empirical work which 
applied this approach to a sample of research proposals could provide evidence as 
to whether the current level of research and development is optimal and whether 
patients would benefit from a reallocation of resources between research and 
development and service provision. 
Clearly the expected net benefits of research can only be realised if this approach 
can be successfully implemented. Implementing a decision-analytic approach to 
evaluative design and research priority setting has implications for those who 
commission, design and use clinical research. Those who commission research 
require guidelines for selectors to identify priority areas, to ensure that proposals 
are technically efficient and to establish the expected net benefits of proposed 
research. Those who design and seek support for clinical research need to be 
convinced of the value of these techniques and require bidding guidelines to 
ensure that research is designed efficiently and can demonstrate expected net 
benefits. Research interests would need to be focused on priority areas. This may 
. be achieved by the incentives created as those who commission research give 
higher priority to funding research in these areas. 
The impact on the users (clinical practitioners and purchasers) of clinical research 
ultimately determine whether the expected benefits of research are realised by 
213 
changing clinical practice. A key issue is the impact on decision-making of 
alternative approaches to evaluative design and research priority setting. One 
approach to the impact of research could be described as positive, and this 
attempts to establish how decision-makers make decisions and what type of 
information will have an impact on their practice. The approach accepts the 
current decision-making process and it implies that methods should be adopted 
which address decision-makers current concerns. This approach implicitly assumes 
that either the current decision-making process is optimal, with regard to the 
objectives of the NHS, or it is not amenable to change. This is the rationale for 
specifying a reference treatment difference in the traditional approach to 
evaluative design. 
The decision-analytic approach takes what could be described as a normative and 
extra-welfarist 33, 34,129 approach to the impact of research findings. This approach 
does not accept that the current decision-making process is necessarily optimal. It 
suggests how decisions should be made given specified objectives, prior evidence 
and the explicit assumptions and judgements that must be made. The aim is to 
establish methods and decision rules which best meet the specified objectives of 
social decision-makers (the objective which is embodied in the decision rules used 
throughout this thesis is the maximisation of health benefits). To change the 
existing decision-making process and persuade decision-makers of the issues 
which should be considered when interpreting alternative approaches to 
evaluative design, a campaign of dissemination, education and incentives is 
required. If they can be persuaded to abandon the traditional approach to 
significance testing and confidence intervals then this approach to the value of 
information could also be used to identify their own informational needs. They 
would be able to set their own priorities by establishing the cost of uncertainty or 
the EVPI of the decision problems that they face. This could be used to focus 
their efforts in searching the published literature, commissioning scientific reviews 
and acquiring new skills by recruiting personnel and purchasing training and 
consultancy. 
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